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A B S T R A C T
Background
TNF-alpha inhibitors have been shown to reduce the risk of joint damage and improve physical function and quality of life in people
with rheumatoid arthritis (RA). This is the first Cochrane review of certolizumab pegol, a new TNF-alpha inhibitor.
Objectives
To assess the effectiveness and safety of certolizumab pegol (CDP870) in patients with RA who have not responded well to conventional
disease modifying anti-rheumatic drugs (DMARDs).
Search methods
We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2009, Issue 3), MEDLINE (1966 to November
2009), EMBASE (1966 to November 2009), Scopus (January 2004 to November 2009), TOXLINE (until November 2009), Web of
Knowledge (until November 2009); websites of the US Food and Drug Administration (FDA) and European Medicines Evaluation
Agency (EMEA) (until November 2009), and reference lists of articles.
Selection criteria
Randomised controlled trials that compared certolizumab pegol with any other agent including placebo or methotrexate (MTX) in
adult RA patients with active rheumatoid arthritis despite current or prior treatment with conventional DMARDs, such as methotrexate
(MTX).
Data collection and analysis
Two authors independently assessed search results, trial quality and extracted data.
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Main results
Five trials were included. We included in the analysis 2394 people for effectiveness and 2094 people for safety. The duration of follow-
up was from 12 to 52 weeks, and the range of doses of certolizumab pegol were from 50 to 400 mg subcutaneously (sc). In three trials
the control was placebo plus methotrexate (MTX) and in two trials it was just placebo. Significant improvements were observed at 24
weeks with the approved dose of 200 mg certolizumab pegol: American College of Rheumatology (ACR) 50% improvement: risk ratio
(RR) 6.01 (95% CI 3.84 to 9.40) with an absolute benefit of 29% (95% CI 25% to 34%), number needed to treat to benefit (NNTB)
of 4 (3 to 5) and the Health Assessment Questionnaire (HAQ) mean difference (MD) - 0.39 (95% CI -0.45 to -0.32) (scale 0 to 3). At
52 weeks the results were quite similar: ACR 50% improvement RR 5.27 (95% CI 3.19 to 8.71), HAQ mean difference (MD) - 0.42
(95% CI -0.52 to -0.32). Serious adverse events were more frequent for certolizumab pegol 200 mg, Peto OR 2.02 (95% CI 1.24 to
3.30). The most common adverse events with certolizumab pegol 200 mg were: upper respiratory tract infections, Peto OR 2.21 (95%
CI 1.15 to 4.25); hypertension, Peto OR 2.81 (95% CI 1.38 to 5.75); and nasopharyngitis, Peto OR 2.71 (95% CI 1.30 to 5.66).
Authors’ conclusions
With an overall high grade of evidence this review revealed an improvement of clinical results (ACR50, 28 joint disease activity score
(DAS-28) remission and HAQ scores) with certolizumab pegol. Adverse events were more frequent with certolizumab; there was a
statistically significant increase in the number of serious adverse events, infections and hypertension.
P L A I N L A N G U A G E S U M M A R Y
Certolizumab pegol for adults with rheumatoid arthritis
This summary of a Cochrane review presents what we know from research about the effect of certolizumab pegol on adult people with
rheumatoid arthritis:
The review shows that in people with rheumatoid arthritis who did not respond well to conventional treatments such as
methotrexate (MTX):
- certolizumab pegol probably improves pain, function and other symptoms of rheumatoid arthritis;
- certolizumab pegol probably reduces disease activity;
- certolizumab pegol probably reduces joint damage as seen on the x-ray;
- side effects probably were more frequent in patients treated with certolizumab pegol.
What is rheumatoid arthritis and what is certolizumab?
When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints. This
makes your joints swollen, stiff and painful. There is no cure for rheumatoid arthritis at present, so the treatments aim to relieve pain
and stiffness, and improve your ability to move.
A new group of biologics has increased the number of treatment options. Certolizumab pegol belongs to this group. It is prescribed as
self injection.
Best estimate of what happens to people with rheumatoid arthritis who take certolizumab pegol:
ACR 50 (number of tender or swollen joints, and other outcomes such as pain and disability)
- 29 more people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis after 6 months with certolizumab
pegol 200 mg sc (29% absolute improvement)
- 35 people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis
- 6 people out of 100 who took a placebo experienced improvement
2Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Remission (absence of clinical signs of inflammation)
- 9 more people out of 100 experienced remission in the symptoms of their rheumatoid arthritis after 6 months with certolizumab
pegol 200 mg sc (12% absolute improvement)
- 11 people out of 100 experienced remission of their rheumatoid arthritis
- 1 person out of 100 who took a placebo experienced improvement
Serious adverse events (can include a serious infections or tuberculosis)
-5 more people out of 100 experienced serious adverse events related and not related to their rheumatoid arthritis after 6 months with
certolizumab pegol 200 mg sc (5% absolute improvement)
-10 people out of 100 experienced serious adverse events related and not related to their rheumatoid arthritis
- 5 people out of 100 who took a placebo experienced serious adverse events
Limited data regarding safety of certolizumab pegol use, especially in the long term, is available.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Summary of findings Certolizumab pegol 200 mg sc (with or without MTX) versus Placebo (with or without MTX) for rheumatoid arthritis in adults
Patient or population: patients with rheumatoid arthritis in adults
Settings: adults (18 years old or more) who have persistent disease activity despite current or previous use of conventional disease modifying anti-rheumatic drugs (DMARDs)
Intervention: Summary of findings Certolizumab pegol 200 mg sc (with or without MTX) versus Placebo (with or without MTX)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Summary of findings
Certolizumab pegol 200
mg sc (with or with-
outMTX) versus Placebo
(with or without MTX)
ACR 50% improvement
Follow-up: mean 24
weeks
58 per 1000 349 per 1000
(223 to 545)
RR 6.01
(3.84 to 9.4)
965
(2 studies)
⊕⊕⊕⊕
high
Absolute risk difference=
29%(95% CI 25% to
34%). Relative percent
change= 455% (345% to
593%). NNTB= 4 (3 to 5)
HAQ change from base-
line
Scale from: 0 to 3.
Follow-up: mean 24
weeks
The mean haq change
from baseline in the con-
trol groups was
1.6 1
The mean HAQ change
from baseline in the inter-
vention groups was
0.39 lower
(0.45 to 0.32 lower)
965
(2 studies)
⊕⊕⊕⊕
high
Absolute risk difference
= - 13%(95% CI -11%
to -15%). Relative percent
change= -24%(-28% to -
20%). NNTB=4 (3 to 5)2
Serious adverse events
Follow-up: mean 24
weeks
46 per 1000 89 per 1000
(56 to 137)
OR 2.02
(1.24 to 3.3)
964
(2 studies)
⊕⊕⊕⊕
high
Absolute risk difference=
5.2%(95% CI 2.3% to
7%). Relative percent
change= 101% (-45% to
179%). NNTH= 24 (11 to
96)
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Proportion of patients
achieving DAS <2.6 (Re-
mission)
Follow-up: mean 24
weeks
12 per 1000 45 per 1000
(28 to 73)
OR 3.88
(2.33 to 6.45)
957
(2 studies)
⊕⊕⊕⊕
high
Absolute risk difference=
9%(95% CI 7% to
12%). Relative percent
change= 892% (583% to
1687%). NNTB= 31 (17
to 65)
Radiological changes:
Erosion Scores (ES)
Scale from: 0 to 230.
Follow-up: mean 24
weeks
The mean radiological
changes: erosion scores
(es) in the control groups
was
23.1 1
The mean Radiological
changes: Erosion Scores
(ES) in the intervention
groups was
0.67 lower
(0.96 to 0.38 lower)
859
(2 studies)
⊕⊕⊕⊕
high
Absolute risk difference=
-0.29%(95% CI -0.42% to
-0.17%). Relative percent
change =- 2.90 %(-4.
16% to -1.65 %)
All Withdrawals: 715 per 1000 279 per 1000
(257 to 307)
RR 0.39
(0.36 to 0.43)
2107
(5 studies)
⊕⊕⊕⊕
high
All doses of certolizumab
vs placebo 24-52 weeks.
Absolute risk difference=
45% (95% CI 49% to
41%). Relative percent
change= 61% (64% to
57%). NNTH= 3 (3 to 4)
Withdrawals due to ad-
verse events
Follow-up: 24-52 weeks
23 per 1000 43 per 1000
(26 to 71)
OR 1.93
(1.15 to 3.23)
2071
(4 studies)
⊕⊕⊕⊕
high
All doses certolizumab vs
placebo. Absolute risk dif-
ference= 2.%(95% CI 1%
to 4%). Relative percent
change= 117% (15% to
310%). NNTH= 51 (19 to
393)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 From RAPID2 trial
2 RAPID1 used to calculate NNT
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Rheumatoid arthritis (RA) is a chronic illness which typically
causes asymmetrical arthritis. The arthritis causes pain, swelling
and stiffness of affected joints. Affected joints may become ir-
reversibly damaged if disease persists. Patients commonly experi-
ence fatigue and show changes in the blood, such as anaemia, and
an acute phase reaction. In some patients organs such as the skin
(as rheumatoid nodules), lungs (pleural inflammation and alveoli-
tis), heart (pericarditis), blood vessels (vasculitis) and the eyes (dry
eyes or inflammation) may be affected. RA occurs throughout the
world. Important genetic influences are recognised, in particular
genes linked to activation of the immune system (Barton 2009),
however environmental factors such as an urban versus a rural en-
vironment and smoking are also associated with an increased risk
of RA (Edwards 2005). People of all ages are affected but the dis-
ease begins most commonly between the ages of 40 and 70 years.
Three times as many women as men are affected and the pop-
ulation prevalence in Western countries is between 0.5 and 1%.
The incidence of RA rises with increasing age (Doran 2002) and
RA is associated with reduced life expectancy, particularly due to
cardiovascular disease (Meune 2009) but in early years also due
to pulmonary disease and lymphoma (Young 2007). Significant
functional limitations occur in 15% of patients five years after
disease onset and around a third of those in paid work experience
work disability (Young 2000). In Spain, RA causes around 10%
of total disability and 5% of transitory disability (Carmona 2002)
including occupational disability (Doeglas 1995).
The objective of treatment in early disease is to induce remission,
and at all stages of disease to control symptoms of joint pain and
stiffness, improve function and quality of life and minimise the
risk of structural damage by reducing inflammation. These ob-
jectives may be met and the prognosis improved by timely use
of disease modifying anti-rheumatic drugs (DMARDs), such as
methotrexate (Landewe 2003).
RA is characterised by immunological activation of many cell
types and a network of cytokines, particularly tumour necrosis
factor alpha (TNF-alpha) (Brennan 2008). Inhibitors of TNF-
alpha have been a major development in the treatment of RA.
Randomised trials have shown that these drugs are highly effective
in patients with RA who have not responded well to conventional
DMARDs. TNF-alpha inhibitors have been shown to reduce the
risk of joint damage, improve physical function and quality of life
(Chen 2006). A systematic review of infliximab and adalimumab
showed that the risk of malignancy and serious infection was in-
creased with odds ratios of 3.3 (95% confidence interval (CI) 1.2
to 9.1) and 2.0 (95% CI 1.3 to 3.1) respectively (Bongartz 2006).
Five agents are currently licensed for use in RA in Europe and
the US. These are adalimumab (Navarro Sarabia 2005), etaner-
cept (Blumenauer 2003), golimumab (Singh 2010), infliximab
(Blumenauer 2002) and now certolizumab. No controlled trials
have compared one TNF inhibitor against another. An important
limitation of their wide use is the high cost, between 10,000 and
25,000 USD per patient a year.
Certolizumab is a newly approved TNF inhibitor and consists
of a humanised immunoglobulin fragment (Fab) conjugated to
polyethylene glycol (PEG), also termed pegylation. Pegylation of
this molecule yields a longer half-life and reduces the need for fre-
quent dosing (Choy 2002). However lasting immunosuppression
may be disadvantageous in the event of infections such as tuber-
culosis (Bongartz 2006).
O B J E C T I V E S
To determine the efficacy and safety of certolizumab pegol
(CDP870) compared to placebo or any disease modifying anti-
rheumatic drug (DMARD) in patients with rheumatoid arthritis
(RA) who have not responded well to conventional DMARDs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
Adults (18 years of age and older) with RA who have persistent
disease activity despite current or previous use of conventional
DMARDs.
Patients with RA were defined as those meeting the American
College of Rheumatology (ACR) 1987 revised criteria (Arnett
1988) for RA. That is to say, they must have had an active form
of the disease as demonstrated by at least two of the following
symptoms:
1. three or more tender joint areas observed by a physician;
2. three or more swollen joint areas observed by a physician;
3. duration of early morning stiffness > 30 minutes;
4. acute phase reactants such as Westergren erythrocyte
sedimentation rate (ESR) more than 30 mm/hour or C reactive
protein (CRP) more than 10 mg/mL.
Types of interventions
The intervention was certolizumab pegol (CDP870) at any dose.
The comparators were placebo or any disease modifying anti-
rheumatic drug including other biologic agents used to treat RA.
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Types of outcome measures
The major outcomes for this systematic review were:
• the proportion of patients achieving an ACR50;
• frequency of adverse events;
• health-related quality of life, such as the Health Assessment
Questionnaire (HAQ) or Short Form Health Survey (SF-36).
ACR50 is defined as a 50% improvement in the number of tender
and swollen joints and a 50% improvement in at least three of
the following items: observer evaluation of overall disease activity,
patient evaluation of overall disease activity, patient evaluation of
pain, a score of physical disability, or improvements in blood acute-
phase responses.
The following adverse events were sought: headache, fever, blood
disorders, laboratory disorders, abdominal pain, nasopharyngitis,
nausea, respiratory tract infections, urinary tract infections, neck
pain, congestive heart failure, pruritus and anaphylaxis. Serious
adverse effects were defined as malignancies; all infections, espe-
cially tuberculosis; and death. All causes of discontinuation of the
medication were sought.
Minor outcomes were:
• ACR20 and ACR70 (a 20% or 70% improvement in the
parameters described above);
• Disease Activity Score (DAS28, or other versions of DAS)
and
• radiological changes (erosion score, modified total Sharp
score, joint space narrowing).
Search methods for identification of studies
Electronic searches
The search strategy used the revision of the Cochrane Highly Sen-
sitive Search Strategy (HSSS) for PubMed (Glanville 2006) and
the best sensitivity filter developed by the Hedges Team (Wong
(a) 2006; Wong (b) 2006) and followed the Cochrane Mus-
culoskeletal Review Group recommendations. Searches included
bothMeSH headings and text terms for CDP870 and rheumatoid
arthritis. We performed a search and, before the review was con-
cluded, we updated the searches. The first and the second search
strategies are shown in the appendices: MEDLINE (Appendix
1); EMBASE (Appendix 2); CINAHL (Appendix 3); Cochrane
Database of Systematic Reviews (CDSR) and CENTRAL, HTA,
DARE, NHS EED (The Cochrane Library) (Appendix 4); SCO-
PUS (Appendix 5); TOXLINE (TOXNET) (Appendix 6).
Safety data were obtained from clinical trials. The search strategy
combined index and text terms for CDP870 and adverse effects
reported in RCTs of certolizumab pegol and another anti-TNF al-
pha, with a strategy based onGolder (a) 2006.No language restric-
tions were applied. Search strategies to identify studies were car-
ried out following the Cochrane Musculoskeletal Review Group
recommendations.
The following databases were searched: Cochrane Central Register
of Controlled Trials Register (CENTRAL) (The Cochrane Library
2009, Issue 3); MEDLINE (1966 to November 2009; EMBASE
(1966 to November 2009); Web of Knowledge (until November
2009); Scopus (January 2004 to November 2009). The Food and
Drug Administration (FDA) and the European Medicines Evalu-
ation Agency (EMEA) websites were also searched (until Novem-
ber 2009). We performed a search, which we updated prior to
finishing the review.
Searching other resources
1. Abstracts for the two key annual international
rheumatology meetings, the American College of Rheumatology
and the Congress of the European League Against Rheumatism
(2006 to December 2008) were handsearched.
2. We consulted the information made available by the main
researchers and sponsors.
3. We reviewed information on the clinical trial meta-register
database (www.controlled-trials.com/mrct/).
4. We looked for Health Technology Assessment reports from
the European, Canadian, North American and Australian
national agencies to identify further trials.
5. The reference lists of all identified studies were inspected
for more trials.
6. When published data were missing, incomplete, or
inconsistent with the trial protocols, further information was
sought from the authors and manufacturers (UCB) to request
additional information.
Data collection and analysis
Selection of studies
Inclusion criteria
1. RCTs that compared certolizumab pegol with any other
agent including placebo in adult RA patients with active RA
despite current or prior treatment with DMARDs.
2. Trials that were fully published as a paper or available as a
complete trial report. Where published only as abstracts the trial
reports were requested from the manufacturers.
3. Studies having at least three months of follow-up to assess
effectiveness.
To assess safety we also sought studies having a suboptimal length
of follow-up, from eight weeks.
Exclusion criteria
1. Trials of certolizumab pegol in juvenile arthritis, Crohn’s
disease, psoriatic arthritis and other forms of spondyloarthritis.
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2. Trials of certolizumab pegol comparing different doses or
routes without another active or placebo control group (except
for use for assessing safety outcomes).
3. Studies reporting solely on laboratory measures aimed at
investigating disease or treatment mechanisms and which did not
report relevant clinical outcomes.
4. Observational studies of certolizumab pegol.
5. Interim results of trials.
Data extraction and management
Two review authors independently reviewed titles and abstracts
of studies identified in the search to assess which studies might
potentially meet the inclusion criteria.Where there was doubt, the
full article was acquired for further inspection. Potential studies
identified by this process were then obtained and two authors
independently screened them to see if they met the review criteria
using aWeb interface. A final table was produced in Excel. We did
not need to resolve any disagreements through discussion.
Data were extracted, when possible for intention-to-treat popula-
tions, as raw numbers plus any summary measures with standard
deviations, confidence intervals and P values of the outcomes re-
ported. These were compiled into an Excel spreadsheet. Differ-
ences of opinion and data discrepancies were to be resolved by
reference to a third review author (Encarnación Saiz) but that did
not happen.
Assessment of risk of bias in included studies
According to the recommendations in the Cochrane Handbook
(Higgins 2008), the risk of bias was assessed by creating a ’risk of
bias’ table for each study and a summary is presented below as a
risk of bias graph.
The main criteria used to measure the risk of bias included: blind-
ing of participants, allocation concealment, random sequence gen-
eration, incomplete outcomedata, selective reporting of outcomes,
and other biases (early stopping of trials or imbalance in the base-
line characteristics of people in the different groups). The risk of
bias in each study was explicitly judged on the basis of each crite-
rion using the following standard: Yes (low risk of bias), No (high
risk of bias), Unclear (either lack of information or uncertainty
over the potential bias). These criteria were included in tables.
Disagreements were resolved by discussion between the two re-
view authors. If needed, a third review author was available for
discussion, but we did not have any disagreements.
Measures of treatment effect
It has been shown that risk ratio (RR) is more intuitive (Boissel
1999) than odds ratios and that odds ratios tend to be interpreted
as RR by clinicians (Higgins 2008). The risk difference was used to
quantify the number needed to treat (NNT) (Laupacis 1988). For
continuous data we used mean differences when the results were
measured in the same way in the different studies. We used stan-
dardised mean differences when the results obtained were concep-
tually the same but used different measurement scales. The cen-
tral estimate (mean) and standard deviation were recorded.Where
these were not directly stated they were calculated from the stan-
dard error or the different means and their respective confidence
intervals (CIs) or P values.Whenmedians and interquartile ranges
were the only data provided, the median was used as a proxy mea-
sure of the mean and the difference between the first and third
interquartile as equivalent to 1.35 of the SD.
Unit of analysis issues
Most of the clinical trials had a simple parallel group design with
participants individually randomised to one of two intervention
groups, and unit of analysis was not an issue in this review.
Dealing with missing data
We carried out an intention-to-treat analysis. Everyone allocated
to the intervention was counted whether they completed the fol-
low-up or not. We have assumed that those who dropped out had
no change in their outcome. This rule is conservative concerning
response to treatment because it assumes that those discontinu-
ing the studies would not have responded. It is not conservative
concerning adverse effects but we felt that assuming that all those
leaving early had developed side effects would overestimate risk.
When published data were missing, incomplete or inconsistent
with the RCT protocols or meeting abstracts, we asked for fur-
ther information from the authors and manufacturers. We only
excluded abstracts of studies that were interim reports of studies
that had not yet finished recruiting.
Assessment of heterogeneity
We have explored heterogeneity between the trials using the Chi
2 test for heterogeneity, using a 10% level of significance, and the
I2 statistic. We complied with the recommendations put forward
in the Cochrane Handbook, which determine that a 0% to 40%
might not be important; 30% to 60% may represent moderate
heterogeneity; 50% to 90%may represent substantial heterogene-
ity; and 75% to 100% considerable heterogeneity (Deeks 2008)
Assessment of reporting biases
We planned to explore reporting bias using funnel plots and het-
erogeneity when doing a meta-analysis for 10 or more studies.
Since only five studies met the criteria, a funnel plot could not be
made.
Data synthesis
The need to analyse the results according to a fixed-effect or ran-
dom-effects analysis was explored (Laird 1990); or in the event of
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significant heterogeneity a decision may be made to not present
a combined result of the two (Schulz 1993). We have used fixed-
effect models throughout, except where heterogeneity exists in
which case a random-effects model was used as it introduces less
bias than excluding trials altogether. The number needed to treat
to benefit (NNT or NNTB) and the number needed treat to harm
(NNTH) were calculated. The mean difference was used to cal-
culate the benefit (absolute change expressed as both a percentage
and in its original units) for continuous outcomes such as HAQ,
SF-36 and radiological changes.
When studies were homogeneous we pooled them (for example,
similarities between participants, interventions, outcome assess-
ment). Forest plots (mean differences and risk ratios) were done.
We chose the fixed-effect model to pool the data because statistical
heterogeneity was not high and it was reasonable from a clinical
point of view.
We have used the ’Grades of Recommendation, Assessment, De-
velopment and Evaluation’ developed by the GRADE Working
Group for grading the quality of evidence. The GRADE approach
specifies four levels of quality. The highest quality rating is for
randomised controlled trial evidence. Review authors can, how-
ever, downgrade randomised trial evidence to moderate, low, or
even very low quality evidence depending on the presence of five
specific factors (see Handbook Chapter XII (Higgins 2008)). We
used the GRADE software to provide an overall grading of the
quality of the evidence by outcome.
Subgroup analysis and investigation of heterogeneity
If heterogeneity was detected then a subgroup analysis would be
carried out (Yusuf 1991), or a meta-regression, in order to explain
it (Thompson 1999). Subgroup analyses were planned for the du-
ration of the illness (approximately three years evolution), patients’
sex, drug dose and administration and methodological quality.
Sensitivity analysis
The main criteria applied to measure the risk of bias included:
blinding of participants, allocation concealment, random se-
quence generation, incomplete outcome data, selective outcome
reporting and other sources of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
See flow chart (Figure 1)
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We screened 52 papers. We excluded 27 related to reviews; 17 that
had a different drug of study; and two related to trials for which
no informative papers were published. Six full text articles were
assessed further.
Included studies
Finally five trials involving 2394 people for effectiveness studies
andfive trialswith 2094people for safety studieswere included (see
Characteristics of included studies table and Table 1). Of the trials
identified (CDP870-004 2001; Choy 2002; FAST4WARD 2005;
RAPID1 2005;RAPID2 2007;CDP870-014 2009), all trialswere
used to assess effectiveness and safety except two (CDP870-004
2001; Choy 2002). Due to the short follow-up to assess effective-
ness in Choy’s study, it was only included for safety data. The re-
sults of the other study (CDP870-004 2001) on effectiveness were
considered in the present review and the study did not report any
safety data. The data from these two studies could not be meta-
analysed together with the rest of the studies due to the different
follow-ups and doses used.
Phase II
Choy 2002
This was an 8-week, randomised, double-blind, placebo-con-
trolled study. Thirty-six patientsmeeting the AmericanCollege for
Rheumatology (ACR) classification criteria for rheumatoid arthri-
tis were included. Patients were required to have active disease, de-
fined by having at least three of the following four criteria: tender
joint count (TJC) > 6, swollen joint count (SJC) > 3 (based on
28 joint counts), morning stiffness of > 45 minutes, and ESR >
28 mm/h. Patients had to have failed treatment with at least one
DMARD and have been off DMARD treatment for at least four
weeks. Corticosteroids at a dose of prednisolone ≤ 7.5 mg per day
were permitted.
The trial was a phase II ascending-dose group study in which 36
patients were divided into three groups. Each group of 12 patients
was randomly assigned to a single intravenous infusion of placebo
(four patients) or 1, 5 or 20 mg/kg of certolizumab (eight patients
each). Thus a total of 12 patients were allocated placebo. The
outcomes of the ACR20, ACR50, ACR70; pain score (0 to 10 cm);
disease activity score (DAS); tender joint count (TJC); swollen
joint count (SJC); Health Assessment Questionnaire (HAQ); and
C-reactive protein (CRP) were examined after one, two, four, six
and eight weeks of treatment. Following the blinded period of
eight weeks, 32 patients received a single open-label infusion of
either 1, 5 or 20 mg/kg of certolizumab, if the initial infusion
was well tolerated. This study was only considered to assess safety
because follow-up was less than eight weeks.
No funding sources were declared in the publication but Dr Choy
confirmed that this study was funded by Celltech.
CDP870-004 2001
This was a double-blind, multiple dose, 12-week, placebo-con-
trolled dose-ranging study to compare the efficacy and safety of
certolizumab pegol and placebo in 326 participants with a history
of inadequate response or intolerance to at least one DMARD and
active RA at screening. DMARD therapywas discontinued at least
one month prior to the start of the study; concomitant NSAID
and ≤ 10 mg prednisone or equivalent/day were allowed. Patients
in panel 1 received: 50, 100, 200, 400 mg subcutaneously (sc)
every four weeks; and in panel 2: 600 and 800 mg sc every four
weeks. The primary measure of efficacy was ACR20 responder
rates at week 12. A number of secondary efficacy measures were
also included, for example the ACR20 at all available visits except
week 12, ACR50, ACR70, a subset of the ACR criteria, DAS. We
only got data for ACR20, ACR50 and ACR70 in panel 1 (Key-
stone study) and panel 2 from the EMEA 2009. No data were
described for adverse events that included mortality, tuberculosis,
serious adverse events and serious infections.
Phase III
We retrieved four phase III trials (FAST4WARD 2005; RAPID1
2005; RAPID2 2007; CDP870-014 2009). All the studies used
a lyophilised formulation but RAPID2 used a liquid formulation
that was a proposed commercial form. All trials were funded by
UCB.Data fromCDP870-014 2009 were provided byUCB from
the Clinical Study Summary www.clinicalstudyresults.org/docu-
ments/company-study˙4348˙0.pdf and the EMEA 2009 reports.
This study was completed in 2004 but there are not any papers
from this trial.
In Table 1 demographic and baseline characteristics in phase III
trials are shown: age, gender, rheumatoid factor (RF) positive,
MTX concomitant dose, number of previous DMARDs, basal
HAQ, and basal DAS28 among others outcomes. We have also
added the follow-up. Table 2 provides the flow chart of patients
in phase III studies.
Excluded studies
Themain reasons for exclusionwere: 1) reviews, 2) different drugs,
3) another outcome reported. See the table of Characteristics of
excluded studies.
Risk of bias in included studies
All studies reported adequate methods of randomisation and al-
location concealment. Blinding was unclear for some trials. The
overall possibility of bias seemed to be low. Refer to Figure 2 and
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’Risk of bias’ tables for more information on all criteria for risk of
bias.
Figure 2. Methodological quality summary: review authors’s judgements about each methodological quality
item for each included study.
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Allocation
All six studies but the two phase II trials (CDP870-004 2001;
Choy 2002) reported adequatemethods of allocation concealment
and randomisation. Neither the authors nor UCB provided any
further detail. Four studies (FAST4WARD 2005; RAPID1 2005;
RAPID2 2007; CDP870-014 2009) used the interactive voice
response system (IVRS) method of allocation concealment. The
risk of bias seemed low.
Blinding
RAPID1 2005 did not disclose the methods of blinding but ex-
plained: “Patients who withdrew at week 16 or who successfully
completed the trial were offered enrolment in an open-label ex-
tension study of certolizumab pegol 400 mg every 2 weeks. Ra-
diographs were read at a central location by 3 independent read-
ers. Readers were blinded as to the patient’s identity, clinical data,
treatment, and time point (sequence) at which the radiograph was
taken”.
RAPID2 2007 did not disclose the methods of blinding, but ex-
plained: “Radiographs were read centrally and blinded (for treat-
ment, visit and patient identification) and independently by two
experienced readers”.
FAST4WARD 2005 disclosed methods of blinding: “Solutions of
active drug or placebo were prepared by the pharmacist or other
unblinded, qualified site personnel, before distributing to blinded
study personnel for administration”.
CDP870-014 2009 did not disclose the methods of blinding
(“Subjects who completed the current study or who withdrew on
or after the Week 12 visit were eligible to participate in the open-
label safety study (CDP870-015)”. Neither the EMEA report nor
the clinical study summary that UCB sent to us provided any fur-
ther information on this issue.
CDP870-004 2001 did not disclose the methods of blinding.
Choy’s study disclosed themethods of blinding: “Placebo (sodium
acetate buffer) was given similarly as a single intravenous infusion
of 100 ml over 60 min”. Is unlikely that the blinding could have
been broken.
In some studies we had some information about blinding (regard-
ing the readers of radiographs) but not for the major outcomes
(ACR50, HAQ, etc). So the risk of bias for outcomes such as
ACR50 and HAQ could be different in each study, and the risk
of bias was unclear.
Incomplete outcome data
All studies except the small phase II trial (CDP870-004 2001)
reported adequate methods of handling missing outcome data.
In all the studies, as expected there were higher losses in the placebo
groups compared with the active treatment groups, due to the lack
of efficacy of the placebo. We have no data from CDP870-004
2001; and in the Choy 2002 study, 50% were missing data in the
placebo group versus 9% in the different certolizumab groups. In
phase III trials, missing data were: 1) 19% in the placebo group
and 20% in the certolizumab group in FAST4WARD 2005; 2)
33% in the placebo group and 26% in the certolizumab group
in CDP870-014 2009; 3) 79% in the placebo group, 31% in the
certolizumab 200 mg group and 35 % in the certolizumab 200
mg group in RAPID1 2005; 4) 87% in the placebo group, 30%
in the certolizumab 200 mg group and 27% in the certolizumab
200 mg group in RAPID2 2007.
The risk of bias seemed low.
Selective reporting
We could not discard the possibility of selective reporting in the
trials, but not for the major outcomes. The risk of bias seemed
high in 50% of studies.
FAST4WARD 2005 was poorly described: “ACR20, safety, health
outcome measures and immunogenic profiles”; so it was difficult
to know if some outcomes were not reported.
In CDP870-014 2009 ACR20, HAQ disability index and acute
phase reactant (CRP) were described in the clinical study sum-
mary but the results only showed ACR20; no papers have been
published.
All the outcomes reported in RAPID1 2005 on the Internet were
shown in the paper.
We did not find details on the Internet of the protocol for RAPID2
2007 and Choy 2002.
In CDP870-004 2001 ACR20, ACR50, ACR70, a subset of the
ACR criterion, DAS responder rates at week 12 were studied, but
only ACR20 was reported.
Other potential sources of bias
All studies included in this review were sponsored by themanufac-
turer of certolizumab. We did not detect other potential threats to
validity, such as early stopping or imbalance in the groups (relating
to the baseline characteristics).
We searched for more trials as well as for more information re-
garding those trials that we had found as unpublished trials during
the second search: NCT00160602 (see Characteristics of ongoing
studies table). But no information was found, neither from the
sponsors nor from any publication, so we cannot discard a serious
bias.
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Effects of interventions
See: Summary of findings for the main comparison Summary
of findings certolizumab pegol 200 mg sc (with or without MTX)
versus placebo (with or without MTX) for rheumatoid arthritis in
adults
When we were about to finish this review, new data came out
(from EMEA 2009; NICE 2009). As new trials were reported,
we decided to perform less restrictive searches to be sure that we
had not missed more trials. The strategies for these searches are
presented in the appendices section (Appendix 1; Appendix 2;
Appendix 3; Appendix 4; Appendix 6; Appendix 7).
The analysis was performed depending on the drug exposure time
for doses of 200 mg and 400 mg sc, since these were the doses
that appeared in the trials. As we had two periods of follow-up
(six months and one year) in one study, we could not pool them,
thus we pooled each outcome at each follow-up.Moreover, we had
studies with more than one dose so we split the placebo arm to
obtain a pooled value.
We used RR and the Peto odds ratio; we did not find any out-
come using different measures for the same construct, therefore
standardized mean difference was not used in this review.
Major outcomes
ACR50
Significant improvements were observed for all doses at any given
time for the ACR50, ACR20 and ACR70. We calculated NNT
from the risk ratio according to the formula NNT= 1/ACR*(1-
RR), where ACR = assumed control risk and RR = risk ratio (see
effectiveness tables, ACR Table 3, Data and analyses).
The main outcome ACR50 showed, for any dose at 24 weeks, a
RR of 3.26 (95% CI 2.47 to 4.29) and at 52 weeks a RR of 2.58
(95% CI 1.83 to 3.62). The NNT was close to 5.
Adverse events (see Table 4)
We reported all adverse events in Data and analyses but not all of
them were commented on in the present section, only those that
we thought were the most interesting (see Table 4). We used Peto
odds ratio (Peto OR) where the events rate was < 10%.
Any adverse event
We pooled data on any adverse event from four trials (CDP870-
004 2001; FAST4WARD 2005; RAPID1 2005; RAPID2 2007):
certolizumab 200 mg RR 1.21 (95% CI 1.08 to 1.35) and cer-
tolizumab 400 mg RR 1.20 (95% CI 1.10 to 1.30).
We excluded Choy’s study because it showed more events than
patients in the certolizumab group (62 events in 24 patients), as
well as in the placebo group (19 events in 12 patients). Thus the
RR could not be estimated.
Serious adverse events (SAE) as defined in the studies
Important adverse events were reported in all the studies. In
FAST4WARD2005 theywere not defined and, furthermore, were
calculated as the number of new cases per 100 patient-years (cen-
sored at the time of the first event by preferred term). In RAPID1,
adverse events were defined according to the Medical Dictionary
for Regulatory Activities (version 9.0). RAPID2 2007 described
which severe infections were considered: erysipelas, disseminated
tuberculosis, peritoneal tuberculosis, pulmonary tuberculosis, gas-
troenteritis, postoperative wound infection, tooth abscess and
urosepsis, etc. The clinical study summary of CDP870-004 2001
did not define serious adverse events.
We reported adverse events depending on the doses: SAE for cer-
tolizumab 200 mg and any follow-up (Peto OR 2.02, 95% CI
1.24 to 3.30) and SAE for certolizumab 400 mg and any follow-up
(Peto OR 1.92, 95% CI 1.30 to 2.83); 153 events were reported
in the certolizumab groups versus 45 events in the control groups.
See more details in Analysis 8.6; Analysis 9.7.
Adverse events: severe intensity as defined in the studies
There were no differences in the number of severe intensity adverse
events between patients treated with 400mg of certolizumab (Peto
OR 1.24, 95% CI 0.79 to 1.95) and patients treated with 200 mg
(RR 1.21, 95% CI 1 to 1.47). Moreover, treatment interruptions
were similar with both doses: 68 events in the certolizumab groups
were reported versus six events in the control groups. See more
details in Analysis 8.4; Analysis 9.4.
Adverse events leading to death as defined in the studies
We did not find statistically significant differences in the num-
ber of adverse events leading to death between placebo and cer-
tolizumab-treated groups. Eight events in the certolizumab groups
were reported versus two events in the control groups. Although
the confidence interval was wide and non-significant for death, it
has to be highlighted that it is due to the absence of mortality in
the control groups. See more details in Analysis 8.8; Analysis 9.8.
Death
In RAPID1 2005, 2008, in the placebo treated group one patient
died of myocardial infarction. In the certolizumab 200 mg treated
group, one patient died of hepatic neoplasm, another died of peri-
tonitis and cirrhosis and one more died during the post-treatment
period (> 84 days after the last injection). In the certolizumab 400
mg treated group one died of cerebral stroke, one of myocardial
necrosis, one of cardiac arrest and one of atrial fibrillation.
InRAPID2 2007, 2008, in the certolizumab 200mg treated group
one patient died of myocardial infarction; one patient died during
the study in the certolizumab 400 mg treated group (fracture,
shock), which was assessed as unlikely to be related to the study
medication.
In Choy 2002, in the open phase, one patient in the certolizumab
treated group (20 mg/kg CDP870) died from complications fol-
lowing rapid drainage of a large, chronic rheumatoid pericardial
effusion. In the opinion of the investigator this event was unre-
lated to treatment with CDP870.
No deaths were reported in FAST4WARD 2005 and CDP870-
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For certolizumab 200 mg the Peto OR was 1.85 (95% CI 0.29 to
11.86); and for certolizumab 400 mg the Peto OR was 2.16 (95%
CI 0.40 to 11.79).
Serious adverse infections (SAI)
This composite outcome included any severe event of infections,
infestations and tuberculous infections (disseminated tuberculo-
sis, peritoneal tuberculosis, pulmonary tuberculosis, lymph node
tuberculosis, tuberculosis), lower respiratory tract infection and
obstructive chronic bronchitis with acute exacerbation. More seri-
ous adverse infections were reported in the certolizumab 200 mg
treated group (Peto OR 3.30, 95% CI 1.45 to 7.51) and in the
certolizumab 400 mg treated group (Peto OR 3.25, 95% CI 1.65
to 6.39); 58 events were reported in the certolizumab groups ver-
sus six events in the control groups. See more details in Analysis
8.7; Analysis 9.6.
Tuberculosis
A significant increase in the number of cases of tuberculosis was
observed in both groups: five patients (0.8%) in the certolizumab
200 mg group and five patients (0.7%) in the certolizumab 400
mg group versus no cases in either placebo group: certolizumab
200 mg Peto OR 4.53 (95% CI 0.71 to 29.11); certolizumab 400
mg Peto OR 4.55 (95% CI 0.71 to 29.11). Both doses (200 and
400 mg) appeared to have a non-significant confidence interval
because of the absence of events in the control group. Only one
phase III trial (CDP870-014 2009) did not provide any data on
tuberculosis incidence. InRAPID1a total of five patients (one each
from Estonia, Bulgaria, and Ukraine; two from Russia) developed
tuberculosis after 1.5 to 9 months of treatment. In RAPID2, five
patients in the certolizumab pegol arms developed tuberculosis
(three from Russia, one each from Poland and Latvia).
Different infections
The types of different infections reported (pneumonitis, bacterial
arthritis, mastitis, urinary tract infection, herpes viral, bacterial
peritonitis and opportunistic infection) are presented in figures
in ’Data and analyses’. Upper respiratory tract infection and na-
sopharyngitis were more frequent with certolizumab 200 mg than
in the placebo group (Peto OR 2.21, 95% CI 1.15 to 4.25; Peto
OR 2.71, 95% CI 1.30 to 5.66 respectively). Nasopharyngitis
was more frequent with certolizumab 400 mg than in the placebo
group (Peto OR 2.99, 95% CI 1.50 to 5.95).
Other adverse events
Hypertension was more frequent with both doses of certolizumab
than in the placebo group: certolizumab 200 mg, Peto OR of
2.81 (95% CI 1.38 to 5.75); certolizumab 400 mg Peto OR of
3.23 (95% CI 1.71 to 6.08). The following secondary events:
headache, fever, blood disorders, laboratory disorders, abdominal
pain, nasopharyngitis, nausea, respiratory tract infections, urinary
tract infections, neck pain, congestive heart failure, pruritus and
anaphylaxis are described in detail in the ’Data and analyses’ tables
8 and 9.
Health-related quality of life
The Health Assessment questionnaire (HAQ) scale ranged from
0 to 3, with a negative change indicating improvement.
The findings showed an improvement in quality of life measured
as HAQ and SF-36 (in mental and physical components) at any
time of follow-up (see ’Health-related quality of life’ tables, Table
5).
HAQ disability index (Di), 24 weeks, any dose: MD -0.41 (95%
CI -0.46 to -0.35); HAQ-Di 52 weeks, any doses: MD-0.43 (95%
CI -0.52 to -0.35).
SF-36 physical component summary (PCS), 24 weeks, any dose:
MD 5.47 (95% CI 4.47 to 6.48); SF-36 PCS, 52 weeks, any dose:
MD 6.47 (95% CI 5.13 to 7.81).
SF-36 mental component summary (MCS), 24 weeks, any dose:
MD 4.29 (95% CI 2.95 to 5.63); SF-36 MCS, 52 weeks, any
dose: MD 4.30 (95% CI 2.57 to 6.03).
Minor outcomes
We have included in Summary of findings for the main
comparison, DAS remission, some radiological changes and with-
drawals.
ACR20 and ACR70
ACR20 for any dose at 24 weeks: RR 2.57 (95% CI 2.16 to 3.05);
at 52 weeks: RR 2.06 (95% CI 1.61 to 2.62).
ACR70 for any dose at 24 weeks: RR 3.93 (95% CI 2.41 to 6.41);
at 52 weeks: RR 3.14 (95% CI 1.86 to 5.29).
Pain
The appearance of pain at the injection site in the certolizumab
200 mg treated group was not statistically significant (Peto OR
4.60, 95% CI 1.05 to 20.10); certolizumab 400 mg treated group
(PetoOR 1.74, 95%CI 0.41 to 7.42). These wide CIs were due to
the fact that pain was not observed in any placebo group. Similar
values were observed for local reactions at the injection site.
Patients’ assessment of arthritis pain (visual analogue scale (VAS)
score 0 to 100 mm) improved at any dose and at any time. At
week 24, the overall mean difference (MD) was -21.63 (95% CI
-24.23 to -19.02) and at week 52 the MD was -23.48 (95% CI -
27.09 to -19.88).
DAS-28
Significant improvements were observed for all doses and at any
given time. The proportion of patients achieving remission (< 2.6)
was higher in the certolizumab 200 mg group than in the placebo
group (Peto OR 3.88, 95% CI 2.33 to 6.45 at 24 weeks; Peto OR
10.36, 95% CI 3.29 to 32.58 at 52 weeks).
Despite the report from the EMEA,we could not extractmore data
on adverse events because those data were disclosed as combined
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data, without the number of events in each trial; moreover, the
adverse events were grouped by “primary system organ class”.
Radiological changes
Radiological changes were expressed as modified total Sharp scores
(mTSS), erosion score (ES) and joint space narrowing (JSN). All
certolizumab groups showed improvements compared to placebo
in the mean changes from baseline. There was a clear radiological
improvement, regardless of the dose, that was associated with drug
exposure time (see Radiological changes Table 6).
Erosion score (ES), any dose, 24 weeks: MD -0.70 (95% CI -0.98
to -0.42).
Erosion score (ES), any dose, 52 weeks: MD -1.45 (95% CI -2.11
to -0.79).
Joint space narrowing (JSN), any dose, 24 weeks:MD -0.50 (95%
CI -0.79 to -0.21).
Joint space narrowing (JSN), any dose, 52 weeks:MD -1.10 (95%
CI -1.88 to -0.33).
Modified total Sharp scores (mTSS), any dose, 24 weeks: MD -
1.19 (95% CI -1.67 to -0.69).
Modified total Sharp scores (mTSS), any dose, 52 weeks: MD -
2.50 (95% CI -3.70 to -1.30).
Withdrawals
There were more withdrawals because of lack of efficacy in the
placebo group than in the certolizumab group. Adverse events
leading to withdrawal did not seem to be dose dependent.
The placebo-treated patients withdrew because of lack of efficacy.
Withdrawn at any dose and at any follow-up: RR 0.39 (95% CI
0.36 to 0.43) (Analysis 45.1).
Withdrawn at any dose and at any follow-up due to lack of efficacy:
RR 0.29 (95% CI 0.26 to 0.33) (Analysis 45.2).
Withdrawn at any dose and at any follow-up due to adverse events:
RR 2.17 (95% CI 1.15 to 4.10) (Analysis 45.3).
Assessment of heterogeneity
When we analysed ACR50 response with 400 mg at week 24
for the four studies, we obtained a low probability of statistical
heterogeneity, I2 = 23%. Thus, heterogeneity did not seem to
be important in the studies. When we analysed all studies but
CDP870-014 2009, we obtained no statistical heterogeneity, I2
= 0%. When we reviewed the demographics of phase III stud-
ies (Table 1): CDP870-014 2009 had a lower percentage of fe-
males (69%) than the other studies (83.6% in FAST4WARD
2005, 83.2% in RAPID1 2005 and 81.6% in RAPID2 2007) and
higher MTX concomitant dose (mg/week) of 16.8 (versus 13.6 in
RAPID1 2005 and 12.5 in RAPID2 2007). This could explain
the heterogeneity results.
We did not find an important clinical or statistical heterogeneity
that could hinder combining the data of the trials for the most
important variables.
The funnel plot was not calculated to assess publication bias in
view of the small number of studies for most of the results.
Subgroup analysis
We have not performed subgroup analysis. See the Differences
between protocol and review.
Sensitivity analysis
We have done a sensitivity analysis with the major outcomes
ACR50 and HAQ. The results remain unchanged when we re-
analysed studies with adequate sequence generation (ACR50 RR
5.55, 95%CI 4.45 to 6.93), good allocation concealment (ACR50
RR 5.55, 95% CI 4.45 to 6.93), adequate blinding (ACR50 RR
6.14, 95% CI 2.21 to 17.05), lack of incomplete outcome data
(ACR50 RR 5.74, 95% CI 4.56 to 7.23), free of selective report-
ing (ACR50 RR 5.74, 95% CI 4.56 to 7.23) and free of other
bias (ACR50 RR 5.73, 95% CI 4.52 to 7.25). HAQ did not show
changes in the same sensitivity analysis.
D I S C U S S I O N
Summary of main results
The main results showed that when certolizumab pegol is used
with or without MTX it produces a better efficacy than placebo
for achieving ACR20, ACR50, ACR70, lower DAS 28 scores, and
a higher remission of RA. The improvements in the physical and
mental components measured by SF-36 and HAQ were signifi-
cantly more impressive in the certolizumab pegol group than the
placebo group. The improvements in radiological changes mea-
sured as modified total Sharp scores (mTSS), erosion scores (ES)
and joint space narrowing (JSN) were also significantly more im-
pressive in the certolizumab pegol groups than in the placebo
group. Certolizumab pegol was associated with a higher risk of
total adverse events than the placebo group. In addition, the risk
of serious infections events was higher in the certolizumab groups
than in the placebo group.
Withdrawals due to any reason and withdrawals due to an absence
of efficacy were lower in the certolizumab pegol group than in
the placebo group. This could indicate a better efficacy for cer-
tolizumab pegol compared to placebo.
The ACR50 at 24 weeks for any dose was RR 3.26 (95% CI 2.47
to 4.29), quite similar to that obtained when the study with the
highest weight (RAPID1 2005) was removed (RR 4.70, 95% CI
2.93 to 7.54). The statistical heterogeneity was low (I2 = 8%).
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Moreover, when we analysed trials where MTX was added to the
placebo group versus just placebo as comparator, the RR remained
similar (RR 5.79, 95% CI 4.31 to 7.78).
This review has shown that certolizumab is effective when used
with or withoutMTX in loweringRA disease activity (DAS-28), as
well as improving RA disease activity (ACR20, ACR50, ACR70).
The NNT for the ACR50 rates at any follow-up period and any
dose was around 4, similar to that obtained in other reviews for the
anti-rheumatic anti-TNF treatments: golimumab (Singh 2010),
infliximab (Blumenauer 2002), etanercept (Blumenauer 2003;
Chen2006), abatacept (Maxwell L 2008), rituximab (Lopez-Olivo
2008) and adalimumab (Navarro Sarabia 2005).
The improvement in functional limitations has been shown to
be important. HAQ scores in patients treated with certolizumab
showed mean differences from placebo that ranged from 0.35 to
0.42 on a 0 to 3 scale.
Not all the variables that we analysed appeared in all the stud-
ies, and only one study provided information at 52 weeks. There-
fore, conclusions on effectiveness with long-term treatment should
be made with caution. The lack of information in studies like
FAST4WARD 2005 concerning some variables, such as the physi-
cal component (SF-36 physical component summary, PCS) or the
mental component (SF-36 mental component summary, PCS),
has caused an underestimation of the statistical power of the
present review when performing the meta-analysis.
Amajority of patients in clinical trials ofDMARDsover one to two
years do not show radiographic progression. These data therefore
reflect progression in fewer than half of the included patients and,
indeed, if radiographic measurement error is taken into account
an even smaller proportion of patients show radiographic pro-
gression. Laboratory and radiological changes are surrogate end-
points. They could be statistically but not clinically significant.
We do not have any information about the use of prospective or
routine monitoring, spontaneous reporting, use of checklists, or
systematic surveys of patients. Moreover, we do not have any defi-
nitions of reported adverse effects. No categories of adverse effects
were reported by the investigators. The papers do not provide a
definition for the terms serious adverse events, severe infections,
adverse events of mild intensity and adverse events of severe in-
tensity. None of the trials were designed with safety as the primary
outcome. However, we have found more serious infections and
more tuberculosis infections as adverse events. In addition, only
one trial was designed with a long duration, so we cannot rule out
that more adverse events, or more intense adverse events, could
occur over time.
The review did not show a statistically significant increase in deaths
(10 deaths in the certolizumab pegol group versus two in the
placebo group), but in the open-label trials mentioned by EMEA
2009, 23 additional deaths were reported. So there could be a
power problem with our meta-analysis, and an increase in deaths
cannot be ruled out.
In the present review, a non-statistically significant increase in the
number of tuberculosis infections was shown at 24 weeks and 52
weeks, even for patients with low probability (explored by thoracic
x-rays, clinical history, tuberculin tests, etc.) of having the disease
before starting the treatment. Our data (10 participants experi-
enced tuberculosis) do not match the EMEA 2009 data that de-
scribed “..30 subjects experienced 32 events of tuberculosis. Fifteen
had pulmonary tuberculosis, 5 had tuberculosis, 5 disseminated
tuberculosis, 1 peritoneal tuberculosis, 3 subjects had lymph node
tuberculosis, and 2 subjects had tuberculous pleurisy”. However,
our data matches the data reported in the papers. These trials were
performed in different countries with a different prevalence of tu-
berculosis. In the RAPID1 2005 and RAPID2 2007 papers, all the
reported tuberculosis cases occurred in Eastern Europe (Russia,
Latvia, Ukraine, Estonia, Bulgaria and Poland) and the authors
assumed a high incidence of tuberculosis and a high prevalence
of latent tuberculosis in all of these countries. However, a high
incidence of tuberculosis is a rate of 40 per 100,000 population or
higher. Only Russia, Ukraine and Latvia can be considered coun-
tries with a high incidence of tuberculosis, with 110, 102 and 53
per 100,000 population respectively (WHO 2009). In summary,
it can be concluded that, as expected for other anti-TNF agents,
certolizumab pegol is associated with an increased risk of tubercu-
losis, not only in countries with a high incidence of tuberculosis.
The risk of serious infections with certolizumab 200 mg and cer-
tolizumab 400 mg (Peto OR 3.30, 95% CI 1.45 to 7.51; Peto
OR 3.25, 95% CI 1.65 to 6.39 respectively) is similar to other
anti-TNFs; Bongartz 2006 reported a RR of 2 (95% CI 1.3 to
3.1). This adverse effect seems to be common to all anti-TNFs.
With regard to infections, in two studies (FAST4WARD 2005;
RAPID1 2005) patients were non-eligible if they had a previous
history of infections or a high risk of infections according to the
researcher’s criteria, thus the populations in the trials might not
represent the real population.
The review of Bongartz 2006 and the FDAwarnings issued on 04/
06/2008 and 09/04/2009 indicate the possibility of developing
lymphomas and other cancers in children and young adults. How-
ever, we were not able to detect these diseases. The studies were
too short to detect an increase in cancer incidence. In addition, we
did not detect an increase in histoplasmosis, other invasive fungal
infections or leukaemia, as was mentioned in the FDA warning
issued on 04/09/2008, again possibly because the studies were too
short.
Overall completeness and applicability of
evidence
We have included all RCTs available for patients with RA.
This evidence is relevant and applicable because it is the best data
obtained from those RCTs. The present systematic review has a
potential weakness regarding themeta-analysis, namely the lack of
information from one RCT (NCT00160602). The fact that the
results of that trial were not published could be that good results
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for effectiveness were not obtained or the rates of adverse events
were higher than expected. However, even in those instances the
possibility that one trial could change the results of the major
outcomes (ACR50, HAQ, etc) or increase the significance of some
adverse events seems to be low.
At least in the most important studies (RAPID1 2005; RAPID2
2007), patients could not participate if they had previously partic-
ipated in other anti-TNF trials and did not show a good response.
Consequently, it should be considered that the studied population
could possibly represent a population with a high response rate to
anti-TNF agents.
Quality of the evidence
The quality of evidence found in the trials included in this review
appears to be high because the studies reported adequate methods
of allocation concealment and sequence generation. Methods of
blinding for all outcomes were disclosed in one phase III trial;
and it was only assured for the readers of radiographs in two more
trials. Moreover, there are two more sources of concern for the
quality of evidence: 1) we did not have access to information,
such as complete study protocols, to make definitive judgments
regarding the risk of selective reporting; and 2) we have found
an unpublished trial. However, we doubt that more studies are
likely to change the overall estimates. Using GRADE, the quality
of evidence is variable, from low for some adverse events such as
death (basically due to the low number of events in both groups)
to high for ACR20, ACR50, ACR70 and for DAS remission.
Potential biases in the review process
This systematic review has some limitations. Initially, the present
review was performed based on four trials (Choy 2002;
FAST4WARD 2005; RAPID1 2005; RAPID2 2007), the only
ones retrieved in the first search. However, when we were about to
finish the review, other trials came to light that had to be included
as well: one phase II and two phase III trials, namely CDP870-004
2001, and two phase III trials (CDP870-014 2009 without all
the results, and NCT00544154 with no data at all). The finding
of these trials at this late stage was surprising, because these trials
were completed many years ago, but the data were either never
disclosed or only partially disclosed. In fact, CDP870-004 2001
was cited in a conference proceeding, and the other two trials were
finished in 2004 and 2005 but no data were published. Due to the
limited scope of the data, we tried to obtain more information by
contacting the sponsors. According to the sponsors the data were
available at www.studyresults.org. We could not find any informa-
tion on that website (accessed 10-12-2009) due to technical prob-
lems. After reporting this problem to the sponsors, they sent us the
clinical study summary of CDP870-014 2009, and provided us
with a new link to it, but no other information forNCT00544154
and CDP870-004 2001. Eventually, we decided to find out why
the sponsors did not publish the information regarding the above
clinical trials. Their justification was that making more data pub-
licly available could jeopardize future publications. However, in
a second search, we came across new data for all of the trials but
NCT00544154 in two reports (EMEA 2009; NICE 2009). After
reading these reports, again to our surprise the NICE report was
made by the sponsors as a systematic review, but none of the two
phase III trials were reported. In the EMEA report, the phase III
trial NCT00544154 was also missing.
Our explanation for the absence of publications of some of the
trials carried out with certolizumab pegol in RA could be, as the
EMEA reported in CDP870-004 2001, that the difference in ef-
fectiveness between certolizumab pegol and control was lower than
that observed with other anti-TNF agents in similar populations.
This discrepancy led the sponsors to question the clinical relevance
of their results, including secondary end-points.
The NICE 2009 (www.nice.org.uk/nicemedia/
live/11903/45812/45812.pdf) and EMEA 2009 reports provided
data to improve the information regarding the quality of the trials
included in our review, such as randomisation, allocation conceal-
ment, withdrawals, demographics, etc. (see Table 1; Table 2). De-
spite the fact that these reports contained tables of adverse events,
we could not use them in our review due to the way the data were
presented. For example, the numbers of adverse events in all the
trials were added together, both in NICE 2009 and EMEA 2009.
Furthermore, the adverse effects were grouped in both reports ac-
cording to the primary organ system affected, whereas in the pa-
pers corresponding to the trials the adverse effects were specified
one by one and not grouped.
Agreements and disagreements with other
studies or reviews
The NICE 2009 and EMEA 2009 reports, performed as system-
atic reviews, have shown results quite similar to those in our re-
view. The effectiveness (ACR50) of another anti-TNF agent was
also quite similar to certolizumab pegol.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Certolizumab pegol is the first pegylated anti-TNF agent approved
by the FDA for the treatment of adult patients with moderate
to severe, active RA. This review revealed an improvement in the
clinical results (ACR20, ACR50, ACR70, and DAS-28 remission
as well as HAQ scores) and SF-36 when patients were treated with
certolizumab pegol. From week 16, it was associated with inhi-
bition of the structural joint damage progression from baseline
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in the modified total Sharp score (mTSS) at 24 and 54 weeks of
treatment compared to MTX alone. Adverse events were more
frequent in patients treated with certolizumab pegol than in those
treated with placebo. An increase in the number of serious infec-
tions, especially tuberculosis, has been observed.
Implications for research
Limited data regarding the safety of certolizumab pegol, espe-
cially in the long term, are available. The preferred target for fu-
ture research on treatments with certolizumab pegol should be the
youngest population, since it is known that this population has
developed lymphomas, tumours and leukaemia when treated with
other anti-TNF agents and these adverse events have not been
reported in the studies included in the present review. Clinical
trials in this cohort population and follow-up studies will provide
information in this regard.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CDP870-004 2001
Methods Double-blind, multiple dose, 12-week, placebo-controlled dose-ranging study
Participants 326 subjects with a history of inadequate response or intolerance to at least one DMARD
and active RA at screening
Interventions Patients received placebo, 50, 100, 200, 400, 600 and 800 mg sc q4w in two dose groups,
panel 1 and panel 2
Outcomes ACR20, ACR50, ACR70, subset of the ACR criterion, DASResponder Rates at week
12
Notes We only have data from ACR20 at week 12
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk The EMEA report and UCBdid not report
any detail
Allocation concealment? Unclear risk The EMEA report and UCBdid not report
any detail
Incomplete outcome data addressed?
Placebo
Low risk Only data for ACR20
Incomplete outcome data addressed?
certolizumab sc
Low risk Only data for ACR20
Incomplete outcome data addressed?
All outcomes
Low risk Only data for ACR20
CDP870-014 2009
Methods Randomised double-blind placebo controlled trial
Participants Patients with rheumatoid arthritis (RA) who are partial responders to MTX. RA defined
by the ACR classification criteria who had received MTX for ≥ 6 months (with at a
stable dose of ≥ 15 mg/week ) before baseline were included. At inclusion, patients had
to have active disease as defined by: Active disease was defined as ≥ 9 tender and 9
swollen joints at screening and at baseline, with either an erythrocyte sedimentation rate
(ESR; Westergen) ≥ 30 mm/hour or a C-reactive protein (CRP) level ≥ 15 mg/litre.
Other DMARDs had to be discontinued at least 28 days before baseline or five half-
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CDP870-014 2009 (Continued)
lives,whatever longer, prior to first dose of study drug. We do not have more exclusion
criteria in the files reported from UCB but probably were similar to another Phase III
trial
It was a 24 weeks, phase III, double-blind, randomised, multicenter, placebo-controlled
study. 250 patients were randomised to one of two regimens of subcutaneous Cer-
tolizumab pegol 400mg or placebo sc every 4weeks for a total of 6 injections. Methotrex-
ate treatment continue during the study taken prior to enrolment in the study. Subjects
who completed the current study or who withdrew on or after the Week 12 visit were
eligible to participate in the open-label safety study (CDP870-015)
The primary objective of this study was to compare the efficacy of certolizumab pegol
(CDP870 or CZP) in combination with methotrexate (MTX) toMTX alone in treating
the signs and symptoms of subjects with rheumatoid arthritis (RA) who are partial
responders to MTX. The study included 250 patients aged over 18 years with RA.
Inclusion and exclusion criteria were identical to RAPID1, but were discontinued all
DMARD at least 28 days or five half-lives, whatever longer, prior to first dose of study
drug. The primary endpoint was ACR20 response at week 24 and safety. Secondary
efficacy endpoints at week 24 included ACR50, ACR70
Interventions Certolizumab pegol 400 mg plus MTX or placebo sc plus MTX every 4 weeks for a total
of 6 injections
Outcomes Primary: ACR20 and safety at 24 weeks. Secondary endpoints: Subject’s Assessment of
Pain (VAS), Subject’s Global Assessment of Arthritis, Physician’s Global Assessment of
Arthritis, Subject’s Assessment of Physical function byHealth Assessment Questionnaire
- disability index (HAQ-DI), acute phase reactant value (only CRP for this study)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk The randomisation code was generated by
an independent group following instruc-
tion of the randomisation procedures, pre-
pared by the Project statistician (EMEA re-
port for the all Phase III)
Allocation concealment? Low risk Via Interactive voice recognition system
(IVRS)
Incomplete outcome data addressed?
Placebo
Low risk We have data only for ACR20, ACR50 and
ACR70and for safety
Incomplete outcome data addressed?
certolizumab sc
Low risk See above
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CDP870-014 2009 (Continued)
Incomplete outcome data addressed?
All outcomes
Low risk See above
Choy 2002
Methods Randomised double-blind placebo controlled trial
Participants 36 patients with rheumatoid arthritis defined by the AmericanCollege for Rheumatology
(ACR) classification criteria. Patients with active diseased defined as having 3 or the
following 4 criteria: tender joint count (TJC) ≥ 6, swollen joint count (SJC) ≥ 3 (based
on 28 joint counts), morning stiffness of ≥ 45 minutes, and ESR ≥ 28 mm/h. Patients
had to have failed treatment with at least one DMARD and have been off treatment for
at least 4 weeks
Interventions Ascending-dose group study of a single intravenous infusion of placebo (n = 12) or 1, 5
or 20 mg/kg of certolizumab pegol (each n = 8) for 8 weeks
Outcomes ACR20, ACR50, ACR70, Pain score (0-10 cm), Disease Activity score (DAS), TJC,
SJC, Health assessment questionnaire (HAQ), C-reactive protein (CRP)
Notes This study was only considered to assess safety because follow-up was less than 8 weeks
Following the blinded dosing period of 8 weeks, 32 patients received a single open-label
infusion of either 5 or 20 mg/kg of certolizumab
In the open phase, one patient who received 20mg/kg died from complications following
rapid drainage of a large, chronic rheumatoid pericardial effusion. No infective agent
was isolated from either the pericardial fluid or peripheral blood. In the opinion of the
investigator, this event was unrelated to treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Patients were divided into 4 groups. In each
group of 12 patients 8 received active treat-
ment and 4 received placebo. Methods for
sequence generation: no information pro-
vided
Allocation concealment? Unclear risk Not described
Incomplete outcome data addressed?
Placebo
Low risk 6 patients were withdrawn for deteriorating
RA
Incomplete outcome data addressed?
certolizumab sc
Low risk 2 patients were withdrawn for deteriorating
RA or lost to follow-up
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Choy 2002 (Continued)
Incomplete outcome data addressed?
All outcomes
Low risk Data for pain scores, TJC, SJC, HAQ,
ESR, physicians global assessment of dis-
ease and CRP were reported in figures but
numerical data were not available
FAST4WARD 2005
Methods Randomised double-blind trial
Participants 220 patients aged between 18 and 75 years and with RA defined by the ACR classifi-
cation criteria who had previously failed at least one disease modifying anti-rheumatic
drug (DMARD) were included. Patients previously treated with a TNF inhibitor were
excluded. Patients had to have a TJC of ≥ 9 (out of 68), SJC of ≥ 9 (out of 66) and one
of the following: morning stiffness of ≥ 45 minutes; ESR≥ 28 mm/h; or CRP > 10 mg/
L. Patients with a previous history of a serious or life threatening infection were excluded.
Patients with a history of tuberculosis (TB), or evidence of TB on a chest radiograph,
or those with a positive reaction to purified protein derivative (PPD) reaction were also
excluded. Patients on concurrent corticosteroids were allowed entry provided the dose
was the equivalent of 10 mg or less of prednisolone. Parenteral corticosteroids were not
permitted
Interventions Certolizumab 400 mg sc every four weeks (n=111) or placebo (n=109) for 24 weeks
Outcomes ACR20,50,70, HAQ-Di, Pain (VAS) and modified Brief pain Inventory (mBPI), DAS
28, Fatigue, and SF-36 at 24 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Code list prepared by independent group
Allocation concealment? Low risk Interactive voice recognition system (IVRS) used to
allocate patient to treatment group (1:1 ratio)
Incomplete outcome data addressed?
Placebo
Low risk 28 patients ended study
Incomplete outcome data addressed?
certolizumab sc
Low risk 76 patients ended study
Incomplete outcome data addressed?
All outcomes
High risk All outcomes were shown
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RAPID1 2005
Methods Randomised double-blind trial
Participants 982 patients aged over 18 years and with RA defined by the ACR classification criteria
who had received MTX for ≥ 6 months (with at a stable dose of ≥ 10 mg/week for
at least 2 months) before baseline were included. Patients with a disease duration of
>15 years were excluded. Patients previously treated with a TNF inhibitor were also
excluded if they had previously failed to respond to treatment. Other DMARDs had
to be discontinued at least 28 days before baseline. At inclusion, patients had to have
active disease as defined by: Active disease was defined as ≥ 9 tender and 9 swollen
joints at screening and at baseline, with either an erythrocyte sedimentation rate (ESR;
Westergen) ≥ 30 mm/hour or a C-reactive protein (CRP) level ≥ 15 mg/L
Interventions 982 patients were randomised 2:2:1 to receive treatmentwith subcutaneous certolizumab
pegol at an initial dosage of 400 mg given at weeks 0, 2, and 4, with a subsequent dosage
of 200 mg or 400 mg given every 2 weeks, plus MTX, or placebo plus MTX
Outcomes Co-primary end points were the ACR20 at week 24 and the mean change from baseline
in the modified total Sharp score at week 52. Major secondary end points were: the
change from baseline in modified total Sharp score at week 24, the change from baseline
in the disability Index (DI) of the Health Assessment Questionnaire (HAQ) at weeks 24
and 52, the ACR20 responder rate at week 52, and the ACR50 and ACR70 responder
rates at weeks 24 and 52
Notes Patients with a history of tuberculosis or a chest radiograph showing active or latent
tuberculosis or those with a positive reaction to purified protein derivative (PPD) reaction
were also excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Code list prepared by independent group
Allocation concealment? Low risk Interactive voice recognition system (IVRS) used to
allocate patient to treatment group (2:2:1 ratio)
Incomplete outcome data addressed?
Placebo
Low risk One patient in each group was lost to follow-up. For
patients who withdrew before 52 weeks and who had
radiographs taken at their withdrawal visit the modi-
fied total Sharp score was estimated by linear extrap-
olation of radiographic scores at the withdrawal visit
or at week 24. Multiple sensitivity analyses were done
on various assumptions regarding data imputation
Incomplete outcome data addressed?
certolizumab sc
Low risk See above
Incomplete outcome data addressed?
All outcomes
Low risk See above
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RAPID2 2007
Methods Randomised double-blind trial
Participants 619 patients (see note) aged over 18 years and with RA of at least 6 months and defined
by the ACR classification criteria who had receivedMTX for≥ 6 months with at a stable
dose of ≥ 10 mg/week for at least 2 months before baseline were included. Patients
with a disease duration of > 15 years were excluded. At inclusion, patients had to have
active disease as defined by: TJC and SJC of ≥ 9, ESR ≥ 30 mm/h, and a CRP of ≥15
mg/L. Patients previously treated with a TNF inhibitor were also excluded if they had
previously failed to respond to treatment
Interventions Patients were randomised 2:2:1 to one of two regimens of subcutaneous liquid cer-
tolizumab pegol (400 mg at weeks 0, 2 and 4, followed by 200 or 400 mg every 2 weeks)
plus MTX, or placebo (saline) plus MTX
Outcomes The primary end point was ACR20 response at week 24, and physician’s global assess-
ment of disease activity, patient’s assessment of pain, Health Assessment Questionnaire-
Disability Index (HAQ-DI) and serum CRP or ESR
Secondary efficacy end-points at week 24 included ACR50, ACR70, mean change from
baseline in van der Heijde modified Total Sharp Scores (mTSS), Short Form-36 (SF-36)
Health Survey,and individual ACR core set variables. Disease activity was assessed using
the Disease Activity Score 28-joint assessment 4 (DAS28 (ESR)
Notes Patients who did not show an ACR20 response at both weeks 12 and 14 were to be
withdrawn from the study, designated ACR20 non-responders in the primary analysis
and allowed to enter an open-label extension study at week 16 with certolizumab pegol
400 mg every 2 weeks
Patients with history of, or positive chest x-ray findings for, tuberculosis, or a positive pu-
rified protein derivative (PPD) skin test (defined as positive indurations per local medical
practice) were excluded. As per protocol, if a positive PPD skin test was assumed by the
local investigators to be related to previous bacille Calmette-Guerin (BCG) vaccination
and was not associated with clinical or radiographic suspicion of tuberculosis, patients
could be enrolled at the discretion of the investigator. In total, 101 patients (16%) were
enrolled with a PPD test > 5 mm at baseline
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Code list prepared by independent group
Allocation concealment? Low risk Interactive voice recognition system (IVRS) used to
allocate patient to treatment group (2:2:1 ratio)
Incomplete outcome data addressed?
Placebo
Low risk More placebo-treated patients (79.5%; n=101) dis-
continued treatment owing to lack of ACR20 response
at week 16
Incomplete outcome data addressed?
certolizumab sc
Low risk Discontinued treatment owing to lack of ACR20 re-
sponse at week 16 versus certolizumab pegol 200 mg
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RAPID2 2007 (Continued)
(19.9%; n=49) and 400 mg (18.7%; n=46)
Incomplete outcome data addressed?
All outcomes
Low risk All outcomes were reported
Choy’s study didn’t show number of patients in each arm, mean age (SD), percentage of female, of previous DMARD, on steroids, on
NSAIDs and DAS was reported as mean change from baseline without SD.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andreakos 2003 Different drug/agent studied
Anonymous 2003 Review; different drug/agent studied
Bain 2003 Different drug/agent studied
Bansback 2005 Different drug/agent studied
Barnes 2007 Review
Baugh 2001 Review
Bayes M 2006 Review
Chang 2006 Different drug/agent studied
Chikanza 2000a Review in children
Chikanza 2000b Review
Evans 2003 Different drug/agent studied
Fanet-Goguet 2004 Review
Fleischmann 2005 Review
Gabay 2002 Review
Garber 2005 Different drug/agent studied
Genovese 2005 Review
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Goldblatt 2005 Review
Graninger 2002 Different drug/agent studied
Kathmann 2005 Review
Kaushik 2005 Review
Kavanaugh A Assessed in RAPID1 and RAPID2 a work productivity survey (WPS-RA)
Kochbati 2004 Review
Mealy 2005 Different drug/agent studied
Mok 2004 Review
Mount 2005 Review
Osbourn 2003 Review
Paleolog 2003 Review
Pearce 2001 Review
Rose-John 2003 Review
Russo 2005 Different drug/agent studied
Sandborn 2003 Crohn’s disease/ Review
Schreiber Crohn’s disease
Sorbera 2005 Review
Takeuchi 2005 Review
Taylor 2003 Different drug/agent studied
Taylor 2003a Review
Toussirot 2004 Review
Toussirot 2007 Review
Zwerina 2005 Review
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Characteristics of ongoing studies [ordered by study ID]
NCT00160602
Trial name or title A Study of LiquidCertolizumabPegol as AdditionalMedication toMethotrexate in the Treatment of Signs and
Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid
Arthritis
Methods Treatment, randomised, double-blind, placebo control, parallel assignment, safety/efficacy study
Participants Patients with active rheumatoid arthritis who have an incomplete response to methotrexate
Interventions Compare efficacy of two dose regimens of certolizumab pegol in combination with MTX to MTX alone in
patients with RA measured by the ACR20 at week 24
Outcomes Not reported in clinical.trials.gov
Starting date June 2005. Study completion date September 2006. No publications provided
Contact information UCB Clinical Trial Call Center Tel: +1 877 822 9493
Notes The link to the study summary on clinicalstudyresults.org does not work
NCT00160641
Trial name or title A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Efficacy and Safety of Liquid Cer-
tolizumab Pegol (CDP870) as Additional Medication to Methotrexate, in the Treatment of Signs and Symp-
toms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated
in Study CDP870-050
Methods Treatment, open-label, uncontrolled, single-group assignment, safety/efficacy study
Participants Patients with active rheumatoid arthritis who participated in Study CDP870-050
Interventions Follow-up
Outcomes To assess the safety of certolizumab pegol, in patients with active rheumatoid arthritis (RA) by measuring
ACR 20/50/70 responder rates every 12 weeks. Time Frame: 3 years. [Designated as safety issue: No ]
Starting date Dec 2005; expected completed data Mar 2011
Contact information UCB Clinical Trial Call Center+1 877 822 9493 (UCB)
Notes
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NCT00160693
Trial name or title Open Label Long-Term Safety Study of CDP870 (Certolizumab Pegol) for PatientsWith Rheumatoid Arthri-
tis
Methods Non-randomised, open-label, uncontrolled, single group assignment
Participants Patients who have participated in CDP870 trial -014 for -011
Interventions 400 mg of certolizumab pegol subcutaneously every 4 weeks
Outcomes To assess the long-term safety and tolerability of certolizumab pegol in subjects with rheumatoid arthritis
[Time Frame: 8 years]
Starting date Mar 2003; Expected completed data Mar 2011
Contact information UCB Clinical Trial Call Center+1 877 822 9493 (UCB)
Notes
NCT00175877
Trial name or title A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and
Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid
Arthritis
Methods A phase III multi-centre, open-label, follow-on study to CDP870-027
Participants An open-ended study in which patients who completed the double-blind study (CDP870-027) are given
certolizumab pegol and assessed for signs and symptoms of rheumatoid arthritis
Interventions
Outcomes To assess effectiveness of CDP870 in patients with active rheumatoid arthritis (RA) by measuring ACR 20/
50/70 responder rates every 12 weeks [Time Frame: 3 years]
Starting date June 2005; expected completion Mar 2011
Contact information UCB Clinical Trial Call Center+1 877 822 9493 (UCB)
Notes
NCT00580840
Trial name or title Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
Methods Treatment, randomised, double blind (subject, investigator), placebo control, parallel assignment, safety/
efficacy study
Participants Patients with active rheumatoid arthritis
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NCT00580840 (Continued)
Interventions The study design consists of an open-label run-in period (400mg CZP at week 0,2,4 and 200mg CZP plus
placebo at week 6 through 16). At week 18 all patients will be grouped as responders or non-responders (based
on ACR10 results at week 16). Non-responders will be withdrawn. Responders will be randomised at week
18 into one of three treatment arms (1:1:1): 400mg CZP q4w, 200mg CZP q2w, or placebo
Outcomes Clinical response rate: ACR20, ACR50 and ACR70 week 16 (all patients) and week 34 (randomised patients)
No reduction of disease activity: change from baseline in DAS28, SDAI and CDAI scores week 16 (all
patients); week 34 (randomised patients) No achievement of clinical remission as measured by DAS28; SDAI
and CDAI scores week 16 (all patients)
Starting date December 2007 expected completion September 2010
Contact information UCB Clinical Trial Call Center Tel: +1 877 822 9493
Notes
NCT00674362
Trial name or title Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Methods A phase IIIB, multi-centre, double-blind, placebo-controlled, parallel group study to evaluate the safety and
efficacy of certolizumab pegol, administered With DMARD
Participants Patients with low to moderate disease activity rheumatoid arthritis on DMARDs therapy for at least six
months
Interventions Drug: certolizumab pegol 400 mg at W0, W2, W4 200 mg Q2W; placebo
Outcomes Investigation of certolizumab pegol clinical efficacy in achieving clinical remission in patients with moderate
to low disease activity rheumatoid arthritis both week 20 and week 24 No
Starting date June 2008
Contact information UCB Clinical Trial Call Center Tel: 1 877 822 9493
Notes
NCT00717236
Trial name or title Certolizumab Pegol for the Treatment of Patients With Active RA (Realistic)
Methods Treatment, randomized, double blind (subject, outcomes assessor), parallel assignment, safety/efficacy study
Participants Patients with established adult rheumatoid arthritis
Interventions Not reported in clinical.trials.gov
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NCT00717236 (Continued)
Outcomes To assess the clinical responses rate as measured by ACR20 response rate Week 12 No. Another outcomes:
responder rate, disease activity, fatigue, physical functioning. In the group remaining in the study after week
12: responder rate, disease activity, fatigue, physical functioning. [Time Frame: Week 12 and every 8 weeks
thereafter, until study completion] [Designated as safety issue: No]
Starting date July 2008. Expected completion Nov 2010
Contact information UCB Clinical Trial Call Center Tel: 1 877 822 9493
Notes
NCT00753454
Trial name or title Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid
Arthritis (RA) (Dose Flex II)
Methods Open-label, single group assignment
Participants Patients having completed the week 34 assessment in C87077 or having met the pre-defined criteria for
flare, will be given the option to enrol in C87084 and receive: 400mg CZP at Entry, Week 2, and Week 4
followed by 200mg every two weeks in combination with MTX until the drug is commercially available for
the indication of RA in the patient’s country or region (or until further notice from UCB)
Interventions Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at entry, week 2, week
4, followed by 200 mg every 2 weeks)
Outcomes Primary outcome measures:
To continue to assess the safety of certolizumab pegol in combinationwithMTXasmeasured by adverse events
frequency, severity and nature; PE and vitals; and laboratory values, blood parameters and urine parameters.
[Time Frame: Time frame will vary - Treatment will continue until the drug is commercially available in the
country or region] [Designated as safety issue: No]
To assess the clinical response rate measured by ACR20, ACR50 and ACR70 responder rate. [Time Frame:
Time frame will vary - Treatment will continue until the drug is commercially available in the country or
region] [Designated as safety issue: No ]
To assess the reduction of disease activity measured by change from Baseline (in C87077) in DAS28, SDAI
and CDAI scores. [ Time Frame: Time frame will vary - Treatment will continue until the drug is commercially
available in the country or region ] [ Designated as safety issue: No]
To assess the achievement of clinical remission measured by DAS28 remission rate (< 2.6), SDAI remission
rate (< 3.3) and CDAI remission rate (< 2.8.). [Time Frame: Time frame will vary - Treatment will continue
until the drug is commercially available in the country or region] [Designated as safety issue: No]
The improvement in physical function as measured by the Health Assessment Questionnaire Disability Index
(HAQ-DI). [Time Frame: Time frame will vary - Treatment will continue until the drug is commercially
available in the country or region] [Designated as safety issue: No]
Reduction in fatigue as measured by the Fatigue Assessment Scale. [Time Frame: Time frame will vary -
Treatment will continue until the drug is commercially available in the country or region] [Designated as
safety issue: No]
Improvement in patient’s Health-Related Quality of Life (HRQOL) as measured by the 36-item Short Form
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NCT00753454 (Continued)
Health Survey (SF-36). [Time Frame: Time frame will vary - Treatment will continue until the drug is
commercially available in the country or region] [Designated as safety issue: No]
The relief in arthritis pain as measured by the Patient’s Assessment of Arthritis Pain - Visual Analog Scale
(VAS) [Time Frame: Time frame will vary - Treatment will continue until the drug is commercially available
in the country or region] [Designated as safety issue: No]
The reduction in disease activity as measured by the Patient’s Global Assessment of Disease Activity - VAS.
[Time Frame: Time frame will vary - Treatment will continue until the drug is commercially available in the
country or region] [Designated as safety issue: No]
Starting date Sep 2008; expected completion date: Apr 2011
Contact information UCB Clinical Trial Call Center+1 877 822 9493 (UCB)
Notes
NCT00791999
Trial name or title A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy,
Pharmacokinetics and Safety of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Active
Rheumatoid Arthritis (RA) Patients Who Have an Incomplete Response to MTX
Methods Treatment, randomised, double-blind (subject, caregiver, investigator, outcomes assessor), dose comparison,
parallel assignment, safety/efficacy study
Participants
Interventions Drug: CDP870 400mg
Drug: CDP870 200mg
Drug: CDP870 100mg
Drug: placebo of CDP870
Outcomes Primary outcome measures:
ACR20 responder rate [Time Frame: Week12, 24] [Designated as safety issue: Yes]
Secondary outcome measures:
ACR20/50/70 responder rate [Time Frame: Week 1, 2, 4, 6, 8, 12, 14, 16, 20, 24] [Designated as safety
issue: Yes]
DAS28 (ESR) [Time Frame: Week 1, 2, 4, 6, 8, 12, 14, 16, 20, 24] [Designated as safety issue: Yes]
Modified Total Sharp Score [Time Frame: Week 24] [Designated as safety issue: Yes]
Starting date Nov 2008; expected completed date: Mar 2011
Contact information Drug Information Center opc ctr@otsuka.jp
Notes
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NCT00843778
Trial name or title Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN 2)
Methods Treatment, non-randomised, open-label, single group assignment, safety/efficacy study
Participants Patients with active rheumatoid arthritis who were included in C87076 study
Interventions Follow-up
Outcomes Further assessment of the safety of Certolizumab pegol. [Time frame: every 8 weeks throughout the entire
treatment period] Demonstration of clinical remission and improvement of physical function. [Time Frame:
every 8 weeks throughout the entire treatment period]
Starting date Jan 2009
Contact information UCB Clinical Trial Call Center+1-877-822-9493 (UCB)
Notes
NCT00850343
Trial name or title Long-term Treatment Study of CDP870Without Coadministration ofMTX in Japanese Rheumatoid Arthri-
tis (RA) Patients
Methods Randomized, open-label, uncontrolled, parallel assignment
Participants Japanese RA patients who are transferred from the study (Study 275-08-003), as well as to evaluate the effects
of dosing regimens on safety and efficacy of CDP870 in the ACR20 responders who completed Study 275-
08-003
Interventions Drug: CDP870 200mg and CDP870 400mg
Outcomes Primary outcome: adverse events [Time Frame: At any time] [Designated as safety issue: Yes]; Secondary
outcome: ACR20/50/70 responder rate
DAS28(ESR), Modified Total Sharp Score
Starting date Mar 2009; expected completed date: Mar 2012
Contact information Drug Information Centeropc ctr@otsuka.jp
Notes
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NCT00851318
Trial name or title Long-term Treatment Study of CDP870 as Add-on Medication to MTX in Japanese Rheumatoid Arthritis
(RA) Patients
Methods Randomised, open-label, uncontrolled, parallel assignment, safety/efficacy study
Participants
Interventions Two arms: CDP870 200 mg given every 2 weeks, SC; CP870 400mg given every 2 weeks, sc
Outcomes ACR20/50/70 responder rate [Time Frame: Week 24, 52] [Designated as safety issue: Yes]
DAS28(ESR) [Time Frame: Week 24, 52] [Designated as safety issue: Yes]
Modified Total Sharp Score [Time Frame: Week 24] [Designated as safety issue: Yes]
Starting date Mar 2009; expected completion Mar 2011
Contact information Contact: Drug Information Centeropc ctr@otsuka.jp
Notes
NCT00993317
Trial name or title A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to
Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With
Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
Methods Treatment, randomized, double-blind (subject, investigator, outcomes assessor), placebo control, parallel
assignment, safety/efficacy study
Participants Adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 ARA
criteria, with active disease
Interventions Drug: CDP870 200mg 400mg CDP870 given at Week 0, 2, 4 and thereafter 200mg CDP870 given every
2 weeks until week 22(sc)
Outcomes ACR20 responder rate . Time Frame: week 24
Starting date October 2009; expected completion June 2011
Contact information Korea Otsuka Pharmaceutical Clinical Research Team82 2 3465 4351eunyoung1@otsuka.co.kr
Notes
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NCT00993668
Trial name or title TheUse of Certolizumab Pegol in Adult SubjectsWith Rheumatoid Arthritis to Assess the Antibody Response
When Receiving Influenza Virus and Pneumococcal Vaccines
Methods A phase 4, randomized, single-blind, placebo-controlled, multicentre study to evaluate the immunogenicity
of pneumococcal and influenza vaccines in adult subjects with rheumatoid arthritis receiving certolizumab
pegol or placebo
Participants Patients with rheumatoid arthritis who had received influenza vaccine
Interventions Biological: placebo
Biological: certolizumab pegol
Outcomes Percentage of subjects without baseline protective titers achieving a ≥ 2-fold titter increase in ≥ 3 of 6
pneumococcal antigens (6B, 9V, 14, 18C, 19F, and 23F) at week 6. Percentage of subjects without baseline
protective titers achieving a ≥ 4-fold titre increase in ≥ 2 of 3 influenza antigens (2009/2010 composition)
at week 6
Starting date September 2009; expected completion September 2010
Contact information UCB Clinical Trial Call Center+1-877-822-9493 (UCB)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Efficacy at 12 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR20 1 287 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.48, 0.68]
1.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.13, 0.57]
1.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.13, 0.56]
1.3 certolizumab 200 mg sc 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.25, 0.82]
1.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.50, 1.27]
1.5 certolizumab 600 mg sc 1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.51, 0.90]
1.6 certolizumab 800 mg sc 1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.04]
2 ACR50 1 194 Risk Ratio (M-H, Fixed, 95% CI) 3.31 [0.83, 13.26]
2.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.09, 27.88]
2.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.06, 20.96]
2.3 certolizumab 200 mg sc 1 49 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.20, 51.33]
2.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Fixed, 95% CI) 7.33 [0.48, 110.96]
3 ACR70 1 194 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.52, 8.76]
3.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.06, 21.47]
3.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.03, 14.89]
3.3 certolizumab 200 mg sc 1 49 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.08, 26.57]
3.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Fixed, 95% CI) 5.23 [0.34, 80.54]
Comparison 2. Efficacy at 24 weeks 200 mg certolizumab sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR 20 2 965 Risk Ratio (M-H, Fixed, 95% CI) 4.95 [3.65, 6.72]
2 ACR 50 2 965 Risk Ratio (M-H, Fixed, 95% CI) 6.01 [3.84, 9.40]
3 ACR 70 2 965 Risk Ratio (M-H, Fixed, 95% CI) 8.87 [4.20, 18.75]
Comparison 3. Efficacy at 24 weeks, 400 mg sc certolizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR 20 4 1429 Risk Ratio (M-H, Fixed, 95% CI) 4.09 [3.27, 5.13]
2 ACR 50 4 1429 Risk Ratio (M-H, Fixed, 95% CI) 5.68 [3.93, 8.20]
3 ACR 70 4 1429 Risk Ratio (M-H, Fixed, 95% CI) 6.39 [3.32, 12.27]
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Comparison 4. Efficacy at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR20 4 2068 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [2.16, 3.05]
1.1 certolizumab 200 mg sc 2 803 Risk Ratio (M-H, Fixed, 95% CI) 2.49 [1.87, 3.32]
1.2 certolizumab 400 mg sc 4 1265 Risk Ratio (M-H, Fixed, 95% CI) 2.62 [2.11, 3.25]
2 ACR50 4 2068 Risk Ratio (M-H, Fixed, 95% CI) 3.26 [2.47, 4.29]
2.1 certolizumab 200 mg sc 2 803 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [1.96, 4.67]
2.2 certolizumab 400 mg sc 4 1265 Risk Ratio (M-H, Fixed, 95% CI) 3.43 [2.40, 4.90]
3 ACR70 4 2068 Risk Ratio (M-H, Fixed, 95% CI) 3.93 [2.41, 6.41]
3.1 certolizumab 200 mg sc 2 803 Risk Ratio (M-H, Fixed, 95% CI) 4.46 [2.13, 9.36]
3.2 certolizumab 400 mg sc 4 1265 Risk Ratio (M-H, Fixed, 95% CI) 3.51 [1.83, 6.75]
Comparison 5. Efficacy at 52 weeks, 200 mg sc certolizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR 20 1 592 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [2.80, 5.87]
2 ACR 50 1 592 Risk Ratio (M-H, Fixed, 95% CI) 5.03 [3.04, 8.32]
3 ACR 70 1 592 Risk Difference (M-H, Fixed, 95% CI) 0.18 [0.13, 0.22]
Comparison 6. Efficacy at 52 weeks, 400 mg sc certolizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR 20 1 589 Risk Ratio (M-H, Fixed, 95% CI) 4.18 [2.89, 6.05]
2 ACR 50 1 589 Risk Ratio (M-H, Fixed, 95% CI) 5.27 [3.19, 8.71]
3 ACR 70 1 589 Risk Ratio (M-H, Fixed, 95% CI) 6.56 [3.10, 13.89]
Comparison 7. Efficacy at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR20 1 982 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [1.61, 2.62]
1.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [1.44, 2.87]
1.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [1.48, 2.93]
2 ACR50 1 982 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [1.83, 3.62]
2.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.56, 4.10]
2.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Fixed, 95% CI) 2.62 [1.62, 4.25]
43Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3 ACR70 1 982 Risk Ratio (M-H, Fixed, 95% CI) 3.14 [1.86, 5.29]
3.1 certolizumab 200 mg sc 1 493 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [1.44, 6.32]
3.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Fixed, 95% CI) 3.26 [1.56, 6.82]
Comparison 8. Safety certolizumab 200 mg sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any adverse event 2 964 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.08, 1.35]
2 Adverse events Intensity mild 2 964 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.14, 1.53]
3 Adverse events Intensity
moderate
2 964 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.00, 1.47]
4 Adverse events Intensity severe 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.38 [0.82, 2.34]
5 Adverse events related to study
drug
2 964 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.26, 1.98]
6 Serious Adverse Events (SAE) 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [1.24, 3.30]
7 Serious Infections 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.30 [1.45, 7.51]
8 Adverse events leading to death 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [0.18, 11.76]
9 Adverse events leading to
withdrawal
2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.40 [1.16, 4.95]
10 Death 2 962 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.85 [0.29, 11.86]
11 Tuberculosis 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.53 [0.71, 29.11]
12 Malignancies included
lymphoma
2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.85 [0.50, 6.93]
13 Injection site pain 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.60 [1.05, 20.10]
14 Injection side reactions 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.59 [1.38, 15.32]
15 Neutralising Anti-certolizumab
pegol antibodies
1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.57 [0.71, 29.59]
16 Systemic lupus erythematosus 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.50 [0.07, 286.06]
17 Prolonged activated partial
thromboplastin time (aPTT)
1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.45 [0.79, 7.57]
18 Urinary tract infection 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.43, 1.35]
19 Upper respiratory tract
infection
2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.21 [1.15, 4.25]
20 Lower respiratory tract
infection/ lung infection
1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.54 [0.41, 49.96]
21 Headache 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.31 [0.68, 2.50]
22 Bacteriuria 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.30, 3.40]
23 Nasopharyngitis 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.71 [1.30, 5.66]
24 Hypertension 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.81 [1.38, 5.75]
25 Hematuria 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.36 [0.09, 1.47]
26 Hepatic enzyme increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.07, 1.66]
27 AST increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.18 [0.04, 0.86]
28 ALT increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.09 [0.02, 0.45]
29 Back pain 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.91 [1.11, 7.65]
30 Herpes viral infection 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.52 [0.07, 285.70]
31 Bacterial peritonitis 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.52 [0.07, 285.70]
32 Opportunistic infections 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
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33 Infections and infestations 2 947 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.10, 1.69]
34 Gastroenteritis 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
35 Hematologic abnormalities 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.53 [0.24, 85.22]
36 Decreased haemoglobin 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.09, 11.18]
37 Increased platelet count 1 591 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
Comparison 9. Safety certolizumab 400 mg sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any adverse events 4 1422 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.10, 1.30]
2 Adverse events Intensity mild 3 1179 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.19, 1.54]
3 Adverse events Intensity
moderate
3 1179 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [1.05, 1.45]
4 Adverse events Intensity severe 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.24 [0.79, 1.95]
5 Adverse events related to study
drug
3 1179 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.19, 1.80]
6 Serious infections 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.25 [1.65, 6.39]
7 Serious Adverse Events (SAE) 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.92 [1.30, 2.83]
8 Adverse events leading to death 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [0.40, 11.79]
9 Adverse events leading to
withdrawal
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.41 [1.26, 4.63]
10 Death 4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [0.40, 11.79]
11 Vomiting 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.70]
12 Pneumonitis 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.70]
13 Tuberculosis 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.55 [0.71, 29.11]
14 Arthritis bacterial 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
15 Mastitis 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
16 Benign Tumour 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.32 [0.46, 117.84]
17 Ischaemeic stroke 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
18 Dizziness postural 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
19 Menorrhagia 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
20 Malignancies included
lymphoma
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.26, 6.08]
21 Injection site pain 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [0.41, 7.42]
22 Injection side reactions 3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.31, 1.49]
23 Anti-certolizumab pegol
antibodies
2 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.70 [2.18, 20.55]
24 Antinuclear antibodies (ANA) 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.65 [0.77, 3.53]
25 Prolonged activated partial
thromboplastin time (aPTT)
1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.46 [0.80, 7.60]
26 Urinary tract infection 2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.87 [0.50, 1.52]
27 Back pain 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.15 [1.28, 7.74]
28 Upper respiratory tract
infection
2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [0.83, 3.67]
29 Lower respiratory tract
infection/ lung infection
1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.57 [0.57, 36.44]
30 Headache 2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.11 [0.56, 2.20]
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31 Bacteriuria 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.75 [0.20, 2.82]
32 Hypertension 2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.23 [1.71, 6.08]
33 Hematuria 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.09, 1.49]
34 Hepatic enzyme increased 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.07, 1.67]
35 AST increased 1 371 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.58 [0.16, 2.07]
36 ALT increased 1 373 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.22, 2.05]
37 Herpes viral infection 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.53 [0.07, 285.35]
38 Bacterial peritonitis 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
39 Opportunistic infections 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
40 Infections and infestations 3 1202 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [1.31, 1.95]
41 Nasopharyngitis 2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.99 [1.50, 5.95]
42 Gastrointestinal disorders 2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.54, 2.03]
43 Hematologic abnormalities 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.12, 4.86]
44 Decreased Haemoglobin 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.03, 9.10]
45 Increased platelet count 1 588 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.09, 11.23]
Comparison 10. Mean HAQ-DI from baseline at week 24
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 certolizumab 200 mg sc 2 965 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.45, -0.32]
2 certolizumab 400 mg sc 3 1182 Mean Difference (IV, Fixed, 95% CI) -0.41 [-0.48, -0.35]
Comparison 11. HAQ-Di at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 3 1821 Mean Difference (IV, Fixed, 95% CI) -0.41 [-0.46, -0.35]
1.1 certolizumab 200 mg sc 2 803 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.47, -0.30]
1.2 certolizumab 400 mg sc 3 1018 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.50, -0.35]
Comparison 12. HAQ-Di at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -0.43 [-0.52, -0.35]
1.1 certolizumab 200 mg sc 1 493 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.54, -0.30]
1.2 certolizumab 400 mg sc 1 489 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.57, -0.33]
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Comparison 13. SF-36 Physical Component Summary (PCS) week 24
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 certolizumab 200 mg sc 2 965 Mean Difference (IV, Fixed, 95% CI) 5.26 [4.17, 6.36]
2 certolizumab 400 mg sc 2 962 Mean Difference (IV, Fixed, 95% CI) 5.72 [4.62, 6.81]
Comparison 14. SF-36 Mental Component Summary (MCS) week 24
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 certolizumab 200 mg sc 2 965 Mean Difference (IV, Fixed, 95% CI) 4.18 [2.70, 5.66]
2 certolizumab 400 mg sc 2 962 Mean Difference (IV, Fixed, 95% CI) 4.39 [2.91, 5.88]
Comparison 15. SF-36 Mental Component Summary (MCS) week 52
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 certolizumab 200 mg sc 1 592 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.40, 6.20]
2 certolizumab 400 mg sc 1 589 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.40, 6.20]
Comparison 16. SF-36 Physical Component Summary (PCS) week 52
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 certolizumab 200 mg sc 1 592 Mean Difference (IV, Fixed, 95% CI) 6.06 [4.59, 7.53]
2 certolizumab 400 mg sc 1 589 Mean Difference (IV, Fixed, 95% CI) 6.88 [5.42, 8.34]
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Comparison 17. SF-36 Physical Component Summary (PCS) week 24, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 1601 Mean Difference (IV, Fixed, 95% CI) 5.47 [4.47, 6.48]
1.1 certolizumab 200 mg sc 2 803 Mean Difference (IV, Fixed, 95% CI) 5.25 [3.84, 6.66]
1.2 certolizumab 400 mg sc 2 798 Mean Difference (IV, Fixed, 95% CI) 5.70 [4.28, 7.12]
Comparison 18. SF-36 Mental Component Summary (MCS) week 24, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 1601 Mean Difference (IV, Fixed, 95% CI) 4.29 [2.95, 5.63]
1.1 certolizumab 200 mg sc 2 803 Mean Difference (IV, Fixed, 95% CI) 4.18 [2.29, 6.07]
1.2 certolizumab 400 mg sc 2 798 Mean Difference (IV, Fixed, 95% CI) 4.39 [2.49, 6.29]
Comparison 19. SF-36 Physical Component Summary (PCS) week 52, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) 6.47 [5.13, 7.81]
1.1 certolizumab 200 mg sc 1 493 Mean Difference (IV, Fixed, 95% CI) 6.06 [4.17, 7.95]
1.2 certolizumab 400 mg sc 1 489 Mean Difference (IV, Fixed, 95% CI) 6.88 [4.99, 8.77]
Comparison 20. SF-36 Mental Component Summary (MCS) week 52, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.57, 6.03]
1.1 certolizumab 200 mg sc 1 493 Mean Difference (IV, Fixed, 95% CI) 4.3 [1.86, 6.74]
1.2 certolizumab 400 mg sc 1 489 Mean Difference (IV, Fixed, 95% CI) 4.3 [1.85, 6.75]
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Comparison 21. Disease Activity Score (DAS28) (ESR) remission (< 2.6)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients
achieving remission 24 weeks
certolizumab 200 mg
2 957 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.88 [2.33, 6.45]
2 Proportion of patients
achieving remission 24 weeks
certolizumab 400 mg
2 954 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.97 [2.41, 6.54]
3 Proportion of patients
achieving remission 52 weeks
certolizumab 200 mg
1 587 Risk Ratio (M-H, Fixed, 95% CI) 10.36 [3.29, 32.58]
4 Proportion of patients
achieving remission 52 weeks
certolizumab 400 mg
1 583 Risk Ratio (M-H, Fixed, 95% CI) 12.49 [3.99, 39.12]
Comparison 22. Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 24 weeks
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients achieving
remission 24 weeks
2 1595 Risk Ratio (M-H, Fixed, 95% CI) 4.46 [2.21, 9.00]
1.1 certolizumab 200 mg sc 2 800 Risk Ratio (M-H, Fixed, 95% CI) 4.38 [1.62, 11.82]
1.2 certolizumab 400 mg sc 2 795 Risk Ratio (M-H, Fixed, 95% CI) 4.54 [1.69, 12.24]
Comparison 23. Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 52 weeks
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients achieving
remission 52 weeks
1 977 Risk Ratio (M-H, Fixed, 95% CI) 5.80 [2.60, 12.94]
1.1 certolizumab 200 mg sc 1 491 Risk Ratio (M-H, Fixed, 95% CI) 5.29 [1.69, 16.49]
1.2 certolizumab 400 mg sc 1 486 Risk Ratio (M-H, Fixed, 95% CI) 6.31 [2.03, 19.59]
49Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 24. DAS-28 at 24 weeks 200 mg sc certolizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
1 373 Mean Difference (IV, Fixed, 95% CI) -1.77 [-2.02, -1.52]
Comparison 25. DAS-28 at 24 weeks 400 mg sc certolizumab
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
2 593 Mean Difference (IV, Fixed, 95% CI) -1.77 [-1.99, -1.55]
Comparison 26. DAS-28 at week 52, certolizumab 200 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 592 Mean Difference (IV, Fixed, 95% CI) -0.9 [-1.12, -0.68]
Comparison 27. DAS-28 at week 52, certolizumab 400 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 589 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.23, -0.77]
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Comparison 28. DAS-28 at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 839 Mean Difference (IV, Fixed, 95% CI) -1.73 [-1.93, -1.52]
1.1 certolizumab 200 mg sc 1 310 Mean Difference (IV, Fixed, 95% CI) -1.77 [-2.08, -1.46]
1.2 certolizumab 400 mg sc 2 529 Mean Difference (IV, Fixed, 95% CI) -1.69 [-1.96, -1.43]
Comparison 29. DAS-28 at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -0.95 [-1.15, -0.75]
1.1 certolizumab 200 mg sc 1 493 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.19, -0.61]
1.2 certolizumab 400 mg sc 1 489 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.29, -0.71]
Comparison 30. Modified total Sharp scores (mTSS)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from the baseline mean
mTSS 24 weeks 200 mg
certolizumab.
2 859 Mean Difference (IV, Fixed, 95% CI) -1.06 [-1.58, -0.55]
2 Change from the baseline mean
mTSS 24 weeks 400 mg
certolizumab.
2 869 Mean Difference (IV, Fixed, 95% CI) -1.32 [-1.85, -0.78]
3 Change from the baseline mean
mTSS 52 weeks 200 mg
certolizumab sc
1 545 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.68, -1.12]
4 Change from the baseline mean
mTSS 52 weeks 400 mg
certolizumab sc
1 544 Mean Difference (IV, Fixed, 95% CI) -2.60 [-3.84, -1.36]
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Comparison 31. Modified total Sharp scores (mTSS) at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 1437 Mean Difference (IV, Fixed, 95% CI) -1.18 [-1.67, -0.69]
1.1 certolizumab 200 mg sc 2 713 Mean Difference (IV, Fixed, 95% CI) -1.06 [-1.75, -0.38]
1.2 certolizumab 400 mg sc 2 724 Mean Difference (IV, Fixed, 95% CI) -1.30 [-1.99, -0.60]
Comparison 32. Modified total Sharp scores (mTSS) at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 908 Mean Difference (IV, Fixed, 95% CI) -2.50 [-3.70, -1.30]
1.1 certolizumab 200 mg sc 1 455 Mean Difference (IV, Fixed, 95% CI) -2.4 [-4.11, -0.69]
1.2 certolizumab 400 mg sc 1 453 Mean Difference (IV, Fixed, 95% CI) -2.60 [-4.29, -0.91]
Comparison 33. Erosion score (ES)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from the baseline
mean ES at week 24, 200 mg
certolizumab.
2 859 Mean Difference (IV, Fixed, 95% CI) -0.67 [-0.96, -0.38]
2 Change from the baseline
mean ES at week 24, 400 mg
certolizumab.
2 869 Mean Difference (IV, Fixed, 95% CI) -0.74 [-1.06, -0.42]
3 Change from the baseline
mean ES at week 52, 200 mg
certolizumab.
1 544 Mean Difference (IV, Fixed, 95% CI) -1.4 [-2.08, -0.72]
4 Change from the baseline
mean ES at week 52, 400 mg
certolizumab.
1 543 Mean Difference (IV, Fixed, 95% CI) -1.50 [-2.20, -0.80]
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Comparison 34. Erosion score (ES) at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 1437 Mean Difference (IV, Fixed, 95% CI) -0.70 [-0.98, -0.42]
1.1 certolizumab 200 mg sc 2 714 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.06, -0.28]
1.2 certolizumab 400 mg sc 2 723 Mean Difference (IV, Fixed, 95% CI) -0.73 [-1.14, -0.32]
Comparison 35. Erosion score (ES) at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 908 Mean Difference (IV, Fixed, 95% CI) -1.45 [-2.11, -0.79]
1.1 certolizumab 200 mg sc 1 455 Mean Difference (IV, Fixed, 95% CI) -1.4 [-2.32, -0.48]
1.2 certolizumab 400 mg sc 1 453 Mean Difference (IV, Fixed, 95% CI) -1.5 [-2.44, -0.56]
Comparison 36. Joint space narrowing (JSN)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from the baseline
mean JSN 24 weeks 200 mg
certolizumab.
2 861 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.77, -0.13]
2 Change from the baseline
mean JSN 24 weeks 400 mg
certolizumab.
2 869 Mean Difference (IV, Fixed, 95% CI) -0.55 [-0.86, -0.24]
3 Change from the baseline
mean JSN 52 weeks 200 mg
certolizumab.
1 548 Mean Difference (IV, Fixed, 95% CI) 1.00 [-1.85, -0.15]
4 Change from the baseline
mean JSN 52 weeks 400 mg
certolizumab
1 544 Mean Difference (IV, Fixed, 95% CI) -1.2 [-1.98, -0.42]
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Comparison 37. Joint space narrowing (JSN) at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 2 1439 Mean Difference (IV, Fixed, 95% CI) -0.50 [-0.79, -0.21]
1.1 certolizumab 200 mg sc 2 716 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.87, -0.04]
1.2 certolizumab 400 mg sc 2 723 Mean Difference (IV, Fixed, 95% CI) -0.54 [-0.96, -0.13]
Comparison 38. Joint space narrowing (JSN) at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 911 Mean Difference (IV, Fixed, 95% CI) -1.10 [-1.88, -0.33]
1.1 certolizumab 200 mg sc 1 458 Mean Difference (IV, Fixed, 95% CI) 1.00 [-2.11, 0.11]
1.2 certolizumab 400 mg sc 1 453 Mean Difference (IV, Fixed, 95% CI) -1.2 [-2.27, -0.13]
Comparison 39. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change at 24 weeks
certolizumab 200 mg
2 965 Mean Difference (IV, Fixed, 95% CI) -20.49 [-23.43, -17.
55]
2 Mean change at 24 weeks
certolizumab 400 mg
3 1182 Mean Difference (IV, Fixed, 95% CI) -22.69 [-25.53, -19.
84]
3 Mean change at 52 weeks
certolizumab 200 mg
1 592 Mean Difference (IV, Fixed, 95% CI) -22.2 [-26.19, -18.
21]
4 Mean change at 52 weeks
certolizumab 400 mg
1 589 Mean Difference (IV, Fixed, 95% CI) -24.7 [-28.62, -20.
78]
Comparison 40. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 3 1821 Mean Difference (IV, Fixed, 95% CI) -21.63 [-24.23, -19.
02]
1.1 certolizumab 200 mg sc 2 803 Mean Difference (IV, Fixed, 95% CI) -20.48 [-24.26, -16.
69]
1.2 certolizumab 400 mg sc 3 1018 Mean Difference (IV, Fixed, 95% CI) -22.66 [-26.26, -19.
06]
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Comparison 41. Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change from baseline 1 982 Mean Difference (IV, Fixed, 95% CI) -23.48 [-27.09, -19.
88]
1.1 certolizumab 200 mg sc 1 493 Mean Difference (IV, Fixed, 95% CI) -22.2 [-27.37, -17.
03]
1.2 certolizumab 400 mg sc 1 489 Mean Difference (IV, Fixed, 95% CI) -24.7 [-29.73, -19.
67]
Comparison 42. Certolizumab 1mg/kg/day sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Headache 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.5 [0.56, 35.98]
2 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.02, 10.54]
3 Adverse events Intensity severe 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
4 Antinuclear antibodies (ANA) 1 20 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.32, 27.83]
5 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
Comparison 43. Certolizumab 5 mg/kg/day sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.11, 20.68]
2 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
Comparison 44. Certolizumab 20 mg/kg/day sc
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Headache 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.5 [0.56, 35.98]
2 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.32, 27.83]
3 Death 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
4 Antinuclear antibodies (ANA) 1 20 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.11, 20.68]
5 Urinary tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [0.20, 94.83]
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Comparison 45. Withdrawals
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Withdrawn: any doses any
follow up
5 2107 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.36, 0.43]
2 Withdrawn due to lack of
efficacy: any doses any follow
up
4 2071 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.26, 0.33]
3 Withdrawn due to adverse
events: any doses any follow up
4 2071 Risk Ratio (M-H, Fixed, 95% CI) 2.17 [1.15, 4.10]
Comparison 46. Summary of findings: certolizumab (with or without MTX) versus placebo (with or without
MTX)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ACR 50 200 mg certolizumab
24 weeks
2 965 Risk Ratio (M-H, Fixed, 95% CI) 6.01 [3.84, 9.40]
2 HAQ change from baseline 200
mg certolizumab 24 weeks
2 965 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.45, -0.32]
3 Serious adverse events
certolizumab 200 mg sc
2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [1.24, 3.30]
3.1 certolizumab 200 mg 2 964 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [1.24, 3.30]
4 Proportion of patients achieving
DAS <2.6 (Remission) 200 mg
certolizumab 24 weeks
2 957 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.88 [2.33, 6.45]
4.1 certolizumab 200 mg sc
24 weeks
2 957 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.88 [2.33, 6.45]
5 Radiological changes:
Erosion Scores (ES) 200 mg
certolizumab 200 mg sc
2 859 Mean Difference (IV, Fixed, 95% CI) -0.67 [-0.96, -0.38]
5.1 certolizumab 200 mg sc
24 weeks
2 859 Mean Difference (IV, Fixed, 95% CI) -0.67 [-0.96, -0.38]
6 All Withdrawals: 5 2107 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.36, 0.43]
7 Withdrawals due to adverse
events
4 2071 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.93 [1.15, 3.23]
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Analysis 1.1. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 1 ACR20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 50 mg sc
CDP870-004 2001 8/39 6/8 14.7 % 0.27 [ 0.13, 0.57 ]
Subtotal (95% CI) 39 8 14.7 % 0.27 [ 0.13, 0.57 ]
Total events: 8 (Certolizumab), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 certolizumab 100 mg sc
CDP870-004 2001 8/40 6/8 14.8 % 0.27 [ 0.13, 0.56 ]
Subtotal (95% CI) 40 8 14.8 % 0.27 [ 0.13, 0.56 ]
Total events: 8 (Certolizumab), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.51 (P = 0.00045)
3 certolizumab 200 mg sc
CDP870-004 2001 14/41 6/8 14.8 % 0.46 [ 0.25, 0.82 ]
Subtotal (95% CI) 41 8 14.8 % 0.46 [ 0.25, 0.82 ]
Total events: 14 (Certolizumab), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
4 certolizumab 400 mg sc
CDP870-004 2001 25/42 6/8 14.9 % 0.79 [ 0.50, 1.27 ]
Subtotal (95% CI) 42 8 14.9 % 0.79 [ 0.50, 1.27 ]
Total events: 25 (Certolizumab), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
5 certolizumab 600 mg sc
CDP870-004 2001 (1) 25/39 8/8 20.5 % 0.68 [ 0.51, 0.90 ]
Subtotal (95% CI) 39 8 20.5 % 0.68 [ 0.51, 0.90 ]
Total events: 25 (Certolizumab), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
6 certolizumab 800 mg sc
CDP870-004 2001 (2) 30/38 8/8 20.4 % 0.83 [ 0.66, 1.04 ]
Subtotal (95% CI) 38 8 20.4 % 0.83 [ 0.66, 1.04 ]
Total events: 30 (Certolizumab), 8 (Control)
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(. . . Continued)
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 239 48 100.0 % 0.57 [ 0.48, 0.68 ]
Total events: 110 (Certolizumab), 40 (Control)
Heterogeneity: Chi2 = 21.73, df = 5 (P = 0.00059); I2 =77%
Test for overall effect: Z = 6.22 (P < 0.00001)
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(1) From EMEA report, only data for ACR20
(2) From EMEA report, only data for ACR20
Analysis 1.2. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 2 ACR50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 50 mg sc
CDP870-004 2001 3/39 0/8 24.8 % 1.58 [ 0.09, 27.88 ]
Subtotal (95% CI) 39 8 24.8 % 1.58 [ 0.09, 27.88 ]
Total events: 3 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 certolizumab 100 mg sc
CDP870-004 2001 2/40 0/8 24.9 % 1.10 [ 0.06, 20.96 ]
Subtotal (95% CI) 40 8 24.9 % 1.10 [ 0.06, 20.96 ]
Total events: 2 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 certolizumab 200 mg sc
CDP870-004 2001 7/41 0/8 25.1 % 3.21 [ 0.20, 51.33 ]
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(. . . Continued)
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 41 8 25.1 % 3.21 [ 0.20, 51.33 ]
Total events: 7 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 certolizumab 400 mg sc
CDP870-004 2001 17/42 0/8 25.2 % 7.33 [ 0.48, 110.96 ]
Subtotal (95% CI) 42 8 25.2 % 7.33 [ 0.48, 110.96 ]
Total events: 17 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Total (95% CI) 162 32 100.0 % 3.31 [ 0.83, 13.26 ]
Total events: 29 (Certolizumab), 0 (Control)
Heterogeneity: Chi2 = 1.12, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.090)
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Analysis 1.3. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 3 ACR70
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 50 mg sc
CDP870-004 2001 2/39 0/8 24.8 % 1.13 [ 0.06, 21.47 ]
Subtotal (95% CI) 39 8 24.8 % 1.13 [ 0.06, 21.47 ]
Total events: 2 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 certolizumab 100 mg sc
CDP870-004 2001 1/40 0/8 24.9 % 0.66 [ 0.03, 14.89 ]
Subtotal (95% CI) 40 8 24.9 % 0.66 [ 0.03, 14.89 ]
Total events: 1 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
3 certolizumab 200 mg sc
CDP870-004 2001 3/41 0/8 25.1 % 1.50 [ 0.08, 26.57 ]
Subtotal (95% CI) 41 8 25.1 % 1.50 [ 0.08, 26.57 ]
Total events: 3 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
4 certolizumab 400 mg sc
CDP870-004 2001 12/42 0/8 25.2 % 5.23 [ 0.34, 80.54 ]
Subtotal (95% CI) 42 8 25.2 % 5.23 [ 0.34, 80.54 ]
Total events: 12 (Certolizumab), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI) 162 32 100.0 % 2.14 [ 0.52, 8.76 ]
Total events: 18 (Certolizumab), 0 (Control)
Heterogeneity: Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 2.1. Comparison 2 Efficacy at 24 weeks 200 mg certolizumab sc, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks 200 mg certolizumab sc
Outcome: 1 ACR 20
Study or subgroup
Certolizumab
200 mg sc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 228/393 27/199 71.2 % 4.28 [ 2.98, 6.13 ]
RAPID2 2007 141/246 11/127 28.8 % 6.62 [ 3.72, 11.76 ]
Total (95% CI) 639 326 100.0 % 4.95 [ 3.65, 6.72 ]
Total events: 369 (Certolizumab 200 mg sc), 38 (Placebo)
Heterogeneity: Chi2 = 1.61, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 10.25 (P < 0.00001)
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Analysis 2.2. Comparison 2 Efficacy at 24 weeks 200 mg certolizumab sc, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks 200 mg certolizumab sc
Outcome: 2 ACR 50
Study or subgroup
Certolizumab
200 mg sc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 144/393 15/199 79.1 % 4.86 [ 2.94, 8.04 ]
RAPID2 2007 80/246 4/127 20.9 % 10.33 [ 3.87, 27.54 ]
Total (95% CI) 639 326 100.0 % 6.01 [ 3.84, 9.40 ]
Total events: 224 (Certolizumab 200 mg sc), 19 (Placebo)
Heterogeneity: Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 7.84 (P < 0.00001)
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Analysis 2.3. Comparison 2 Efficacy at 24 weeks 200 mg certolizumab sc, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 Efficacy at 24 weeks 200 mg certolizumab sc
Outcome: 3 ACR 70
Study or subgroup
Certolizumab
200 mg sc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 83/393 6/199 85.8 % 7.00 [ 3.11, 15.76 ]
RAPID2 2007 39/246 1/127 14.2 % 20.13 [ 2.80, 144.86 ]
Total (95% CI) 639 326 100.0 % 8.87 [ 4.20, 18.75 ]
Total events: 122 (Certolizumab 200 mg sc), 7 (Placebo)
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 5.71 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab
Analysis 3.1. Comparison 3 Efficacy at 24 weeks, 400 mg sc certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg sc certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 56/126 27/121 31.3 % 1.99 [ 1.35, 2.93 ]
FAST4WARD 2005 50/111 10/109 11.5 % 4.91 [ 2.63, 9.18 ]
RAPID1 2005 236/390 27/199 40.7 % 4.46 [ 3.11, 6.39 ]
RAPID2 2007 141/246 11/127 16.5 % 6.62 [ 3.72, 11.76 ]
Total (95% CI) 873 556 100.0 % 4.09 [ 3.27, 5.13 ]
Total events: 483 (Certolizumab), 75 (Control)
Heterogeneity: Chi2 = 16.64, df = 3 (P = 0.00084); I2 =82%
Test for overall effect: Z = 12.21 (P < 0.00001)
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Analysis 3.2. Comparison 3 Efficacy at 24 weeks, 400 mg sc certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg sc certolizumab
Outcome: 2 ACR 50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 (1) 22/126 7/121 19.7 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 11.1 % 6.14 [ 2.21, 17.05 ]
RAPID1 2005 155/390 15/199 54.7 % 5.27 [ 3.19, 8.71 ]
RAPID2 2007 81/246 4/127 14.5 % 10.45 [ 3.92, 27.88 ]
Total (95% CI) 873 556 100.0 % 5.68 [ 3.93, 8.20 ]
Total events: 283 (Certolizumab), 30 (Control)
Heterogeneity: Chi2 = 3.91, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 9.27 (P < 0.00001)
Test for subgroup differences: Not applicable
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certolizumab and placebo groups for safety.
(1) EMEA report quotes 126 and 121 patients in certoluzimab and placebo group. Clinical Study Summary (CSS) from UCB quotes n=125 for both groups for effectiveness
and 119 and 124 for
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Analysis 3.3. Comparison 3 Efficacy at 24 weeks, 400 mg sc certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 Efficacy at 24 weeks, 400 mg sc certolizumab
Outcome: 3 ACR 70
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 (1) 0/126 2/121 20.7 % 0.19 [ 0.01, 3.96 ]
FAST4WARD 2005 6/111 0/109 4.1 % 12.77 [ 0.73, 223.93 ]
RAPID1 2005 80/390 6/199 64.5 % 6.80 [ 3.02, 15.32 ]
RAPID2 2007 26/246 1/127 10.7 % 13.42 [ 1.84, 97.78 ]
Total (95% CI) 873 556 100.0 % 6.39 [ 3.32, 12.27 ]
Total events: 112 (Certolizumab), 9 (Control)
Heterogeneity: Chi2 = 5.94, df = 3 (P = 0.11); I2 =49%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 1 ACR20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 228/393 27/100 27.1 % 2.15 [ 1.54, 3.00 ]
RAPID2 2007 141/246 11/64 11.0 % 3.33 [ 1.93, 5.77 ]
Subtotal (95% CI) 639 164 38.1 % 2.49 [ 1.87, 3.32 ]
Total events: 369 (Certolizumab), 38 (Control)
Heterogeneity: Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 6.25 (P < 0.00001)
2 certolizumab 400 mg sc
CDP870-014 2009 56/126 27/121 17.4 % 1.99 [ 1.35, 2.93 ]
FAST4WARD 2005 50/111 10/109 6.4 % 4.91 [ 2.63, 9.18 ]
RAPID1 2005 236/390 27/99 27.1 % 2.22 [ 1.59, 3.09 ]
RAPID2 2007 141/246 11/63 11.0 % 3.28 [ 1.90, 5.68 ]
Subtotal (95% CI) 873 392 61.9 % 2.62 [ 2.11, 3.25 ]
Total events: 483 (Certolizumab), 75 (Control)
Heterogeneity: Chi2 = 7.44, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 8.76 (P < 0.00001)
Total (95% CI) 1512 556 100.0 % 2.57 [ 2.16, 3.05 ]
Total events: 852 (Certolizumab), 113 (Control)
Heterogeneity: Chi2 = 9.30, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 10.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 4.2. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 2 ACR50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 144/393 15/100 33.3 % 2.44 [ 1.50, 3.96 ]
RAPID2 2007 80/246 4/64 8.8 % 5.20 [ 1.98, 13.67 ]
Subtotal (95% CI) 639 164 42.2 % 3.02 [ 1.96, 4.67 ]
Total events: 224 (Certolizumab), 19 (Control)
Heterogeneity: Chi2 = 1.96, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 4.98 (P < 0.00001)
2 certolizumab 400 mg sc
CDP870-014 2009 22/126 7/121 10.0 % 3.02 [ 1.34, 6.81 ]
FAST4WARD 2005 25/111 4/109 5.6 % 6.14 [ 2.21, 17.05 ]
RAPID1 2005 155/390 15/99 33.4 % 2.62 [ 1.62, 4.25 ]
RAPID2 2007 81/246 4/63 8.9 % 5.19 [ 1.98, 13.61 ]
Subtotal (95% CI) 873 392 57.8 % 3.43 [ 2.40, 4.90 ]
Total events: 283 (Certolizumab), 30 (Control)
Heterogeneity: Chi2 = 3.23, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 6.76 (P < 0.00001)
Total (95% CI) 1512 556 100.0 % 3.26 [ 2.47, 4.29 ]
Total events: 507 (Certolizumab), 49 (Control)
Heterogeneity: Chi2 = 5.44, df = 5 (P = 0.37); I2 =8%
Test for overall effect: Z = 8.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 4.3. Comparison 4 Efficacy at 24 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 Efficacy at 24 weeks, any dose
Outcome: 3 ACR70
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 83/393 6/100 37.7 % 3.52 [ 1.58, 7.83 ]
RAPID2 2007 39/246 1/64 6.3 % 10.15 [ 1.42, 72.45 ]
Subtotal (95% CI) 639 164 44.0 % 4.46 [ 2.13, 9.36 ]
Total events: 122 (Certolizumab), 7 (Control)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 3.96 (P = 0.000075)
2 certolizumab 400 mg sc
CDP870-014 2009 0/126 2/121 10.1 % 0.19 [ 0.01, 3.96 ]
FAST4WARD 2005 6/111 0/109 2.0 % 12.77 [ 0.73, 223.93 ]
RAPID1 2005 80/390 6/99 37.7 % 3.38 [ 1.52, 7.53 ]
RAPID2 2007 26/246 1/63 6.3 % 6.66 [ 0.92, 48.13 ]
Subtotal (95% CI) 873 392 56.0 % 3.51 [ 1.83, 6.75 ]
Total events: 112 (Certolizumab), 9 (Control)
Heterogeneity: Chi2 = 4.73, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 3.77 (P = 0.00016)
Total (95% CI) 1512 556 100.0 % 3.93 [ 2.41, 6.41 ]
Total events: 234 (Certolizumab), 16 (Control)
Heterogeneity: Chi2 = 5.85, df = 5 (P = 0.32); I2 =14%
Test for overall effect: Z = 5.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 5.1. Comparison 5 Efficacy at 52 weeks, 200 mg sc certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg sc certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 208/393 26/199 100.0 % 4.05 [ 2.80, 5.87 ]
Total (95% CI) 393 199 100.0 % 4.05 [ 2.80, 5.87 ]
Total events: 208 (Certolizumab), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Efficacy at 52 weeks, 200 mg sc certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg sc certolizumab
Outcome: 2 ACR 50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 149/393 15/199 100.0 % 5.03 [ 3.04, 8.32 ]
Total (95% CI) 393 199 100.0 % 5.03 [ 3.04, 8.32 ]
Total events: 149 (Certolizumab), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Efficacy at 52 weeks, 200 mg sc certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 Efficacy at 52 weeks, 200 mg sc certolizumab
Outcome: 3 ACR 70
Study or subgroup Certolizumab Control
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 83/393 7/199 100.0 % 0.18 [ 0.13, 0.22 ]
Total (95% CI) 393 199 100.0 % 0.18 [ 0.13, 0.22 ]
Total events: 83 (Certolizumab), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Efficacy at 52 weeks, 400 mg sc certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg sc certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 213/390 26/199 100.0 % 4.18 [ 2.89, 6.05 ]
Total (95% CI) 390 199 100.0 % 4.18 [ 2.89, 6.05 ]
Total events: 213 (Certolizumab), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Efficacy at 52 weeks, 400 mg sc certolizumab, Outcome 2 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg sc certolizumab
Outcome: 2 ACR 50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 155/390 15/199 100.0 % 5.27 [ 3.19, 8.71 ]
Total (95% CI) 390 199 100.0 % 5.27 [ 3.19, 8.71 ]
Total events: 155 (Certolizumab), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.49 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Efficacy at 52 weeks, 400 mg sc certolizumab, Outcome 3 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Efficacy at 52 weeks, 400 mg sc certolizumab
Outcome: 3 ACR 70
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 90/390 7/199 100.0 % 6.56 [ 3.10, 13.89 ]
Total (95% CI) 390 199 100.0 % 6.56 [ 3.10, 13.89 ]
Total events: 90 (Certolizumab), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 1 ACR20
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 208/393 26/100 50.0 % 2.04 [ 1.44, 2.87 ]
Subtotal (95% CI) 393 100 50.0 % 2.04 [ 1.44, 2.87 ]
Total events: 208 (Certolizumab), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000050)
2 certolizumab 400 mg sc
RAPID1 2005 213/390 26/99 50.0 % 2.08 [ 1.48, 2.93 ]
Subtotal (95% CI) 390 99 50.0 % 2.08 [ 1.48, 2.93 ]
Total events: 213 (Certolizumab), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.19 (P = 0.000028)
Total (95% CI) 783 199 100.0 % 2.06 [ 1.61, 2.62 ]
Total events: 421 (Certolizumab), 52 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 7.2. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 2 ACR50
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 149/393 15/100 50.0 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 393 100 50.0 % 2.53 [ 1.56, 4.10 ]
Total events: 149 (Certolizumab), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
2 certolizumab 400 mg sc
RAPID1 2005 155/390 15/99 50.0 % 2.62 [ 1.62, 4.25 ]
Subtotal (95% CI) 390 99 50.0 % 2.62 [ 1.62, 4.25 ]
Total events: 155 (Certolizumab), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
Total (95% CI) 783 199 100.0 % 2.58 [ 1.83, 3.62 ]
Total events: 304 (Certolizumab), 30 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certoluzimab
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Analysis 7.3. Comparison 7 Efficacy at 52 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Efficacy at 52 weeks, any dose
Outcome: 3 ACR70
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 83/393 7/100 50.0 % 3.02 [ 1.44, 6.32 ]
Subtotal (95% CI) 393 100 50.0 % 3.02 [ 1.44, 6.32 ]
Total events: 83 (Certolizumab), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
2 certolizumab 400 mg sc
RAPID1 2005 90/390 7/99 50.0 % 3.26 [ 1.56, 6.82 ]
Subtotal (95% CI) 390 99 50.0 % 3.26 [ 1.56, 6.82 ]
Total events: 90 (Certolizumab), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0017)
Total (95% CI) 783 199 100.0 % 3.14 [ 1.86, 5.29 ]
Total events: 173 (Certolizumab), 14 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.30 (P = 0.000017)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 8.1. Comparison 8 Safety certolizumab 200 mg sc, Outcome 1 Any adverse event.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 1 Any adverse event
Study or subgroup
Certolizumab
200 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 293/392 115/199 63.5 % 1.29 [ 1.13, 1.48 ]
RAPID2 2007 139/248 66/125 36.5 % 1.06 [ 0.87, 1.30 ]
Total (95% CI) 640 324 100.0 % 1.21 [ 1.08, 1.35 ]
Total events: 432 (Certolizumab 200 mg sc), 181 (Control)
Heterogeneity: Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 3.37 (P = 0.00075)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 8.2. Comparison 8 Safety certolizumab 200 mg sc, Outcome 2 Adverse events Intensity mild.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 2 Adverse events Intensity mild
Study or subgroup
Certolizumab
200 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 244/392 90/199 66.6 % 1.38 [ 1.16, 1.63 ]
RAPID2 2007 108/248 45/125 33.4 % 1.21 [ 0.92, 1.59 ]
Total (95% CI) 640 324 100.0 % 1.32 [ 1.14, 1.53 ]
Total events: 352 (Certolizumab 200 mg sc), 135 (Control)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Safety certolizumab 200 mg sc, Outcome 3 Adverse events Intensity moderate.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 3 Adverse events Intensity moderate
Study or subgroup
Certolizumab
200 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 174/392 66/199 67.3 % 1.34 [ 1.07, 1.68 ]
RAPID2 2007 61/248 32/125 32.7 % 0.96 [ 0.66, 1.39 ]
Total (95% CI) 640 324 100.0 % 1.21 [ 1.00, 1.47 ]
Total events: 235 (Certolizumab 200 mg sc), 98 (Control)
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.98 (P = 0.048)
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Analysis 8.4. Comparison 8 Safety certolizumab 200 mg sc, Outcome 4 Adverse events Intensity severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 4 Adverse events Intensity severe
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 32/392 13/199 66.8 % 1.26 [ 0.66, 2.40 ]
RAPID2 2007 17/248 5/125 33.2 % 1.67 [ 0.67, 4.16 ]
Total (95% CI) 640 324 100.0 % 1.38 [ 0.82, 2.34 ]
Total events: 49 (Certolizumab 200 mg sc), 18 (Control)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Safety certolizumab 200 mg sc, Outcome 5 Adverse events related to study
drug.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 5 Adverse events related to study drug
Study or subgroup
Certolizumab
200 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 167/392 50/199 68.4 % 1.70 [ 1.30, 2.21 ]
RAPID2 2007 61/248 23/125 31.6 % 1.34 [ 0.87, 2.05 ]
Total (95% CI) 640 324 100.0 % 1.58 [ 1.26, 1.98 ]
Total events: 228 (Certolizumab 200 mg sc), 73 (Control)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 3.98 (P = 0.000068)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 Safety certolizumab 200 mg sc, Outcome 6 Serious Adverse Events (SAE).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 6 Serious Adverse Events (SAE)
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 45/392 11/199 71.0 % 2.00 [ 1.12, 3.58 ]
RAPID2 2007 18/248 4/125 29.0 % 2.07 [ 0.83, 5.16 ]
Total (95% CI) 640 324 100.0 % 2.02 [ 1.24, 3.30 ]
Total events: 63 (Certolizumab 200 mg sc), 15 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Safety certolizumab 200 mg sc, Outcome 7 Serious Infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 7 Serious Infections
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 16/392 2/199 69.1 % 2.83 [ 1.05, 7.63 ]
RAPID2 2007 8/248 0/125 30.9 % 4.63 [ 1.05, 20.39 ]
Total (95% CI) 640 324 100.0 % 3.30 [ 1.45, 7.51 ]
Total events: 24 (Certolizumab 200 mg sc), 2 (Control)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Safety certolizumab 200 mg sc, Outcome 8 Adverse events leading to death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 8 Adverse events leading to death
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/392 1/199 75.0 % 1.02 [ 0.09, 11.18 ]
RAPID2 2007 1/248 0/125 25.0 % 4.50 [ 0.07, 286.06 ]
Total (95% CI) 640 324 100.0 % 1.47 [ 0.18, 11.76 ]
Total events: 3 (Certolizumab 200 mg sc), 1 (Control)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 8.9. Comparison 8 Safety certolizumab 200 mg sc, Outcome 9 Adverse events leading to
withdrawal.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 9 Adverse events leading to withdrawal
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 17/392 3/199 58.9 % 2.37 [ 0.92, 6.09 ]
RAPID2 2007 12/248 2/125 41.1 % 2.45 [ 0.79, 7.57 ]
Total (95% CI) 640 324 100.0 % 2.40 [ 1.16, 4.95 ]
Total events: 29 (Certolizumab 200 mg sc), 5 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 8.10. Comparison 8 Safety certolizumab 200 mg sc, Outcome 10 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 10 Death
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 3/392 1/199 79.9 % 1.48 [ 0.18, 11.81 ]
RAPID2 2007 1/246 0/125 20.1 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 638 324 100.0 % 1.85 [ 0.29, 11.86 ]
Total events: 4 (Certolizumab 200 mg sc), 1 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 8.11. Comparison 8 Safety certolizumab 200 mg sc, Outcome 11 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 11 Tuberculosis
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/392 0/199 40.1 % 4.53 [ 0.24, 85.22 ]
RAPID2 2007 3/248 0/125 59.9 % 4.54 [ 0.41, 50.19 ]
Total (95% CI) 640 324 100.0 % 4.53 [ 0.71, 29.11 ]
Total events: 5 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 8.12. Comparison 8 Safety certolizumab 200 mg sc, Outcome 12 Malignancies included lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 12 Malignancies included lymphoma
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 (1) 7/392 1/199 79.9 % 2.61 [ 0.60, 11.41 ]
RAPID2 2007 1/248 1/125 20.1 % 0.48 [ 0.03, 9.01 ]
Total (95% CI) 640 324 100.0 % 1.85 [ 0.50, 6.93 ]
Total events: 8 (Certolizumab 200 mg sc), 2 (Control)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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system], one adrenal adenoma, one hepatic neoplasm one esophageal carcinoma, and uterine cancer
(1) One patient in the arm of placebo suffered a thyroid neoplasm and 7 in the arm of certolizumab 200 mg sc suffered: three basal cell carcinomas [one with metastasis
to the central nervous
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Analysis 8.13. Comparison 8 Safety certolizumab 200 mg sc, Outcome 13 Injection site pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 13 Injection site pain
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 8/392 0/199 100.0 % 4.60 [ 1.05, 20.10 ]
RAPID2 2007 0/248 0/125 Not estimable
Total (95% CI) 640 324 100.0 % 4.60 [ 1.05, 20.10 ]
Total events: 8 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 8.14. Comparison 8 Safety certolizumab 200 mg sc, Outcome 14 Injection side reactions.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 14 Injection side reactions
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 9/392 0/199 74.9 % 4.61 [ 1.15, 18.55 ]
RAPID2 2007 3/248 0/125 25.1 % 4.54 [ 0.41, 50.19 ]
Total (95% CI) 640 324 100.0 % 4.59 [ 1.38, 15.32 ]
Total events: 12 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 8.15. Comparison 8 Safety certolizumab 200 mg sc, Outcome 15 Neutralising Anti-certolizumab
pegol antibodies.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 15 Neutralising Anti-certolizumab pegol antibodies
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 5/248 0/125 100.0 % 4.57 [ 0.71, 29.59 ]
Total (95% CI) 248 125 100.0 % 4.57 [ 0.71, 29.59 ]
Total events: 5 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 8.16. Comparison 8 Safety certolizumab 200 mg sc, Outcome 16 Systemic lupus erythematosus.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 16 Systemic lupus erythematosus
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 1/248 0/125 100.0 % 4.50 [ 0.07, 286.06 ]
Total (95% CI) 248 125 100.0 % 4.50 [ 0.07, 286.06 ]
Total events: 1 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 8.17. Comparison 8 Safety certolizumab 200 mg sc, Outcome 17 Prolonged activated partial
thromboplastin time (aPTT).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 17 Prolonged activated partial thromboplastin time (aPTT)
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 12/248 2/125 100.0 % 2.45 [ 0.79, 7.57 ]
Total (95% CI) 248 125 100.0 % 2.45 [ 0.79, 7.57 ]
Total events: 12 (Certolizumab 200 mg sc), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 8.18. Comparison 8 Safety certolizumab 200 mg sc, Outcome 18 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 18 Urinary tract infection
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 23/392 13/199 64.1 % 0.89 [ 0.44, 1.82 ]
RAPID2 2007 11/248 9/125 35.9 % 0.58 [ 0.22, 1.51 ]
Total (95% CI) 640 324 100.0 % 0.76 [ 0.43, 1.35 ]
Total events: 34 (Certolizumab 200 mg sc), 22 (Control)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 8.19. Comparison 8 Safety certolizumab 200 mg sc, Outcome 19 Upper respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 19 Upper respiratory tract infection
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 24/392 5/199 68.8 % 2.16 [ 0.98, 4.77 ]
RAPID2 2007 11/248 2/125 31.2 % 2.32 [ 0.72, 7.47 ]
Total (95% CI) 640 324 100.0 % 2.21 [ 1.15, 4.25 ]
Total events: 35 (Certolizumab 200 mg sc), 7 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 8.20. Comparison 8 Safety certolizumab 200 mg sc, Outcome 20 Lower respiratory tract infection/
lung infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 20 Lower respiratory tract infection/ lung infection
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 3/392 0/199 100.0 % 4.54 [ 0.41, 49.96 ]
Total (95% CI) 392 199 100.0 % 4.54 [ 0.41, 49.96 ]
Total events: 3 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 8.21. Comparison 8 Safety certolizumab 200 mg sc, Outcome 21 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 21 Headache
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 22/392 11/199 76.2 % 1.02 [ 0.48, 2.13 ]
RAPID2 2007 9/248 1/125 23.8 % 2.95 [ 0.78, 11.14 ]
Total (95% CI) 640 324 100.0 % 1.31 [ 0.68, 2.50 ]
Total events: 31 (Certolizumab 200 mg sc), 12 (Control)
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 8.22. Comparison 8 Safety certolizumab 200 mg sc, Outcome 22 Bacteriuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 22 Bacteriuria
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 8/248 4/125 100.0 % 1.01 [ 0.30, 3.40 ]
Total (95% CI) 248 125 100.0 % 1.01 [ 0.30, 3.40 ]
Total events: 8 (Certolizumab 200 mg sc), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 8.23. Comparison 8 Safety certolizumab 200 mg sc, Outcome 23 Nasopharyngitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 23 Nasopharyngitis
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 21/392 3/199 72.4 % 2.68 [ 1.13, 6.36 ]
RAPID2 2007 8/248 1/125 27.6 % 2.79 [ 0.69, 11.32 ]
Total (95% CI) 640 324 100.0 % 2.71 [ 1.30, 5.66 ]
Total events: 29 (Certolizumab 200 mg sc), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0078)
Test for subgroup differences: Not applicable
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Analysis 8.24. Comparison 8 Safety certolizumab 200 mg sc, Outcome 24 Hypertension.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 24 Hypertension
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 25/392 2/199 76.7 % 3.42 [ 1.51, 7.74 ]
RAPID2 2007 6/248 2/125 23.3 % 1.48 [ 0.34, 6.50 ]
Total (95% CI) 640 324 100.0 % 2.81 [ 1.38, 5.75 ]
Total events: 31 (Certolizumab 200 mg sc), 4 (Control)
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
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Analysis 8.25. Comparison 8 Safety certolizumab 200 mg sc, Outcome 25 Hematuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 25 Hematuria
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 4/248 5/125 100.0 % 0.36 [ 0.09, 1.47 ]
Total (95% CI) 248 125 100.0 % 0.36 [ 0.09, 1.47 ]
Total events: 4 (Certolizumab 200 mg sc), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 8.26. Comparison 8 Safety certolizumab 200 mg sc, Outcome 26 Hepatic enzyme increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 26 Hepatic enzyme increased
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 3/248 4/125 100.0 % 0.34 [ 0.07, 1.66 ]
Total (95% CI) 248 125 100.0 % 0.34 [ 0.07, 1.66 ]
Total events: 3 (Certolizumab 200 mg sc), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 8.27. Comparison 8 Safety certolizumab 200 mg sc, Outcome 27 AST increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 27 AST increased
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 2/248 5/125 100.0 % 0.18 [ 0.04, 0.86 ]
Total (95% CI) 248 125 100.0 % 0.18 [ 0.04, 0.86 ]
Total events: 2 (Certolizumab 200 mg sc), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 8.28. Comparison 8 Safety certolizumab 200 mg sc, Outcome 28 ALT increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 28 ALT increased
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 1/248 6/125 100.0 % 0.09 [ 0.02, 0.45 ]
Total (95% CI) 248 125 100.0 % 0.09 [ 0.02, 0.45 ]
Total events: 1 (Certolizumab 200 mg sc), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 8.29. Comparison 8 Safety certolizumab 200 mg sc, Outcome 29 Back pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 29 Back pain
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 17/392 2/199 100.0 % 2.91 [ 1.11, 7.65 ]
Total (95% CI) 392 199 100.0 % 2.91 [ 1.11, 7.65 ]
Total events: 17 (Certolizumab 200 mg sc), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 8.30. Comparison 8 Safety certolizumab 200 mg sc, Outcome 30 Herpes viral infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 30 Herpes viral infection
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/392 0/199 100.0 % 4.52 [ 0.07, 285.70 ]
Total (95% CI) 392 199 100.0 % 4.52 [ 0.07, 285.70 ]
Total events: 1 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 8.31. Comparison 8 Safety certolizumab 200 mg sc, Outcome 31 Bacterial peritonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 31 Bacterial peritonitis
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/392 0/199 100.0 % 4.52 [ 0.07, 285.70 ]
Total (95% CI) 392 199 100.0 % 4.52 [ 0.07, 285.70 ]
Total events: 1 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 8.32. Comparison 8 Safety certolizumab 200 mg sc, Outcome 32 Opportunistic infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 32 Opportunistic infections
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/392 0/199 Not estimable
Total (95% CI) 392 199 Not estimable
Total events: 0 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 8.33. Comparison 8 Safety certolizumab 200 mg sc, Outcome 33 Infections and infestations.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 33 Infections and infestations
Study or subgroup
Certolizumab
200 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 171/392 52/199 62.2 % 1.67 [ 1.29, 2.16 ]
RAPID2 2007 26/108 69/248 37.8 % 0.87 [ 0.59, 1.28 ]
Total (95% CI) 500 447 100.0 % 1.37 [ 1.10, 1.69 ]
Total events: 197 (Certolizumab 200 mg sc), 121 (Control)
Heterogeneity: Chi2 = 7.55, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.86 (P = 0.0042)
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Analysis 8.34. Comparison 8 Safety certolizumab 200 mg sc, Outcome 34 Gastroenteritis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 34 Gastroenteritis
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/392 1/199 100.0 % 0.05 [ 0.00, 3.25 ]
Total (95% CI) 392 199 100.0 % 0.05 [ 0.00, 3.25 ]
Total events: 0 (Certolizumab 200 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Favours certolizumab 200 mg sc Favours control
Analysis 8.35. Comparison 8 Safety certolizumab 200 mg sc, Outcome 35 Hematologic abnormalities.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 35 Hematologic abnormalities
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/392 0/199 100.0 % 4.53 [ 0.24, 85.22 ]
Total (95% CI) 392 199 100.0 % 4.53 [ 0.24, 85.22 ]
Total events: 2 (Certolizumab 200 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 8.36. Comparison 8 Safety certolizumab 200 mg sc, Outcome 36 Decreased haemoglobin.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 36 Decreased haemoglobin
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/392 1/199 100.0 % 1.02 [ 0.09, 11.18 ]
Total (95% CI) 392 199 100.0 % 1.02 [ 0.09, 11.18 ]
Total events: 2 (Certolizumab 200 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 8.37. Comparison 8 Safety certolizumab 200 mg sc, Outcome 37 Increased platelet count.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 Safety certolizumab 200 mg sc
Outcome: 37 Increased platelet count
Study or subgroup
Certolizumab
200 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/392 1/199 100.0 % 0.05 [ 0.00, 3.25 ]
Total (95% CI) 392 199 100.0 % 0.05 [ 0.00, 3.25 ]
Total events: 0 (Certolizumab 200 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Safety certolizumab 400 mg sc, Outcome 1 Any adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 1 Any adverse events
Study or subgroup
Certolizumab
400 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 97/124 83/119 21.8 % 1.12 [ 0.96, 1.30 ]
FAST4WARD 2005 84/111 63/109 16.4 % 1.31 [ 1.08, 1.59 ]
RAPID1 2005 298/389 115/199 39.2 % 1.33 [ 1.16, 1.51 ]
RAPID2 2007 125/246 66/125 22.6 % 0.96 [ 0.78, 1.18 ]
Total (95% CI) 870 552 100.0 % 1.20 [ 1.10, 1.30 ]
Total events: 604 (Certolizumab 400 mg sc), 327 (Control)
Heterogeneity: Chi2 = 8.19, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 4.28 (P = 0.000019)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Safety certolizumab 400 mg sc, Outcome 2 Adverse events Intensity mild.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 2 Adverse events Intensity mild
Study or subgroup
Certolizumab
400 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FAST4WARD 2005 62/111 43/109 19.5 % 1.42 [ 1.06, 1.88 ]
RAPID1 2005 254/389 90/199 53.6 % 1.44 [ 1.22, 1.71 ]
RAPID2 2007 101/246 45/125 26.9 % 1.14 [ 0.86, 1.51 ]
Total (95% CI) 746 433 100.0 % 1.36 [ 1.19, 1.54 ]
Total events: 417 (Certolizumab 400 mg sc), 178 (Control)
Heterogeneity: Chi2 = 2.11, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Safety certolizumab 400 mg sc, Outcome 3 Adverse events Intensity moderate.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 3 Adverse events Intensity moderate
Study or subgroup
Certolizumab
400 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FAST4WARD 2005 52/111 40/109 23.7 % 1.28 [ 0.93, 1.75 ]
RAPID1 2005 177/389 66/199 51.3 % 1.37 [ 1.10, 1.72 ]
RAPID2 2007 57/246 32/125 24.9 % 0.91 [ 0.62, 1.32 ]
Total (95% CI) 746 433 100.0 % 1.23 [ 1.05, 1.45 ]
Total events: 286 (Certolizumab 400 mg sc), 138 (Control)
Heterogeneity: Chi2 = 3.51, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Safety certolizumab 400 mg sc, Outcome 4 Adverse events Intensity severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 4 Adverse events Intensity severe
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 8/111 11/109 23.1 % 0.69 [ 0.27, 1.78 ]
RAPID1 2005 38/389 13/199 55.4 % 1.50 [ 0.82, 2.76 ]
RAPID2 2007 14/246 5/125 21.4 % 1.41 [ 0.53, 3.75 ]
Total (95% CI) 746 433 100.0 % 1.24 [ 0.79, 1.95 ]
Total events: 60 (Certolizumab 400 mg sc), 29 (Control)
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Safety certolizumab 400 mg sc, Outcome 5 Adverse events related to study
drug.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 5 Adverse events related to study drug
Study or subgroup
Certolizumab
400 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FAST4WARD 2005 27/111 24/109 20.0 % 1.10 [ 0.68, 1.79 ]
RAPID1 2005 166/389 50/199 54.7 % 1.70 [ 1.30, 2.22 ]
RAPID2 2007 56/246 23/125 25.2 % 1.24 [ 0.80, 1.91 ]
Total (95% CI) 746 433 100.0 % 1.46 [ 1.19, 1.80 ]
Total events: 249 (Certolizumab 400 mg sc), 97 (Control)
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 3.65 (P = 0.00027)
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Analysis 9.6. Comparison 9 Safety certolizumab 400 mg sc, Outcome 6 Serious infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 6 Serious infections
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 3/124 2/119 14.6 % 1.44 [ 0.25, 8.44 ]
FAST4WARD 2005 2/111 0/109 5.9 % 7.32 [ 0.46, 117.84 ]
RAPID1 2005 23/389 2/199 63.8 % 3.33 [ 1.43, 7.76 ]
RAPID2 2007 6/246 0/125 15.7 % 4.61 [ 0.84, 25.36 ]
Total (95% CI) 870 552 100.0 % 3.25 [ 1.65, 6.39 ]
Total events: 34 (Certolizumab 400 mg sc), 4 (Control)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00063)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Safety certolizumab 400 mg sc, Outcome 7 Serious Adverse Events (SAE).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 7 Serious Adverse Events (SAE)
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 16/124 12/119 24.5 % 1.32 [ 0.60, 2.89 ]
FAST4WARD 2005 8/111 3/109 10.3 % 2.54 [ 0.76, 8.53 ]
RAPID1 2005 48/389 11/199 46.9 % 2.12 [ 1.20, 3.75 ]
RAPID2 2007 18/246 4/125 18.3 % 2.09 [ 0.84, 5.19 ]
Total (95% CI) 870 552 100.0 % 1.92 [ 1.30, 2.83 ]
Total events: 90 (Certolizumab 400 mg sc), 30 (Control)
Heterogeneity: Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Safety certolizumab 400 mg sc, Outcome 8 Adverse events leading to death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 8 Adverse events leading to death
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 4/389 1/199 83.3 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 1/246 0/125 16.7 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 2.16 [ 0.40, 11.79 ]
Total events: 5 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 9.9. Comparison 9 Safety certolizumab 400 mg sc, Outcome 9 Adverse events leading to
withdrawal.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 9 Adverse events leading to withdrawal
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 5/111 2/109 18.8 % 2.37 [ 0.53, 10.64 ]
RAPID1 2005 22/389 3/199 59.4 % 2.77 [ 1.19, 6.44 ]
RAPID2 2007 7/246 2/125 21.8 % 1.69 [ 0.42, 6.84 ]
Total (95% CI) 746 433 100.0 % 2.41 [ 1.26, 4.63 ]
Total events: 34 (Certolizumab 400 mg sc), 7 (Control)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
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Analysis 9.10. Comparison 9 Safety certolizumab 400 mg sc, Outcome 10 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 10 Death
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 0/124 0/119 Not estimable
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 4/389 1/199 83.3 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 1/246 0/125 16.7 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 870 552 100.0 % 2.16 [ 0.40, 11.79 ]
Total events: 5 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 9.11. Comparison 9 Safety certolizumab 400 mg sc, Outcome 11 Vomiting.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 11 Vomiting
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 1/109 100.0 % 0.13 [ 0.00, 6.70 ]
Total (95% CI) 111 109 100.0 % 0.13 [ 0.00, 6.70 ]
Total events: 0 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
105Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.12. Comparison 9 Safety certolizumab 400 mg sc, Outcome 12 Pneumonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 12 Pneumonitis
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 1/109 100.0 % 0.13 [ 0.00, 6.70 ]
Total (95% CI) 111 109 100.0 % 0.13 [ 0.00, 6.70 ]
Total events: 0 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 9.13. Comparison 9 Safety certolizumab 400 mg sc, Outcome 13 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 13 Tuberculosis
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 3/389 0/199 60.0 % 4.56 [ 0.42, 50.01 ]
RAPID2 2007 2/246 0/125 40.0 % 4.54 [ 0.24, 85.48 ]
Total (95% CI) 746 433 100.0 % 4.55 [ 0.71, 29.11 ]
Total events: 5 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Safety certolizumab 400 mg sc, Outcome 14 Arthritis bacterial.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 14 Arthritis bacterial
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.15. Comparison 9 Safety certolizumab 400 mg sc, Outcome 15 Mastitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 15 Mastitis
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.16. Comparison 9 Safety certolizumab 400 mg sc, Outcome 16 Benign Tumour.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 16 Benign Tumour
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 2/111 0/109 100.0 % 7.32 [ 0.46, 117.84 ]
Total (95% CI) 111 109 100.0 % 7.32 [ 0.46, 117.84 ]
Total events: 2 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.17. Comparison 9 Safety certolizumab 400 mg sc, Outcome 17 Ischaemeic stroke.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 17 Ischaemeic stroke
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.18. Comparison 9 Safety certolizumab 400 mg sc, Outcome 18 Dizziness postural.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 18 Dizziness postural
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.19. Comparison 9 Safety certolizumab 400 mg sc, Outcome 19 Menorrhagia.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 19 Menorrhagia
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.20. Comparison 9 Safety certolizumab 400 mg sc, Outcome 20 Malignancies included lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 20 Malignancies included lymphoma
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 0/109 Not estimable
RAPID1 2005 (1) 4/389 1/199 71.4 % 1.86 [ 0.29, 11.96 ]
RAPID2 2007 (2) 1/246 1/125 28.6 % 0.48 [ 0.03, 9.06 ]
Total (95% CI) 746 433 100.0 % 1.26 [ 0.26, 6.08 ]
Total events: 5 (Certolizumab 400 mg sc), 2 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
one papilloma.
(1) In the placebo arm one patient suffered a thyroid neoplasm and 4 in the certolizumab 400 mg sc suffered two tongue neoplasm, 1 extranodal marginal zone B cell
limphoma and
(2) One case of malignant neoplasm was reported in each arm, namely bladder cancer in the placebo group and colon cancer in certolizumab pegol 400 mg group
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Analysis 9.21. Comparison 9 Safety certolizumab 400 mg sc, Outcome 21 Injection site pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 21 Injection site pain
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 0/111 2/109 27.2 % 0.13 [ 0.01, 2.12 ]
RAPID1 2005 5/389 0/199 60.7 % 4.58 [ 0.71, 29.39 ]
RAPID2 2007 1/246 0/125 12.2 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 1.74 [ 0.41, 7.42 ]
Total events: 6 (Certolizumab 400 mg sc), 2 (Control)
Heterogeneity: Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 9.22. Comparison 9 Safety certolizumab 400 mg sc, Outcome 22 Injection side reactions.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 22 Injection side reactions
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 5/111 15/109 72.0 % 0.33 [ 0.13, 0.82 ]
RAPID1 2005 3/389 0/199 10.6 % 4.56 [ 0.42, 50.01 ]
RAPID2 2007 5/246 0/125 17.4 % 4.59 [ 0.71, 29.64 ]
Total (95% CI) 746 433 100.0 % 0.69 [ 0.31, 1.49 ]
Total events: 13 (Certolizumab 400 mg sc), 15 (Control)
Heterogeneity: Chi2 = 8.88, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab 400 mg sc Favours control
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Analysis 9.23. Comparison 9 Safety certolizumab 400 mg sc, Outcome 23 Anti-certolizumab pegol
antibodies.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 23 Anti-certolizumab pegol antibodies
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 9/111 0/109 71.0 % 7.82 [ 2.07, 29.62 ]
RAPID2 2007 4/246 0/125 29.0 % 4.57 [ 0.57, 36.68 ]
Total (95% CI) 357 234 100.0 % 6.70 [ 2.18, 20.55 ]
Total events: 13 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.24. Comparison 9 Safety certolizumab 400 mg sc, Outcome 24 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 24 Antinuclear antibodies (ANA)
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
FAST4WARD 2005 19/111 12/109 100.0 % 1.65 [ 0.77, 3.53 ]
Total (95% CI) 111 109 100.0 % 1.65 [ 0.77, 3.53 ]
Total events: 19 (Certolizumab 400 mg sc), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
114Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.25. Comparison 9 Safety certolizumab 400 mg sc, Outcome 25 Prolonged activated partial
thromboplastin time (aPTT).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 25 Prolonged activated partial thromboplastin time (aPTT)
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 12/246 2/125 100.0 % 2.46 [ 0.80, 7.60 ]
Total (95% CI) 246 125 100.0 % 2.46 [ 0.80, 7.60 ]
Total events: 12 (Certolizumab 400 mg sc), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.26. Comparison 9 Safety certolizumab 400 mg sc, Outcome 26 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 26 Urinary tract infection
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 33/389 13/199 75.9 % 1.31 [ 0.69, 2.47 ]
RAPID2 2007 5/246 9/125 24.1 % 0.24 [ 0.08, 0.75 ]
Total (95% CI) 635 324 100.0 % 0.87 [ 0.50, 1.52 ]
Total events: 38 (Certolizumab 400 mg sc), 22 (Control)
Heterogeneity: Chi2 = 6.54, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab 400 mg sc Favours control
Analysis 9.27. Comparison 9 Safety certolizumab 400 mg sc, Outcome 27 Back pain.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 27 Back pain
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 20/389 2/199 100.0 % 3.15 [ 1.28, 7.74 ]
Total (95% CI) 389 199 100.0 % 3.15 [ 1.28, 7.74 ]
Total events: 20 (Certolizumab 400 mg sc), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 9.28. Comparison 9 Safety certolizumab 400 mg sc, Outcome 28 Upper respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 28 Upper respiratory tract infection
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 21/389 5/199 80.8 % 1.98 [ 0.86, 4.54 ]
RAPID2 2007 4/246 2/125 19.2 % 1.02 [ 0.18, 5.59 ]
Total (95% CI) 635 324 100.0 % 1.74 [ 0.83, 3.67 ]
Total events: 25 (Certolizumab 400 mg sc), 7 (Control)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.29. Comparison 9 Safety certolizumab 400 mg sc, Outcome 29 Lower respiratory tract infection/
lung infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 29 Lower respiratory tract infection/ lung infection
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 4/389 0/199 100.0 % 4.57 [ 0.57, 36.44 ]
Total (95% CI) 389 199 100.0 % 4.57 [ 0.57, 36.44 ]
Total events: 4 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.30. Comparison 9 Safety certolizumab 400 mg sc, Outcome 30 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 30 Headache
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 18/389 11/199 75.9 % 0.83 [ 0.38, 1.82 ]
RAPID2 2007 8/246 1/125 24.1 % 2.81 [ 0.69, 11.36 ]
Total (95% CI) 635 324 100.0 % 1.11 [ 0.56, 2.20 ]
Total events: 26 (Certolizumab 400 mg sc), 12 (Control)
Heterogeneity: Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.31. Comparison 9 Safety certolizumab 400 mg sc, Outcome 31 Bacteriuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 31 Bacteriuria
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 6/246 4/125 100.0 % 0.75 [ 0.20, 2.82 ]
Total (95% CI) 246 125 100.0 % 0.75 [ 0.20, 2.82 ]
Total events: 6 (Certolizumab 400 mg sc), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.32. Comparison 9 Safety certolizumab 400 mg sc, Outcome 32 Hypertension.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 32 Hypertension
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 32/389 2/199 75.0 % 3.76 [ 1.81, 7.80 ]
RAPID2 2007 9/246 2/125 25.0 % 2.04 [ 0.57, 7.25 ]
Total (95% CI) 635 324 100.0 % 3.23 [ 1.71, 6.08 ]
Total events: 41 (Certolizumab 400 mg sc), 4 (Control)
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.33. Comparison 9 Safety certolizumab 400 mg sc, Outcome 33 Hematuria.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 33 Hematuria
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 4/246 5/125 100.0 % 0.37 [ 0.09, 1.49 ]
Total (95% CI) 246 125 100.0 % 0.37 [ 0.09, 1.49 ]
Total events: 4 (Certolizumab 400 mg sc), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.34. Comparison 9 Safety certolizumab 400 mg sc, Outcome 34 Hepatic enzyme increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 34 Hepatic enzyme increased
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 3/246 4/125 100.0 % 0.34 [ 0.07, 1.67 ]
Total (95% CI) 246 125 100.0 % 0.34 [ 0.07, 1.67 ]
Total events: 3 (Certolizumab 400 mg sc), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.35. Comparison 9 Safety certolizumab 400 mg sc, Outcome 35 AST increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 35 AST increased
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 6/246 5/125 100.0 % 0.58 [ 0.16, 2.07 ]
Total (95% CI) 246 125 100.0 % 0.58 [ 0.16, 2.07 ]
Total events: 6 (Certolizumab 400 mg sc), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.36. Comparison 9 Safety certolizumab 400 mg sc, Outcome 36 ALT increased.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 36 ALT increased
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID2 2007 8/246 6/127 100.0 % 0.67 [ 0.22, 2.05 ]
Total (95% CI) 246 127 100.0 % 0.67 [ 0.22, 2.05 ]
Total events: 8 (Certolizumab 400 mg sc), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 9.37. Comparison 9 Safety certolizumab 400 mg sc, Outcome 37 Herpes viral infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 37 Herpes viral infection
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/389 0/199 100.0 % 4.53 [ 0.07, 285.35 ]
Total (95% CI) 389 199 100.0 % 4.53 [ 0.07, 285.35 ]
Total events: 1 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.38. Comparison 9 Safety certolizumab 400 mg sc, Outcome 38 Bacterial peritonitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 38 Bacterial peritonitis
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/389 0/199 Not estimable
Total (95% CI) 389 199 Not estimable
Total events: 0 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
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Analysis 9.39. Comparison 9 Safety certolizumab 400 mg sc, Outcome 39 Opportunistic infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 39 Opportunistic infections
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 0/389 0/199 Not estimable
Total (95% CI) 389 199 Not estimable
Total events: 0 (Certolizumab 400 mg sc), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.40. Comparison 9 Safety certolizumab 400 mg sc, Outcome 40 Infections and infestations.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 40 Infections and infestations
Study or subgroup
Certolizumab
400 mg sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 33/124 17/119 14.4 % 1.86 [ 1.10, 3.16 ]
RAPID1 2005 184/389 52/199 57.0 % 1.81 [ 1.40, 2.34 ]
RAPID2 2007 53/246 26/125 28.6 % 1.04 [ 0.68, 1.57 ]
Total (95% CI) 759 443 100.0 % 1.60 [ 1.31, 1.95 ]
Total events: 270 (Certolizumab 400 mg sc), 95 (Control)
Heterogeneity: Chi2 = 5.39, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 4.58 (P < 0.00001)
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Analysis 9.41. Comparison 9 Safety certolizumab 400 mg sc, Outcome 41 Nasopharyngitis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 41 Nasopharyngitis
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 30/389 3/199 86.3 % 3.22 [ 1.53, 6.76 ]
RAPID2 2007 4/246 1/125 13.7 % 1.86 [ 0.29, 11.99 ]
Total (95% CI) 635 324 100.0 % 2.99 [ 1.50, 5.95 ]
Total events: 34 (Certolizumab 400 mg sc), 4 (Control)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 400 mg sc Favours control
Analysis 9.42. Comparison 9 Safety certolizumab 400 mg sc, Outcome 42 Gastrointestinal disorders.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 42 Gastrointestinal disorders
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 22/124 19/119 97.4 % 1.13 [ 0.58, 2.22 ]
RAPID1 2005 0/389 1/199 2.6 % 0.05 [ 0.00, 3.28 ]
Total (95% CI) 513 318 100.0 % 1.05 [ 0.54, 2.03 ]
Total events: 22 (Certolizumab 400 mg sc), 20 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 9.43. Comparison 9 Safety certolizumab 400 mg sc, Outcome 43 Hematologic abnormalities.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 43 Hematologic abnormalities
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 3/389 2/199 100.0 % 0.76 [ 0.12, 4.86 ]
Total (95% CI) 389 199 100.0 % 0.76 [ 0.12, 4.86 ]
Total events: 3 (Certolizumab 400 mg sc), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 9.44. Comparison 9 Safety certolizumab 400 mg sc, Outcome 44 Decreased Haemoglobin.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 44 Decreased Haemoglobin
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 1/389 1/199 100.0 % 0.49 [ 0.03, 9.10 ]
Total (95% CI) 389 199 100.0 % 0.49 [ 0.03, 9.10 ]
Total events: 1 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 9.45. Comparison 9 Safety certolizumab 400 mg sc, Outcome 45 Increased platelet count.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 Safety certolizumab 400 mg sc
Outcome: 45 Increased platelet count
Study or subgroup
Certolizumab
400 mg sc Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 2/389 1/199 100.0 % 1.02 [ 0.09, 11.23 ]
Total (95% CI) 389 199 100.0 % 1.02 [ 0.09, 11.23 ]
Total events: 2 (Certolizumab 400 mg sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Mean HAQ-DI from baseline at week 24, Outcome 1 certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 10 Mean HAQ-DI from baseline at week 24
Outcome: 1 certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -0.58 (0.59) 199 -0.17 (0.56) 50.3 % -0.41 [ -0.51, -0.31 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 49.7 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 639 326 100.0 % -0.39 [ -0.45, -0.32 ]
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 10.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Mean HAQ-DI from baseline at week 24, Outcome 2 certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 10 Mean HAQ-DI from baseline at week 24
Outcome: 2 certolizumab 400 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
FAST4WARD 2005 (1) 111 -0.36 (0.51) 109 0.13 (0.51) 20.8 % -0.49 [ -0.62, -0.36 ]
RAPID1 2005 390 -0.6 (0.59) 199 -0.17 (0.56) 39.8 % -0.43 [ -0.53, -0.33 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 39.4 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 747 435 100.0 % -0.41 [ -0.48, -0.35 ]
Heterogeneity: Chi2 = 2.49, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 13.24 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
Analysis 11.1. Comparison 11 HAQ-Di at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 11 HAQ-Di at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 -0.58 (0.59) 100 -0.17 (0.56) 20.8 % -0.41 [ -0.53, -0.29 ]
RAPID2 2007 246 -0.5 (0.47) 64 -0.14 (0.45) 20.6 % -0.36 [ -0.48, -0.24 ]
Subtotal (95% CI) 639 164 41.4 % -0.39 [ -0.47, -0.30 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 8.57 (P < 0.00001)
2 certolizumab 400 mg sc
FAST4WARD 2005 111 -0.36 (0.51) 109 0.13 (0.51) 17.7 % -0.49 [ -0.62, -0.36 ]
RAPID1 2005 390 -0.6 (0.59) 99 -0.17 (0.56) 20.6 % -0.43 [ -0.55, -0.31 ]
RAPID2 2007 246 -0.5 (0.47) 63 -0.14 (0.45) 20.3 % -0.36 [ -0.49, -0.23 ]
Subtotal (95% CI) 747 271 58.6 % -0.42 [ -0.50, -0.35 ]
Heterogeneity: Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 11.22 (P < 0.00001)
Total (95% CI) 1386 435 100.0 % -0.41 [ -0.46, -0.35 ]
Heterogeneity: Chi2 = 2.67, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 14.10 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 12.1. Comparison 12 HAQ-Di at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 12 HAQ-Di at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 -0.6 (0.59) 100 -0.18 (0.56) 50.2 % -0.42 [ -0.54, -0.30 ]
Subtotal (95% CI) 393 100 50.2 % -0.42 [ -0.54, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.62 (P < 0.00001)
2 certolizumab 400 mg sc
RAPID1 2005 390 -0.63 (0.59) 99 -0.18 (0.56) 49.8 % -0.45 [ -0.57, -0.33 ]
Subtotal (95% CI) 390 99 49.8 % -0.45 [ -0.57, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.06 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -0.43 [ -0.52, -0.35 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 9.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 13.1. Comparison 13 SF-36 Physical Component Summary (PCS) week 24, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 13 SF-36 Physical Component Summary (PCS) week 24
Outcome: 1 certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 7.7 (7.93) 199 1.8 (8.46) 60.2 % 5.90 [ 4.49, 7.31 ]
RAPID2 2007 246 5.23 (8.31) 127 0.93 (8) 39.8 % 4.30 [ 2.56, 6.04 ]
Total (95% CI) 639 326 100.0 % 5.26 [ 4.17, 6.36 ]
Heterogeneity: Chi2 = 1.96, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 9.41 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 SF-36 Physical Component Summary (PCS) week 24, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 13 SF-36 Physical Component Summary (PCS) week 24
Outcome: 2 certolizumab 400 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 8.3 (7.9) 199 1.8 (8.46) 60.2 % 6.50 [ 5.09, 7.91 ]
RAPID2 2007 246 5.46 (8.31) 127 0.93 (8) 39.8 % 4.53 [ 2.79, 6.27 ]
Total (95% CI) 636 326 100.0 % 5.72 [ 4.62, 6.81 ]
Heterogeneity: Chi2 = 2.98, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 10.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 SF-36 Mental Component Summary (MCS) week 24, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 14 SF-36 Mental Component Summary (MCS) week 24
Outcome: 1 certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 6.3 (11.89) 199 2.3 (11.29) 56.9 % 4.00 [ 2.04, 5.96 ]
RAPID2 2007 246 6.05 (10.82) 127 1.63 (10.36) 43.1 % 4.42 [ 2.17, 6.67 ]
Total (95% CI) 639 326 100.0 % 4.18 [ 2.70, 5.66 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 SF-36 Mental Component Summary (MCS) week 24, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 14 SF-36 Mental Component Summary (MCS) week 24
Outcome: 2 certolizumab 400 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 6.5 (11.85) 199 2.3 (11.29) 57.2 % 4.20 [ 2.24, 6.16 ]
RAPID2 2007 246 6.28 (10.98) 127 1.63 (10.36) 42.8 % 4.65 [ 2.39, 6.91 ]
Total (95% CI) 636 326 100.0 % 4.39 [ 2.91, 5.88 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 SF-36 Mental Component Summary (MCS) week 52, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 15 SF-36 Mental Component Summary (MCS) week 52
Outcome: 1 certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 6.35 (11.1) 199 2.05 (11.14) 100.0 % 4.30 [ 2.40, 6.20 ]
Total (95% CI) 393 199 100.0 % 4.30 [ 2.40, 6.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 SF-36 Mental Component Summary (MCS) week 52, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 15 SF-36 Mental Component Summary (MCS) week 52
Outcome: 2 certolizumab 400 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 6.35 (11.06) 199 2.05 (11.14) 100.0 % 4.30 [ 2.40, 6.20 ]
Total (95% CI) 390 199 100.0 % 4.30 [ 2.40, 6.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 SF-36 Physical Component Summary (PCS) week 52, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 16 SF-36 Physical Component Summary (PCS) week 52
Outcome: 1 certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 7.79 (8.72) 199 1.73 (8.61) 100.0 % 6.06 [ 4.59, 7.53 ]
Total (95% CI) 393 199 100.0 % 6.06 [ 4.59, 7.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 SF-36 Physical Component Summary (PCS) week 52, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 16 SF-36 Physical Component Summary (PCS) week 52
Outcome: 2 certolizumab 400 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 8.61 (8.49) 199 1.73 (8.61) 100.0 % 6.88 [ 5.42, 8.34 ]
Total (95% CI) 390 199 100.0 % 6.88 [ 5.42, 8.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 SF-36 Physical Component Summary (PCS) week 24, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 17 SF-36 Physical Component Summary (PCS) week 24, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 7.7 (7.93) 100 1.8 (8.46) 29.8 % 5.90 [ 4.07, 7.73 ]
RAPID2 2007 246 5.23 (8.31) 64 0.93 (8) 20.4 % 4.30 [ 2.08, 6.52 ]
Subtotal (95% CI) 639 164 50.2 % 5.25 [ 3.84, 6.66 ]
Heterogeneity: Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 7.28 (P < 0.00001)
2 certolizumab 400 mg sc
RAPID1 2005 390 8.3 (7.9) 99 1.8 (8.46) 29.6 % 6.50 [ 4.66, 8.34 ]
RAPID2 2007 246 5.46 (8.31) 63 0.93 (8) 20.2 % 4.53 [ 2.30, 6.76 ]
Subtotal (95% CI) 636 162 49.8 % 5.70 [ 4.28, 7.12 ]
Heterogeneity: Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 7.87 (P < 0.00001)
Total (95% CI) 1275 326 100.0 % 5.47 [ 4.47, 6.48 ]
Heterogeneity: Chi2 = 3.16, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 10.71 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.66), I2 =0.0%
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Analysis 18.1. Comparison 18 SF-36 Mental Component Summary (MCS) week 24, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 18 SF-36 Mental Component Summary (MCS) week 24, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 6.3 (11.89) 100 2.3 (11.29) 28.6 % 4.00 [ 1.49, 6.51 ]
RAPID2 2007 246 6.05 (10.82) 64 1.63 (10.36) 21.7 % 4.42 [ 1.54, 7.30 ]
Subtotal (95% CI) 639 164 50.3 % 4.18 [ 2.29, 6.07 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
2 certolizumab 400 mg sc
RAPID1 2005 390 6.5 (11.85) 99 2.3 (11.29) 28.4 % 4.20 [ 1.68, 6.72 ]
RAPID2 2007 246 6.28 (10.98) 63 1.63 (10.36) 21.3 % 4.65 [ 1.75, 7.55 ]
Subtotal (95% CI) 636 162 49.7 % 4.39 [ 2.49, 6.29 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.53 (P < 0.00001)
Total (95% CI) 1275 326 100.0 % 4.29 [ 2.95, 5.63 ]
Heterogeneity: Chi2 = 0.12, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 19.1. Comparison 19 SF-36 Physical Component Summary (PCS) week 52, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 19 SF-36 Physical Component Summary (PCS) week 52, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 7.79 (8.72) 100 1.73 (8.61) 50.0 % 6.06 [ 4.17, 7.95 ]
Subtotal (95% CI) 393 100 50.0 % 6.06 [ 4.17, 7.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.27 (P < 0.00001)
2 certolizumab 400 mg sc
RAPID1 2005 390 8.61 (8.49) 99 1.73 (8.61) 50.0 % 6.88 [ 4.99, 8.77 ]
Subtotal (95% CI) 390 99 50.0 % 6.88 [ 4.99, 8.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.12 (P < 0.00001)
Total (95% CI) 783 199 100.0 % 6.47 [ 5.13, 7.81 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 9.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
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Analysis 20.1. Comparison 20 SF-36 Mental Component Summary (MCS) week 52, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 20 SF-36 Mental Component Summary (MCS) week 52, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 6.35 (11.1) 100 2.05 (11.14) 50.2 % 4.30 [ 1.86, 6.74 ]
Subtotal (95% CI) 393 100 50.2 % 4.30 [ 1.86, 6.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 certolizumab 400 mg sc
RAPID1 2005 390 6.35 (11.06) 99 2.05 (11.14) 49.8 % 4.30 [ 1.85, 6.75 ]
Subtotal (95% CI) 390 99 49.8 % 4.30 [ 1.85, 6.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.43 (P = 0.00059)
Total (95% CI) 783 199 100.0 % 4.30 [ 2.57, 6.03 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 4.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 21.1. Comparison 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6), Outcome 1
Proportion of patients achieving remission 24 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6)
Outcome: 1 Proportion of patients achieving remission 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
200 mg Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 (1) 45/391 3/196 66.1 % 3.77 [ 2.02, 7.04 ]
RAPID2 2007 (2) 23/245 1/125 33.9 % 4.10 [ 1.71, 9.83 ]
Total (95% CI) 636 321 100.0 % 3.88 [ 2.33, 6.45 ]
Total events: 68 (Certolizumab 200 mg), 4 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.22 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) UCB report for NICE quote Certolizumab n=391
(2) UCB report for NICE quote Certolizumab n=245
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Analysis 21.2. Comparison 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6), Outcome 2
Proportion of patients achieving remission 24 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6)
Outcome: 2 Proportion of patients achieving remission 24 weeks certolizumab 400 mg
Study or subgroup
Certolizumab
400 mg Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
RAPID1 2005 (1) 50/387 3/196 69.9 % 3.96 [ 2.18, 7.19 ]
RAPID2 2007 21/246 1/125 30.1 % 3.99 [ 1.60, 9.91 ]
Total (95% CI) 633 321 100.0 % 3.97 [ 2.41, 6.54 ]
Total events: 71 (Certolizumab 400 mg), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 5.41 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab 400 mg sc
(1) UCB report for NICE quote Certolizumab n=387
Analysis 21.3. Comparison 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6), Outcome 3
Proportion of patients achieving remission 52 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6)
Outcome: 3 Proportion of patients achieving remission 52 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
200 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 (1) 62/391 3/196 100.0 % 10.36 [ 3.29, 32.58 ]
Total (95% CI) 391 196 100.0 % 10.36 [ 3.29, 32.58 ]
Total events: 62 (Certolizumab 200 mg), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000064)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours certolizumab 200 mg sc
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(1) UCB report for NICE quote Certolizumab n=391
Analysis 21.4. Comparison 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6), Outcome 4
Proportion of patients achieving remission 52 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS28) (ESR) remission (< 2.6)
Outcome: 4 Proportion of patients achieving remission 52 weeks certolizumab 400 mg
Study or subgroup
Certolizumab
400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 (1) 74/387 3/196 100.0 % 12.49 [ 3.99, 39.12 ]
Total (95% CI) 387 196 100.0 % 12.49 [ 3.99, 39.12 ]
Total events: 74 (Certolizumab 400 mg), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.34 (P = 0.000015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab 400 mg sc
(1) UCB report for NICE quote Certolizumab n=387
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Analysis 22.1. Comparison 22 Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 24 weeks,
Outcome 1 Proportion of patients achieving remission 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 22 Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 24 weeks
Outcome: 1 Proportion of patients achieving remission 24 weeks
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 (1) 45/391 3/100 37.5 % 3.84 [ 1.22, 12.09 ]
RAPID2 2007 (2) 23/245 1/64 12.5 % 6.01 [ 0.83, 43.65 ]
Subtotal (95% CI) 636 164 50.0 % 4.38 [ 1.62, 11.82 ]
Total events: 68 (Certolizumab), 4 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
2 certolizumab 400 mg sc
RAPID1 2005 (3) 50/387 3/99 37.5 % 4.26 [ 1.36, 13.38 ]
RAPID2 2007 (4) 21/246 1/63 12.5 % 5.38 [ 0.74, 39.22 ]
Subtotal (95% CI) 633 162 50.0 % 4.54 [ 1.69, 12.24 ]
Total events: 71 (Certolizumab), 4 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 1269 326 100.0 % 4.46 [ 2.21, 9.00 ]
Total events: 139 (Certolizumab), 8 (Control)
Heterogeneity: Chi2 = 0.19, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000030)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab
(1) UCB report for NICE quoted Certolizumab n=391 and placebo n=196
(2) In NICE report UCB quoted certoluzimab n= 245 and placebo n =125
(3) In NICE report UCB quoted Certolizumab n= 387 and placebo n = 196
(4) In NICE report UCB quoted placebo n =125
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Analysis 23.1. Comparison 23 Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 52 weeks,
Outcome 1 Proportion of patients achieving remission 52 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 23 Disease Activity Score (DAS28) (ESR) remission (< 2.6) any doses, 52 weeks
Outcome: 1 Proportion of patients achieving remission 52 weeks
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 (1) 62/391 3/100 50.0 % 5.29 [ 1.69, 16.49 ]
Subtotal (95% CI) 391 100 50.0 % 5.29 [ 1.69, 16.49 ]
Total events: 62 (Certolizumab), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
2 certolizumab 400 mg sc
RAPID1 2005 (2) 74/387 3/99 50.0 % 6.31 [ 2.03, 19.59 ]
Subtotal (95% CI) 387 99 50.0 % 6.31 [ 2.03, 19.59 ]
Total events: 74 (Certolizumab), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 778 199 100.0 % 5.80 [ 2.60, 12.94 ]
Total events: 136 (Certolizumab), 6 (Control)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab
(1) In NICE report UCB quoted placebo certoluzimab n= 391 and placebo n =196
(2) UCB report for NICE quoted Certolizumab n=387
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Analysis 24.1. Comparison 24 DAS-28 at 24 weeks 200 mg sc certolizumab, Outcome 1 DAS 28 (ESR)
change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 24 DAS-28 at 24 weeks 200 mg sc certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab
200 mg Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID2 2007 246 -2.27 (1.38) 127 -0.5 (1.05) 100.0 % -1.77 [ -2.02, -1.52 ]
Total (95% CI) 246 127 100.0 % -1.77 [ -2.02, -1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 25.1. Comparison 25 DAS-28 at 24 weeks 400 mg sc certolizumab, Outcome 1 DAS 28 (ESR)
change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 DAS-28 at 24 weeks 400 mg sc certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab
400 mg Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
FAST4WARD 2005 111 -1.5 (2) 109 -0.6 (2) 17.7 % -0.90 [ -1.43, -0.37 ]
RAPID2 2007 246 -2.46 (1.31) 127 -0.5 (1.05) 82.3 % -1.96 [ -2.21, -1.71 ]
Total (95% CI) 357 236 100.0 % -1.77 [ -1.99, -1.55 ]
Heterogeneity: Chi2 = 12.71, df = 1 (P = 0.00036); I2 =92%
Test for overall effect: Z = 15.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 26.1. Comparison 26 DAS-28 at week 52, certolizumab 200 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 26 DAS-28 at week 52, certolizumab 200 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -3.3 (1.3) 199 -2.4 (1.3) 100.0 % -0.90 [ -1.12, -0.68 ]
Total (95% CI) 393 199 100.0 % -0.90 [ -1.12, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.96 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 27.1. Comparison 27 DAS-28 at week 52, certolizumab 400 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 27 DAS-28 at week 52, certolizumab 400 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 -3.4 (1.4) 199 -2.4 (1.3) 100.0 % -1.00 [ -1.23, -0.77 ]
Total (95% CI) 390 199 100.0 % -1.00 [ -1.23, -0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 DAS-28 at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 28 DAS-28 at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID2 2007 246 -2.27 (1.38) 64 -0.5 (1.05) 42.3 % -1.77 [ -2.08, -1.46 ]
Subtotal (95% CI) 246 64 42.3 % -1.77 [ -2.08, -1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.20 (P < 0.00001)
2 certolizumab 400 mg sc
FAST4WARD 2005 111 -1.5 (2) 109 -0.6 (2) 14.5 % -0.90 [ -1.43, -0.37 ]
RAPID2 2007 246 -2.46 (1.31) 63 -0.5 (1.05) 43.2 % -1.96 [ -2.27, -1.65 ]
Subtotal (95% CI) 357 172 57.7 % -1.69 [ -1.96, -1.43 ]
Heterogeneity: Chi2 = 11.56, df = 1 (P = 0.00067); I2 =91%
Test for overall effect: Z = 12.51 (P < 0.00001)
Total (95% CI) 603 236 100.0 % -1.73 [ -1.93, -1.52 ]
Heterogeneity: Chi2 = 11.70, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 16.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 29.1. Comparison 29 DAS-28 at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 DAS-28 at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 393 -3.3 (1.3) 100 -2.4 (1.3) 51.0 % -0.90 [ -1.19, -0.61 ]
Subtotal (95% CI) 393 100 51.0 % -0.90 [ -1.19, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.18 (P < 0.00001)
2 certolizumab 400 mg sc
RAPID1 2005 390 -3.4 (1.4) 99 -2.4 (1.3) 49.0 % -1.00 [ -1.29, -0.71 ]
Subtotal (95% CI) 390 99 49.0 % -1.00 [ -1.29, -0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.73 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -0.95 [ -1.15, -0.75 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 9.12 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
-100 -50 0 50 100
Favours certolizumab Favours control
147Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 30.1. Comparison 30 Modified total Sharp scores (mTSS), Outcome 1 Change from the baseline
mean mTSS 24 weeks 200 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 Modified total Sharp scores (mTSS)
Outcome: 1 Change from the baseline mean mTSS 24 weeks 200 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 353 0.2 (3.2) 180 1.3 (3.8) 62.8 % -1.10 [ -1.75, -0.45 ]
RAPID2 2007 214 0.2 (2.7) 112 1.2 (4.1) 37.2 % -1.00 [ -1.84, -0.16 ]
Total (95% CI) 567 292 100.0 % -1.06 [ -1.58, -0.55 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000049)
Test for subgroup differences: Not applicable
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Analysis 30.2. Comparison 30 Modified total Sharp scores (mTSS), Outcome 2 Change from the baseline
mean mTSS 24 weeks 400 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 Modified total Sharp scores (mTSS)
Outcome: 2 Change from the baseline mean mTSS 24 weeks 400 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 355 0.2 (4.2) 180 1.3 (3.8) 56.7 % -1.10 [ -1.81, -0.39 ]
RAPID2 2007 222 -0.4 (2.1) 112 1.2 (4.1) 43.3 % -1.60 [ -2.41, -0.79 ]
Total (95% CI) 577 292 100.0 % -1.32 [ -1.85, -0.78 ]
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours certolizumab Favours control
148Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 30.3. Comparison 30 Modified total Sharp scores (mTSS), Outcome 3 Change from the baseline
mean mTSS 52 weeks 200 mg certolizumab sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 Modified total Sharp scores (mTSS)
Outcome: 3 Change from the baseline mean mTSS 52 weeks 200 mg certolizumab sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 364 0.4 (5.7) 181 2.8 (7.8) 100.0 % -2.40 [ -3.68, -1.12 ]
Total (95% CI) 364 181 100.0 % -2.40 [ -3.68, -1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Test for subgroup differences: Not applicable
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Analysis 30.4. Comparison 30 Modified total Sharp scores (mTSS), Outcome 4 Change from the baseline
mean mTSS 52 weeks 400 mg certolizumab sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 Modified total Sharp scores (mTSS)
Outcome: 4 Change from the baseline mean mTSS 52 weeks 400 mg certolizumab sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0.2 (4.8) 181 2.8 (7.8) 100.0 % -2.60 [ -3.84, -1.36 ]
Total (95% CI) 363 181 100.0 % -2.60 [ -3.84, -1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
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Analysis 31.1. Comparison 31 Modified total Sharp scores (mTSS) at 24 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 31 Modified total Sharp scores (mTSS) at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 353 0.2 (3.2) 90 1.3 (3.8) 32.6 % -1.10 [ -1.95, -0.25 ]
RAPID2 2007 214 0.2 (2.7) 56 1.2 (4.1) 18.5 % -1.00 [ -2.13, 0.13 ]
Subtotal (95% CI) 567 146 51.1 % -1.06 [ -1.75, -0.38 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
2 certolizumab 400 mg sc
RAPID1 2005 355 0.2 (4.2) 91 1.3 (3.8) 29.6 % -1.10 [ -1.99, -0.21 ]
RAPID2 2007 222 -0.4 (2.1) 56 1.2 (4.1) 19.3 % -1.60 [ -2.71, -0.49 ]
Subtotal (95% CI) 577 147 48.9 % -1.30 [ -1.99, -0.60 ]
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00026)
Total (95% CI) 1144 293 100.0 % -1.18 [ -1.67, -0.69 ]
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 32.1. Comparison 32 Modified total Sharp scores (mTSS) at 52 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 Modified total Sharp scores (mTSS) at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 364 0.4 (5.7) 91 2.8 (7.8) 49.4 % -2.40 [ -4.11, -0.69 ]
Subtotal (95% CI) 364 91 49.4 % -2.40 [ -4.11, -0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
2 certolizumab 400 mg sc
RAPID1 2005 363 0.2 (4.8) 90 2.8 (7.8) 50.6 % -2.60 [ -4.29, -0.91 ]
Subtotal (95% CI) 363 90 50.6 % -2.60 [ -4.29, -0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 727 181 100.0 % -2.50 [ -3.70, -1.30 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 33.1. Comparison 33 Erosion score (ES), Outcome 1 Change from the baseline mean ES at week
24, 200 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 1 Change from the baseline mean ES at week 24, 200 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 353 0 (1.5) 180 0.7 (2.1) 71.9 % -0.70 [ -1.04, -0.36 ]
RAPID2 2007 214 0.1 (2) 112 0.7 (2.6) 28.1 % -0.60 [ -1.15, -0.05 ]
Total (95% CI) 567 292 100.0 % -0.67 [ -0.96, -0.38 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 33.2. Comparison 33 Erosion score (ES), Outcome 2 Change from the baseline mean ES at week
24, 400 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 2 Change from the baseline mean ES at week 24, 400 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 355 0.1 (2.4) 180 0.7 (2.1) 64.8 % -0.60 [ -1.00, -0.20 ]
RAPID2 2007 222 -0.3 (1.8) 112 0.7 (2.6) 35.2 % -1.00 [ -1.54, -0.46 ]
Total (95% CI) 577 292 100.0 % -0.74 [ -1.06, -0.42 ]
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 4.56 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 33.3. Comparison 33 Erosion score (ES), Outcome 3 Change from the baseline mean ES at week
52, 200 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 3 Change from the baseline mean ES at week 52, 200 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 364 0.1 (2.5) 180 1.5 (4.3) 100.0 % -1.40 [ -2.08, -0.72 ]
Total (95% CI) 364 180 100.0 % -1.40 [ -2.08, -0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000053)
Test for subgroup differences: Not applicable
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Analysis 33.4. Comparison 33 Erosion score (ES), Outcome 4 Change from the baseline mean ES at week
52, 400 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Erosion score (ES)
Outcome: 4 Change from the baseline mean ES at week 52, 400 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0 (3) 180 1.5 (4.3) 100.0 % -1.50 [ -2.20, -0.80 ]
Total (95% CI) 363 180 100.0 % -1.50 [ -2.20, -0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
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Analysis 34.1. Comparison 34 Erosion score (ES) at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 34 Erosion score (ES) at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 353 0 (1.5) 91 0.7 (2.1) 37.9 % -0.70 [ -1.16, -0.24 ]
RAPID2 2007 214 0.1 (2) 56 0.7 (2.6) 14.9 % -0.60 [ -1.33, 0.13 ]
Subtotal (95% CI) 567 147 52.8 % -0.67 [ -1.06, -0.28 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00071)
2 certolizumab 400 mg sc
RAPID1 2005 355 0.1 (2.4) 90 0.7 (2.1) 31.9 % -0.60 [ -1.10, -0.10 ]
RAPID2 2007 222 -0.3 (1.8) 56 0.7 (2.6) 15.4 % -1.00 [ -1.72, -0.28 ]
Subtotal (95% CI) 577 146 47.2 % -0.73 [ -1.14, -0.32 ]
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00050)
Total (95% CI) 1144 293 100.0 % -0.70 [ -0.98, -0.42 ]
Heterogeneity: Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 35.1. Comparison 35 Erosion score (ES) at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 35 Erosion score (ES) at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 364 0.1 (2.5) 91 1.5 (4.3) 51.1 % -1.40 [ -2.32, -0.48 ]
Subtotal (95% CI) 364 91 51.1 % -1.40 [ -2.32, -0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
2 certolizumab 400 mg sc
RAPID1 2005 363 0 (3) 90 1.5 (4.3) 48.9 % -1.50 [ -2.44, -0.56 ]
Subtotal (95% CI) 363 90 48.9 % -1.50 [ -2.44, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
Total (95% CI) 727 181 100.0 % -1.45 [ -2.11, -0.79 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 36.1. Comparison 36 Joint space narrowing (JSN), Outcome 1 Change from the baseline mean JSN
24 weeks 200 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 1 Change from the baseline mean JSN 24 weeks 200 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 355 0.2 (2.5) 180 0.7 (2.4) 53.2 % -0.50 [ -0.94, -0.06 ]
RAPID2 2007 214 0.1 (1.4) 112 0.5 (2.3) 46.8 % -0.40 [ -0.87, 0.07 ]
Total (95% CI) 569 292 100.0 % -0.45 [ -0.77, -0.13 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
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Analysis 36.2. Comparison 36 Joint space narrowing (JSN), Outcome 2 Change from the baseline mean JSN
24 weeks 400 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 2 Change from the baseline mean JSN 24 weeks 400 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 355 0.2 (2.4) 180 0.7 (2.4) 51.8 % -0.50 [ -0.93, -0.07 ]
RAPID2 2007 222 -0.1 (1) 112 0.5 (2.3) 48.2 % -0.60 [ -1.05, -0.15 ]
Total (95% CI) 577 292 100.0 % -0.55 [ -0.86, -0.24 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 36.3. Comparison 36 Joint space narrowing (JSN), Outcome 3 Change from the baseline mean JSN
52 weeks 200 mg certolizumab..
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 3 Change from the baseline mean JSN 52 weeks 200 mg certolizumab.
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 367 0.4 (4.2) 181 1.4 (5) 100.0 % -1.00 [ -1.85, -0.15 ]
Total (95% CI) 367 181 100.0 % -1.00 [ -1.85, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 36.4. Comparison 36 Joint space narrowing (JSN), Outcome 4 Change from the baseline mean JSN
52 weeks 400 mg certolizumab.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Joint space narrowing (JSN)
Outcome: 4 Change from the baseline mean JSN 52 weeks 400 mg certolizumab
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 363 0.2 (2.8) 181 1.4 (5) 100.0 % -1.20 [ -1.98, -0.42 ]
Total (95% CI) 363 181 100.0 % -1.20 [ -1.98, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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Analysis 37.1. Comparison 37 Joint space narrowing (JSN) at 24 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Joint space narrowing (JSN) at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 355 0.2 (2.5) 91 0.7 (2.4) 27.7 % -0.50 [ -1.06, 0.06 ]
RAPID2 2007 214 0.1 (1.4) 56 0.5 (2.3) 21.6 % -0.40 [ -1.03, 0.23 ]
Subtotal (95% CI) 569 147 49.4 % -0.46 [ -0.87, -0.04 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
2 certolizumab 400 mg sc
RAPID1 2005 355 0.2 (2.4) 90 0.7 (2.4) 28.0 % -0.50 [ -1.06, 0.06 ]
RAPID2 2007 222 -0.1 (1) 56 0.5 (2.3) 22.7 % -0.60 [ -1.22, 0.02 ]
Subtotal (95% CI) 577 146 50.6 % -0.54 [ -0.96, -0.13 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Total (95% CI) 1146 293 100.0 % -0.50 [ -0.79, -0.21 ]
Heterogeneity: Chi2 = 0.20, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00082)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 38.1. Comparison 38 Joint space narrowing (JSN) at 52 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Joint space narrowing (JSN) at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 367 0.4 (4.2) 91 1.4 (5) 48.1 % -1.00 [ -2.11, 0.11 ]
Subtotal (95% CI) 367 91 48.1 % -1.00 [ -2.11, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
2 certolizumab 400 mg sc
RAPID1 2005 363 0.2 (2.8) 90 1.4 (5) 51.9 % -1.20 [ -2.27, -0.13 ]
Subtotal (95% CI) 363 90 51.9 % -1.20 [ -2.27, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Total (95% CI) 730 181 100.0 % -1.10 [ -1.88, -0.33 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 39.1. Comparison 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 1
Mean change at 24 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 1 Mean change at 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
200 mg sc Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -29.6 (21.81) 199 -8.1 (22.57) 59.7 % -21.50 [ -25.31, -17.69 ]
RAPID2 2007 246 -23.7 (22) 127 -4.7 (21.41) 40.3 % -19.00 [ -23.63, -14.37 ]
Total (95% CI) 639 326 100.0 % -20.49 [ -23.43, -17.55 ]
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 13.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 39.2. Comparison 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 2
Mean change at 24 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 2 Mean change at 24 weeks certolizumab 400 mg
Study or subgroup
Certolizumab
400 mg sc Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
FAST4WARD 2005 (1) 111 -20.6 (42) 109 1.7 (42) 6.6 % -22.30 [ -33.40, -11.20 ]
RAPID1 2005 (2) 390 -31.7 (21.72) 199 -8.1 (22.57) 55.8 % -23.60 [ -27.41, -19.79 ]
RAPID2 2007 246 -26.1 (22) 127 -4.7 (21.41) 37.7 % -21.40 [ -26.03, -16.77 ]
Total (95% CI) 747 435 100.0 % -22.69 [ -25.53, -19.84 ]
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 15.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
(2) Data in RAPID1 from NICE report
Analysis 39.3. Comparison 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 3
Mean change at 52 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 3 Mean change at 52 weeks certolizumab 200 mg
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -31 (22.57) 199 -8.8 (23.79) 100.0 % -22.20 [ -26.19, -18.21 ]
Total (95% CI) 393 199 100.0 % -22.20 [ -26.19, -18.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.91 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 39.4. Comparison 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome 4
Mean change at 52 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 4 Mean change at 52 weeks certolizumab 400 mg
Study or subgroup Certolizumab Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 390 -33.5 (23.7) 199 -8.8 (22.57) 100.0 % -24.70 [ -28.62, -20.78 ]
Total (95% CI) 390 199 100.0 % -24.70 [ -28.62, -20.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 40.1. Comparison 40 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks,
any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 40 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 (1) 393 -29.6 (21.81) 100 -8.1 (22.57) 28.1 % -21.50 [ -26.42, -16.58 ]
RAPID2 2007 246 -23.7 (22) 64 -4.7 (21.41) 19.4 % -19.00 [ -24.92, -13.08 ]
Subtotal (95% CI) 639 164 47.5 % -20.48 [ -24.26, -16.69 ]
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 10.60 (P < 0.00001)
2 certolizumab 400 mg sc
FAST4WARD 2005 111 -20.6 (42) 109 1.7 (42) 5.5 % -22.30 [ -33.40, -11.20 ]
RAPID1 2005 390 -31.7 (21.72) 99 -8.1 (22.57) 27.9 % -23.60 [ -28.54, -18.66 ]
RAPID2 2007 246 -26.1 (22) 63 -4.7 (21.41) 19.2 % -21.40 [ -27.36, -15.44 ]
Subtotal (95% CI) 747 271 52.5 % -22.66 [ -26.26, -19.06 ]
Heterogeneity: Chi2 = 0.31, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 12.34 (P < 0.00001)
Total (95% CI) 1386 435 100.0 % -21.63 [ -24.23, -19.02 ]
Heterogeneity: Chi2 = 1.39, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 16.25 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 41.1. Comparison 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks,
any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Patient’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose
Outcome: 1 Change from baseline
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc
RAPID1 2005 (1) 393 -31 (22.57) 100 -8.8 (23.79) 48.6 % -22.20 [ -27.37, -17.03 ]
Subtotal (95% CI) 393 100 48.6 % -22.20 [ -27.37, -17.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.42 (P < 0.00001)
2 certolizumab 400 mg sc
RAPID1 2005 390 -33.5 (23.7) 99 -8.8 (22.57) 51.4 % -24.70 [ -29.73, -19.67 ]
Subtotal (95% CI) 390 99 51.4 % -24.70 [ -29.73, -19.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.62 (P < 0.00001)
Total (95% CI) 783 199 100.0 % -23.48 [ -27.09, -19.88 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 12.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 42.1. Comparison 42 Certolizumab 1mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Certolizumab 1mg/kg/day sc
Outcome: 1 Headache
Study or subgroup
certolizumab
1mg/Kg/day
sc Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 3/8 1/12 100.0 % 4.50 [ 0.56, 35.98 ]
Total (95% CI) 8 12 100.0 % 4.50 [ 0.56, 35.98 ]
Total events: 3 (certolizumab 1mg/Kg/day sc), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 42.2. Comparison 42 Certolizumab 1mg/kg/day sc, Outcome 2 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Certolizumab 1mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab
1 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 0/8 1/12 100.0 % 0.48 [ 0.02, 10.54 ]
Total (95% CI) 8 12 100.0 % 0.48 [ 0.02, 10.54 ]
Total events: 0 (certolizumab 1 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 1mg/Kg/day sc Favours control
168Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 42.3. Comparison 42 Certolizumab 1mg/kg/day sc, Outcome 3 Adverse events Intensity severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Certolizumab 1mg/kg/day sc
Outcome: 3 Adverse events Intensity severe
Study or subgroup
certolizumab
1 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab 1 mg/kg/day), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 42.4. Comparison 42 Certolizumab 1mg/kg/day sc, Outcome 4 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Certolizumab 1mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab
1 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 2/8 1/12 100.0 % 3.00 [ 0.32, 27.83 ]
Total (95% CI) 8 12 100.0 % 3.00 [ 0.32, 27.83 ]
Total events: 2 (certolizumab 1 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 42.5. Comparison 42 Certolizumab 1mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Certolizumab 1mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab
1 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab 1 mg/kg/day), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 43.1. Comparison 43 Certolizumab 5 mg/kg/day sc, Outcome 1 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 43 Certolizumab 5 mg/kg/day sc
Outcome: 1 Lower respiratory tract infection
Study or subgroup
certolizumab
5 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 1/12 100.0 % 1.50 [ 0.11, 20.68 ]
Total (95% CI) 8 12 100.0 % 1.50 [ 0.11, 20.68 ]
Total events: 1 (certolizumab 5 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 43.2. Comparison 43 Certolizumab 5 mg/kg/day sc, Outcome 2 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 43 Certolizumab 5 mg/kg/day sc
Outcome: 2 Urinary tract infection
Study or subgroup
certolizumab
5 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab 5 mg/kg/day), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 5mg/Kg/day sc Favours control
Analysis 44.1. Comparison 44 Certolizumab 20 mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Certolizumab 20 mg/kg/day sc
Outcome: 1 Headache
Study or subgroup
certolizumab
20 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 3/8 1/12 100.0 % 4.50 [ 0.56, 35.98 ]
Total (95% CI) 8 12 100.0 % 4.50 [ 0.56, 35.98 ]
Total events: 3 (certolizumab 20 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 20 mg/Kg/day sc certolizumab control
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Analysis 44.2. Comparison 44 Certolizumab 20 mg/kg/day sc, Outcome 2 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Certolizumab 20 mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab
20 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 2/8 1/12 100.0 % 3.00 [ 0.32, 27.83 ]
Total (95% CI) 8 12 100.0 % 3.00 [ 0.32, 27.83 ]
Total events: 2 (certolizumab 20 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 20 mg/Kg/day sc Favours control
Analysis 44.3. Comparison 44 Certolizumab 20 mg/kg/day sc, Outcome 3 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Certolizumab 20 mg/kg/day sc
Outcome: 3 Death
Study or subgroup
certolizumab
20 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab 20 mg/kg/day), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 20 mg/Kg/day sc Favours control
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Analysis 44.4. Comparison 44 Certolizumab 20 mg/kg/day sc, Outcome 4 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Certolizumab 20 mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab
20 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 1/12 100.0 % 1.50 [ 0.11, 20.68 ]
Total (95% CI) 8 12 100.0 % 1.50 [ 0.11, 20.68 ]
Total events: 1 (certolizumab 20 mg/kg/day), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 20 mg/Kg/day sc Favours control
Analysis 44.5. Comparison 44 Certolizumab 20 mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 Certolizumab 20 mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab
20 mg/kg/day Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 1/8 0/12 100.0 % 4.33 [ 0.20, 94.83 ]
Total (95% CI) 8 12 100.0 % 4.33 [ 0.20, 94.83 ]
Total events: 1 (certolizumab 20 mg/kg/day), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab 20 mg/Kg/day sc Favours control
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Analysis 45.1. Comparison 45 Withdrawals, Outcome 1 All Withdrawn: any doses any follow up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Withdrawals
Outcome: 1 All Withdrawn: any doses any follow up
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 28/125 56/125 9.8 % 0.50 [ 0.34, 0.73 ]
Choy 2002 2/24 6/12 1.4 % 0.17 [ 0.04, 0.71 ]
FAST4WARD 2005 35/111 81/109 14.4 % 0.42 [ 0.32, 0.57 ]
RAPID1 2005 254/783 156/199 43.7 % 0.41 [ 0.37, 0.47 ]
RAPID2 2007 137/492 110/127 30.7 % 0.32 [ 0.27, 0.38 ]
Total (95% CI) 1535 572 100.0 % 0.39 [ 0.36, 0.43 ]
Total events: 456 (Certolizumab), 409 (Control)
Heterogeneity: Chi2 = 9.99, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 19.39 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Certolizumab Favours control
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Analysis 45.2. Comparison 45 Withdrawals, Outcome 2 Withdrawn due to lack of efficacy: any doses any
follow up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Withdrawals
Outcome: 2 Withdrawn due to lack of efficacy: any doses any follow up
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 16/125 45/125 9.4 % 0.36 [ 0.21, 0.59 ]
FAST4WARD 2005 24/111 75/109 15.7 % 0.31 [ 0.22, 0.46 ]
RAPID1 2005 151/783 125/199 41.5 % 0.31 [ 0.26, 0.37 ]
RAPID2 2007 95/492 101/127 33.4 % 0.24 [ 0.20, 0.30 ]
Total (95% CI) 1511 560 100.0 % 0.29 [ 0.26, 0.33 ]
Total events: 286 (Certolizumab), 346 (Control)
Heterogeneity: Chi2 = 4.22, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 19.02 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Certolizumab Favours control
175Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 45.3. Comparison 45 Withdrawals, Outcome 3 Withdrawn due to adverse events: any doses any
follow up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 Withdrawals
Outcome: 3 Withdrawn due to adverse events: any doses any follow up
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 7/125 6/125 37.5 % 1.17 [ 0.40, 3.37 ]
FAST4WARD 2005 5/111 2/109 12.6 % 2.45 [ 0.49, 12.39 ]
RAPID1 2005 39/783 3/199 29.9 % 3.30 [ 1.03, 10.58 ]
RAPID2 2007 17/492 2/127 19.9 % 2.19 [ 0.51, 9.37 ]
Total (95% CI) 1511 560 100.0 % 2.17 [ 1.15, 4.10 ]
Total events: 68 (Certolizumab), 13 (Control)
Heterogeneity: Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Certolizumab Favours control
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Analysis 46.1. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 1 ACR 50 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 1 ACR 50 200 mg certolizumab 24 weeks
Study or subgroup
Certolizumab
200 mg sc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RAPID1 2005 144/393 15/199 79.1 % 4.86 [ 2.94, 8.04 ]
RAPID2 2007 80/246 4/127 20.9 % 10.33 [ 3.87, 27.54 ]
Total (95% CI) 639 326 100.0 % 6.01 [ 3.84, 9.40 ]
Total events: 224 (Certolizumab 200 mg sc), 19 (Placebo)
Heterogeneity: Chi2 = 1.85, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 7.84 (P < 0.00001)
0.01 0.1 1 10 100
Favours control Favours certolizumab
Analysis 46.2. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 2 HAQ change from baseline 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 2 HAQ change from baseline 200 mg certolizumab 24 weeks
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
RAPID1 2005 393 -0.58 (0.59) 199 -0.17 (0.56) 50.3 % -0.41 [ -0.51, -0.31 ]
RAPID2 2007 246 -0.5 (0.47) 127 -0.14 (0.45) 49.7 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 639 326 100.0 % -0.39 [ -0.45, -0.32 ]
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 10.94 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 46.3. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 3 Serious adverse events certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 3 Serious adverse events certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 certolizumab 200 mg
RAPID1 2005 45/392 11/199 71.0 % 2.00 [ 1.12, 3.58 ]
RAPID2 2007 18/248 4/125 29.0 % 2.07 [ 0.83, 5.16 ]
Total (95% CI) 640 324 100.0 % 2.02 [ 1.24, 3.30 ]
Total events: 63 (Certolizumab), 15 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab Favours control
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Analysis 46.4. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 4 Proportion of patients achieving DAS <2.6 (Remission) 200 mg
certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 4 Proportion of patients achieving DAS <2.6 (Remission) 200 mg certolizumab 24 weeks
Study or subgroup Certolizumab Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 certolizumab 200 mg sc 24 weeks
RAPID1 2005 (1) 45/391 3/196 66.1 % 3.77 [ 2.02, 7.04 ]
RAPID2 2007 (2) 23/245 1/125 33.9 % 4.10 [ 1.71, 9.83 ]
Total (95% CI) 636 321 100.0 % 3.88 [ 2.33, 6.45 ]
Total events: 68 (Certolizumab), 4 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.22 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours Certolizumab
(1) UCB report for NICE quoted Certolizumab n=391 and placebo n=196
(2) In NICE report UCB quoted certoluzimab n= 245 and placebo n =125
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Analysis 46.5. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 5 Radiological changes: Erosion Scores (ES) 200 mg certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 5 Radiological changes: Erosion Scores (ES) 200 mg certolizumab 200 mg sc
Study or subgroup Certolizumab Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab 200 mg sc 24 weeks
RAPID1 2005 353 0 (1.5) 180 0.7 (2.1) 71.9 % -0.70 [ -1.04, -0.36 ]
RAPID2 2007 214 0.1 (2) 112 0.7 (2.6) 28.1 % -0.60 [ -1.15, -0.05 ]
Total (95% CI) 567 292 100.0 % -0.67 [ -0.96, -0.38 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 46.6. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 6 All Withdrawals:.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 6 All Withdrawals:
Study or subgroup Certolizumab Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CDP870-014 2009 28/125 56/125 9.8 % 0.50 [ 0.34, 0.73 ]
Choy 2002 2/24 6/12 1.4 % 0.17 [ 0.04, 0.71 ]
FAST4WARD 2005 35/111 81/109 14.4 % 0.42 [ 0.32, 0.57 ]
RAPID1 2005 254/783 156/199 43.7 % 0.41 [ 0.37, 0.47 ]
RAPID2 2007 137/492 110/127 30.7 % 0.32 [ 0.27, 0.38 ]
Total (95% CI) 1535 572 100.0 % 0.39 [ 0.36, 0.43 ]
Total events: 456 (Certolizumab), 409 (Control)
Heterogeneity: Chi2 = 9.99, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 19.39 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab Favours control
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Analysis 46.7. Comparison 46 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 7 Withdrawals due to adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Certolizumab Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-014 2009 7/125 6/125 21.6 % 1.18 [ 0.39, 3.58 ]
FAST4WARD 2005 5/111 2/109 11.9 % 2.37 [ 0.53, 10.64 ]
RAPID1 2005 39/783 3/199 45.5 % 2.33 [ 1.08, 5.03 ]
RAPID2 2007 17/492 2/127 21.0 % 1.88 [ 0.61, 5.82 ]
Total (95% CI) 1511 560 100.0 % 1.93 [ 1.15, 3.23 ]
Total events: 68 (Certolizumab), 13 (Control)
Heterogeneity: Chi2 = 1.07, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours control Favours certolizumab
A D D I T I O N A L T A B L E S
Table 1. Demographic and disease characteristics of the retrieved phase III trials
Study FAST4WARD
n = 220
CDP870-014
n = 247
RAPID1
n = 982
RAPID2
n = 619
Age (years) Mean SD 53.8 (12.2)
Cer 400mg 52.7 (12.7)
Placebo 54.0 (11.6)
54.3 (12.05) 52.0 (11.6)
Cer 200mg 51.4 (11.6)
Cer 400 mg 52.4 (11.7)
Placebo 52.2 (11.2)
51.9 (11.5)
Cer 200mg 52.2 (11.1)
Cer 400 mg 51.9 (11.8)
Placebo 51.5 (11.8)
Female
n (%)
83.6% 69.2% 83.2%
Cer 200mg 324 (82.4%)
Cer 400 mg 326 (83.
6%)
Placebo 167 (83.9%)
81.6%
Cer 200mg 206 (83.7%)
Cer 400 mg 192 (78%)
Placebo 107 (84.3%)
Disease duration (years)
Mean (SD)
9.5 (NC)
Cer 400mg 8.7 (8.2)
Placebo 10.4 (9.6)
9.6 (NC) 6.1 (4.3)
Cer 200mg 6.1 (4.2)
Cer 400 mg 6.2 (4.4)
6.2 (4.2)
Cer 200mg 6.1 (4.1)
Cer 400 mg 6.5 (4.3)
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Table 1. Demographic and disease characteristics of the retrieved phase III trials (Continued)
Placebo 6.2 (4.4) Placebo 5.6 (3.9)
RF positive ([≥ 14 IU/
ml] (%)
100%
Cer 400mg 110 (99.9%)
Placebo 109 (100%)
78% 81.8%
Cer 200mg 312 (79.6%)
Cer 400 mg 326 (83.
6%)
Placebo 164 (82.8%)
76.9%
Cer 200mg 186 (77.5%)
Cer 400 mg 179 (75.
5%)
Placebo 97 (78.2%)
MTX concomitant dose
(mg/Week) Mean(SD)
N/A 16.8 13.6
Cer 200mg 13.6 (4.3)
Cer 400 mg 13.6 (4)
Placebo 13.4 (4.2)
12.5
Cer 200mg 12.5 (3.6)
Cer 400 mg 12.6 (3.7)
Placebo 12.2 (3.3)
Prednisolone dose al-
lowed
prednisone equivalent
(≤10 mg/day)
prednisone equivalent
(≤10 mg/day)
prednisone equivalent
(≤10 mg/day)
prednisone equivalent
(≤10 mg/day)
Number of previous
DMARDS Mean (SD)
2.0
Cer 400mg 2.0 (1.2)
Placebo 2.0 (1.3)
1.3 1.3
Cer 200mg 1.3 (1.3)
Cer 400 mg 1.3 (1.3)
Placebo 1.4 (1.4)
1.2
Cer 200mg 1.2 (1.3)
Cer 400 mg 1.3 (1.2)
Placebo 1.2 (1.2)
Tender Joint count
Mean (SD)
29.0 (13.13) 30.0 (12.28) 30.7 (12.9) 30.2 (14.0)
Swollen Joint Count
Mean (SD)
20.5 (9.67) 22.5 (9.48) 21.5 (9.8) 21.0 (9.8)
HAQ-DI mean (SD) 1.5 (0.64) 1.4 (0.63) 1.7 (0.60) 1.6 (0.59)
CRP (mg/L) Geometric
mean (CV)
11.5 (NC) 12.4 (NC) 14.7 (144.2) 13.6 (180.9)
DAS28(ESR) Mean
(SD)
6.3 (1.00) 6.2 (0.99) 6.9 (0.8) 6.8 (0.83)
Cer= Certolizumab; CV = coefficient of variation; DAS = disease activity score; DMARD = disease-modifying antirheumatic drug;
ESR = erythrocyte sedimentation rate; IU = international units; L = littre; mg = milligrams; mL = millilitre; RF= rheumatoid factor;
SD = standard deviation; y = years; NC= not calculated; N/A=not applicable All randomised subjects; the actual numbers vary slightly
across parameters
Table 2. Intention to treat and per protocol patients
Study Placebo Certolizumabl 200
mg
Certolizumabl 200 mg Total
ITT PP ITT PP ITT PP ITT PP
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Table 2. Intention to treat and per protocol patients (Continued)
FAST4WARD
109 81 N/A N/A 111 89 220 170
CDP870-
014
119 79 N/A N/A 124 92 243 171
RAPID1 199 43 393 274 390 255 982 572
RAPID2 127 17 246 172 246 181 619 370
ITT Intention-to-treat; PP per protocol populations
In studies RAPID1 and RAPID2, the number of withdrawals was high in the placebo groups, possibly due to the early escape option
at Week 16
Table 3. Effectiveness ACR
Follow up Doses/study Response rate
certolizumab
Response rate
placebo
RR % RAR NNT (close)
ACR20
24 weeks 200
mg/ RAPID1,
RAPID2
58.2% 11.1% 4.95 (3.65 to 6.
72)
46.5 (37.3 to
55.1)
2
24 weeks 400
mg/ RAPID1,
RAPID2,
FAST4WARD,
CDP870-014
55.3% 13.5% 4.09 (3.27 to 5.
13)
41.7 (30.6 to
51.7)
2
52 weeks 200 mg/
RAPID1,
53.2% 13.1% 4.05 (2.80 to 5.
87)
40.1 (28.7 to
51.1)
3
52 weeks 400 mg/
RAPID1
54.1% 13.1% 4.18 (2.89 to 6.
05)
40.9 (29.7 to
51.9)
3
ACR50
24 weeks 200
mg/ RAPID1,
RAPID2
35.4% 5.8% 6.01 (3.84 to 9.
40)
29.8 (19.4 to
41.7)
3
24 weeks 400
mg/ RAPID1,
RAPID2,
FAST4WARD,
CDP870-014
32.4% 5.4% 5.68 (3.93 to 8.
20)
25.3 (15.8 to
38.8)
4
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Table 3. Effectiveness ACR (Continued)
52 weeks 200 mg/
RAPID1,
37.9% 7.5% 5.03 (3.04 to 8.
32)
30.5 (18.2 to
44.4)
3
52 weeks 400 mg/
RAPID1
40% 7.5% 5.27 (3.19 to 8.
71)
32.6 (20 to 46.
6)
3
ACR70
24 weeks 200
mg/ RAPID1,
RAPID2
19.2% 2.1% 8.87 (4.20 to
18.75)
17.4 (7.9 to 32.
6)
6
24 weeks 400
mg/ RAPID1,
RAPID2,
FAST4WARD,
CDP870-014
12.8% 1.6% 6.39 (3.32 to
12.27)
8.7 (3.8 to 18.2) 12
52 weeks 200 mg/
RAPID1,
21.1% 3.5% 6.00 (2.83 to
12.74)
17.6 (7.3 to 33.
7)
5
52 weeks 400 mg/
RAPID1,
23.1% 3.5% 6.56 (3.10 to
13.89)
19.6 (8.4 to 36.
3)
5
Table 4. Adverse events
Doses/study Response
rate in % (num-
ber of events)
certolizumab
Response
rate in % (num-
ber of events)
placebo
RR RAR NNTH
(close)
Serious adverse
events
Peto OR
200 mg/
RAPID1,
RAPID2
9.8% (63) 4.6% (15) 2.02 (1.24 to 3.
30)
0.052 (0.01 to 0.
12)
24 (11-96)
400 mg/
RAPID1,
RAPID2,
FAST4WARD
10.3 % (90) 4.4 % (30) 1.92 (1.30 to 2.
83)
0.05 (0.02 to 0.
10)
27 (15-81)
Adverse events
leading to with-
drawal
Peto OR
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Table 4. Adverse events (Continued)
200 mg/
RAPID1,
RAPID2
4.5% (29) 1.6% (5) 2.40 (1.16 to 4.
95)
0.03 (0.002 to 0.
95)
47 (18-398)
400 mg/
RAPID1,
RAPID2,
FAST4WARD
4.6 % (34) 1.6 % (7) 2.41 (1.26 to 4.
63)
0.03(0.004 to 0.
88)
47 (19-246)
Adverse events,
severe intensity
Peto OR
200 mg/
RAPID1,
RAPID2
7.7% (49) 5.3% (18) 1.21 (1 to 1.47). 0.021 (-0.010 to
0.074)
NS
400 mg/
RAPID1,
RAPID2,
FAST4WARD
8% (60) 6.5% (29) 1.24 (0.79 to 1.
95)
0.015 (-0.014 to
0.192)
NS
Adverse events
leading to death
Peto OR
200 mg/
RAPID1,
RAPID2
0.5% (3) 0.3% (1) 1.47 (0.18 to 11.
76)
0.001 (-0.003 to
0.021)
NS
400 mg/
RAPID1,
RAPID2,
FAST4WARD
0.7% (5) 0% (1) 2.16 (0.4 to 11.
79)
0.002 (-0.002 to
0.024)
NS
Death Peto OR
200 mg/
RAPID1,
RAPID2
0.6% (4) 0.3% (1) 1.85 (0.29 to 11.
86)
(-0.01 to 0.01) NS
400 mg/
RAPID1,
RAPID2,
FAST4WARD
0.6% (5) 0.1% (1) 2.16 (0.40 to 11.
79)
(0.00 to 0.01) NS
Malignan-
cies (neoplasias
including lym-
phoma)
Peto OR
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Table 4. Adverse events (Continued)
200 mg/
RAPID1,
RAPID2
1.3% (8) 0.7% (2) 1.85 (0.50 to 6.
93)
0.006 (-0.004 to
0.050)
NS
400 mg/
RAPID1,
RAPID2,
FAST4WARD
0.7 % (5) 0.5 % (2) 1.26 (0.25 to 6.
54)
0.001 (-0.003 to
0.26)
NS
Infections and
infestations
RR
200 mg/
RAPID1,
RAPID2
39.4% (197) 27.1% (121) 1.37 (1.10 to 1.
69)
0.10 (0.04 to 0.
16)
10
400 mg/
CDP870-14,
RAPID1,
RAPID2
35.5 % (270) 21.2% (95) 1.60 (1.31 to 1.
95)
0.18 (0.09 to 0.
28)
8
Tuberculosis Peto OR
200 mg/
RAPID1,
RAPID2
0.8% (5) 0% (0) 4.53 (0.71 to 29.
11)
Not calculated NS
400 mg/
RAPID1,
RAPID2,
FAST4WARD
0.7% (5) 0% (0) 4.55(0.71 to 29.
11)
Not calculated NS
Table 5. Health-related quality of life
Follow up Doses/study Mean differences NNT( close)
HAQ (0-3)
(Best= 0; Worst 3)
24 weeks 200 mg/ RAPID1, RAPID2 -0.39 (-0.45 to -0.32)
24 weeks 400 mg/ RAPI1, RAPID2,
FAST4WARD
-0.41 (-0.48 to -0.35)
187Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Health-related quality of life (Continued)
52 weeks 200 mg/RAPID1 -0.42 (-0.54 to -0.32)
52 weeks 400 mg/RAPID1 -0.45 (-0.57 to -0.33)
SF-36 PCS (0-100)
(Worst =0; Best=100)
24 weeks 200 mg/ RAPID1, RAPID2 5.26 (4.17 to 6.36)
24 weeks 400 mg/ RAPID1,RAPID2 5.72 (4.62 to 6.81).
SF-36 MCS (0-100)
(Worst =0; Best=100)
24 weeks 200 mg/ RAPID1 RAPID2 4.18 (2.70 to 5.66)
24 weeks 400 mg/ RAPID1, RAPID2 4.39 (2.91 to 5.88)
SF-36 PCS
52 weeks 200 mg/ RAPID1 6.06 (4.59 to 7.53)
52 weeks 400 mg/ RAPID1 6.88 (5.42 to 8.34)
SF-36 MCS (0-100)
(Worst =0; Best=100)
52 weeks 200 mg/ RAPID1 4.3 (2.4 to 6.2)
52 weeks 400 mg/ RAPID1 4.3 (2.4 to 6.2)
Patients VAS score (0-
100)
24 weeks 200 mg/RAPID2 -19.00 (-23.63 to -14.37)
400 mg/RAPID2,
FAST4WARD
-21.53 (-25.81 to -17.26)
52 weeks
DAS28 remission (< 2.6) Peto Odds Ratio
24 weeks 200 mg/RAPID1, RAPID2 3.88 (2.33 to 6.45) 31 (17 to 65)
400 mg/RAPID1,RAPID2, 3.97 (2.41 to 6.54) 30 (17 to 61)
Risk Ratio
188Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Health-related quality of life (Continued)
52 weeks 200 mg/RAPID1 10.36 (3.29 to 32.58) 8 (3 to 30)
400 mg/RAPID1 12.49 (3.99 to 39.12) 6(2 to 23)
Table 6. Radiological changes
Follow up Doses/study Mean differences
Modified Total Sharp Scores
(mTTS) is the sum of the ero-
sion score (ES) and the joint
space narrowing (JSN) score
and has a range of 0 to 398
24 weeks 200 mg/ RAPID1, RAPID2 -1.06 (-1.58 to -0.55)
24 weeks 400 mg/ RAPID1, RAPID2 -1.32 (-1.85 to -0.78)
52 weeks 200 mg/RAPID1 -2.4 (-3.68 to -1.12)
52 weeks 400 mg/RAPID1 -2.6 (-3.84 to -1.36)
ErosionScore is the sumof joint
scores collected for 46 joints
and has a range of 0 to 230
24 weeks 200 mg/ RAPID1, RAPID2 -0.67 (-0.96 to -0.38)
24 weeks 400 mg/ RAPID1, RAPID2 -0.74 (-1.06 to -0.42)
52 weeks 200 mg/RAPID1 -1.4 (-2.08 to -0.72)
52 weeks 400 mg/RAPID1 -1.5 (-2.20 to -0.80)
Joint Space Narrowing (JSN) is
the sum of joint scores collected
for 42 joints and has a range of
0 to 168
24 weeks 200 mg/ RAPID1, RAPID2 -0.45 (-0.77 to -0.13)
24 weeks 400 mg/ RAPID1, RAPID2 -0.55 (- 0.86 to -0.24)
52 weeks 200 mg/RAPID1 -1 (-1.85 to -0.15)
52 weeks 400 mg/RAPID1 -1.2 (-1.98 to -0.42)
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search strategy for effectiveness:
1. (CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia).mp.
2. . (“Rheumatoid Arthritis” or (Caplan$ and Syndrome?) or (Felty$ and S?ndrome) or (Rheumatoid and Nodule?) or (Sjogren$ and
S?ndrome?) or (Sicca$ and S?ndrome?) or (Ankylos$ and Spondylit$) or (Spondylarthritis and Ankylopoietica) or (Rheumatoid$ and
Spondylit$) or (Bechterew$ and Disease?) or (Marie-Struempell and Disease?) or (Adult and Onset and Still$ and Disease?)).mp.
3.. exp Arthritis, Rheumatoid/
4. ( 2 OR 3)
5. 1 AND 4
6. Clinical trial.pt.
7. randomized.ab.
8. Placebo.ab.
9. dt.fs.
10. randomly.ab.
11. trial.ab.
12. groups.ab.
13. or/ 6-12
14. 5 and 13
Search strategy for Safety:
#1. Exp Headache/ci OR Exp Nasopharyngitis/ci OR Exp Arthritis, Rheumatoid/ci OR Exp Nausea/ci OR Exp Infection/ci OR Exp
Respiratory Tract Infections/ci OR Exp Urinary Tract Infections/ci OR Exp Neck Pain/ci OR Exp Antibodies, Antinuclear/ci OR Exp
Granulomatous Disease, Chronic/ci OR Exp Granulomatous Disease, Chronic/ci OR Exp Tuberculosis/ci OR Exp Histoplasmosis/
ci OR Exp Neoplasms/ci OR Exp Skin Neoplasms/ci OR Exp Hematologic Neoplasms/ci OR Exp Death/ci OR Exp Sepsis/ci OR
Exp Abdominal Pain/ci OR Exp Heart Failure, Congestive/ci OR Exp Fever/ci OR Exp Pruritus/ci OR Exp Melanoma/ci OR Exp
Lymphoma/ci OR Exp Pneumonia/ci OR Exp Lupus/ci OR Exp Lupus Erythematosus, Systemic/ci OR Exp Anaphylaxis/ci OR
“blood disorders”.ab,ti. OR “laboratory test abnormalities”.ab,ti. OR Headache.ab,ti. OR Nasopharyngitis.ab,ti. OR “Rheumatoid
Arthritis”.ab,ti. OR Nausea.ab,ti. OR Infection.ab,ti. OR “Respiratory Tract Infections”.ab,ti. OR “Urinary Tract Infections” .ab,ti.
OR “Neck Pain”.ab,ti. OR “Antinuclear Antibodies”.ab,ti. OR “Chronic Granulomatous Disease” .ab,ti. OR Tuberculosis.ab,ti. OR
Histoplasmosis.ab,ti. OR Neoplasms.ab,ti. OR “Skin Neoplasms”.ab,ti. OR “Hematologic Neoplasms”.ab,ti. OR Death.ab,ti. OR
Sepsis.ab,ti. OR “Abdominal Pain” .ab,ti. OR “Heart Failure”.ab,ti. OR Fever.ab,ti. OR Pruritus.ab,ti. OR Melanoma.ab,ti. OR
Lymphoma.ab,ti. OR Pneumonia.ab,ti. OR Lupus.ab,ti. OR “Lupus Erythematosus”.ab,ti. OR Anaphylaxis.ab,ti.
#2. ae.fs OR po.fs OR to.fs OR de.fs OR co.fs
#3. (advers$.ab,ti. OR untoward$.ab,ti. OR avers$.ab,ti. OR detrimental$.ab,ti. OR damage$.ab,ti. OR harmful$.ab,ti. OR crip-
ple$.ab,ti. OR prejudicial$.ab,ti. OR disruptiv$.ab,ti. OR destructive$.ab,ti. OR deleter$.ab,ti. OR untoward$.ab,ti. OR unex-
pect$.ab,ti. OR side$.ab,ti. OR serious$.ab,ti. OR severe$.ab,ti. OR unlikely$.ab,ti. OR malignan$.ab,ti.) AND (consequenc$.ab,ti.
OR implication$.ab,ti. OR result$.ab,ti. OR outgrowth$.ab,ti. OR repercussion$.ab,ti. OR episod$ .ab,ti. OR happen$.ab,ti. OR
reaction$.ab,ti. OR effect$.ab,ti. OR experience$.ab,ti.) OR complication$.tw.
#4. Exp Drug Toxicity
#5. 1 OR 2 OR 3 OR 4
#6. CDP870 OR CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia.mp.
#8. 5 AND 6
Last search on November 2009
Ovid MEDLINE(R) <1950 to November Week 3 2009>
1 (certolizumab or cimzia or cdp870 or cdp 870).mp.
2 rheumatoid arthritis.mp.
3 exp Arthritis, Rheumatoid/
4 2 or 3
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5 1 and 4
6 limit 5 to humans
7 from 6 keep 1-31
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <November 30, 2009>
1 (certolizumab or cimzia or cdp870 or cdp 870).mp.
2 rheumatoid arthritis.mp.
3 1 and 2
4 from 3 keep 1-15
Appendix 2. EMBASE search strategy
Search strategy for effectiveness:
1. ’rheumatoid arthritis’/exp/
2. ’certolizumab pegol’/exp/
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4. 2 OR 3
5. 4 AND 1
6. random:.tw.
7. clinical trial:.mp.
8. exp health care quality
9. or/6-8
10. 5 AND 9
Search strategy for safety:
#1 exp Headache/si or exp Nasopharyngitis/si or exp Arthritis, Rheumatoid/si or exp Nausea/si or exp Infection/si or exp Respiratory
Tract Infections/si or exp Urinary Tract Infections/si or exp Neck Pain/si or exp Antibodies, Antinuclear/si or exp Granulomatous
Disease, Chronic/si or exp Granulomatous Disease, Chronic/si or exp Tuberculosis/si or exp Histoplasmosis/si or exp Neoplasms/si
or exp Skin Neoplasms/si or exp Hematologic Neoplasms/si or exp Death/si or exp Sepsis/si or exp Abdominal Pain/si or exp Heart
Failure, Congestive/si or exp Fever/si or exp Pruritus/si or exp Melanoma/si or exp Lymphoma/si or exp Pneumonia/si or exp Lupus/
si or exp Lupus Erythematosus, Systemic/si or exp Anaphylaxis/si or “blood disorders”.ab,ti. or “laboratory test abnormalities”.ab,ti.
or Headache.ab,ti. or Nasopharyngitis.ab,ti. or “Rheumatoid Arthritis”.ab,ti. or Nausea.ab,ti. or Infection.ab,ti. or “Respiratory Tract
Infections”.ab,ti. or “Urinary Tract Infections”.ab,ti. or “Neck Pain”.ab,ti. or “Antinuclear Antibodies”.ab,ti. or “Chronic Granulo-
matous Disease”.ab,ti. or Tuberculosis.ab,ti. or Histoplasmosis.ab,ti. or Neoplasms.ab,ti. or “Skin Neoplasms”.ab,ti. or “Hematologic
Neoplasms”.ab,ti. or Death.ab,ti. or Sepsis.ab,ti. or “Abdominal Pain”.ab,ti. or “Heart Failure”.ab,ti. or Fever.ab,ti. or Pruritus.ab,ti. or
Melanoma.ab,ti. or Lymphoma.ab,ti. or Pneumonia.ab,ti. or Lupus.ab,ti. or “Lupus Erythematosus”.ab,ti. or Anaphylaxis.ab,ti.
#2 (ae or to or co).fs.
#3 (((advers$ or untoward$ or avers$ or detrimental$ or damage$ or harmful$ or cripple$ or prejudicial$ or disruptiv$ or destructive$
or deleter$ or untoward$ or unexpect$ or side$ or serious$ or severe$ or unlikely$ or malignan$) and (consequenc$ or implication$
or result$ or outgrowth$ or repercussion$ or episod$ or happen$ or reaction$ or effect$ or experience$)) or complication$).tw.
#4 exp Adverse drug reaction/ or exp Side-effect/ or exp Drug Toxicity
#5 or/1-4
#6 CDP870.rn OR (CDP870 or CDP 870 or “certolizumab pegol” or certolizumab or CDP-870 or cimzia).mp.
#7 5 AND 6
Last search on November 2009
EMBASE (Ovid) 1980 - 2009 Week 48
1 (certolizumab or cimzia or cdp870 or cdp 870).mp.
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2 rheumatoid arthritis.mp.
3 exp rheumatoid arthritis/
4 2 or 3
5 1 and 4
6 limit 5 to human
Appendix 3. CINAHL search strategy
Search strategy for effectiveness:
1.’rheumatoid arthritis’/exp/
2.“rheumatoid arthritis”.mp.
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4.(1 or 2) and 3
5.exp prognosis
6.exp study design
7.random:.mp.
8.or/ 5-7
9.4 and 8
Last search on November 2009
S1 certolizumab or cimzia or cdp870 or “cdp 870”
S2 (MH “arthritis, rheumatoid”) or “rheumatoid arthritis”
S3 S1 and S2
Appendix 4. Search strategy for CDSR and CENTRAL, HTA, DARE, NHS EED
Search strategy for effectiveness:
Cochrane Database of Systematic Reviews, Health Technology Assessment (HTA), The Database of Abstracts of Reviews of Effects
(DARE), NHS Economic Evaluation Database (NHS EED) from Ovid:
1.’rheumatoid arthritis’.mp.
2.(CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
3.1 and 2
Search strategy for safety:
DARE, CDSR and CENTRAL from OVID platform (version 10.5.1), will be searched up to October 2007, The search strategy will
combine text and index terms for CDP870 and adverse effects reported in RCTs of certolizumab Pegol and another anti-TNF alpha
with a strategy based on that by Golder (a) 2006 Golder (b) 2006.
#1 Drug and ( hypersensitive$ or tocit$).tw.
#2 ((safe$ or advers$ or tolerabilit$ or toxic$ or adr$ or tolera$ or harm$ or complicat$ or risk$) adj20 objective$).tw.
#3 (side adj3 effect$ adj20 objective$).tw.
#4 (undesirable adj3 effect$ adj20 objetive$).tw.
#5 (treatment adj3 emergent adj20 objective$).tw.
#6 or/1-5
#7 (CDP870 or CDP 870 or certolizumab pegol or certolizumab or CDP-870 or cimzia).tw.
#8 6 and 7
Last search on November 2009
#1 certolizumab or cimzia
#2 cdp870
#3 cdp next 870
#4 (#1 OR #2 OR #3)
#5 rheumatoid next arthritis
#6 MeSH descriptor Arthritis, Rheumatoid explode all trees
#7 (#5 OR #6)
#8 (#4 AND #7)
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Appendix 5. SCOPUS search strategy
Search strategy for effectiveness:
SCOPUS will be searched up to August of 2007, without limits of years:
KEY((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” ))
Web of Knowledge (WOK), was searched up to August of 2007, without limits of years. The search strategy is as follows:
topic=((certolizumab OR cimzia OR CDP-870 OR CDP870 OR “CDP 870”) AND (“rheumatoid arthritis” )
Databases=MEDLINE, Current Contents Connect, Web of Science, Derwent Innovations Index, ISI Proceedings; Timespan=All Years
Appendix 6. TOXLINE (TOXNET) search strategy
Search strategy for safety:
TOXLINE (TOXNET) will be searched up to October 2007. The search strategy will combine index and text terms for CDP870:
#1. certolizumab OR “certolizumab pegol” OR CDP870 OR CDP-870 OR “CDP 870” OR cimzia
Last search on November 2009
Last Search Query: certolizumab OR cimzia OR cdp870
Appendix 7. Web of Knowledge
Last search on November 2009
Web of Knowledge (Science Citation Index and Social Science Citation Index) 1900 - Nov 2009
Search terms: TS= (certolizumab OR cimzia OR or CDP870 OR cdp 870) and (“rheumatoid arthritis”)
Appendix 8. Demographic and disease characteristics of the retrieved phase III trials
Study FAST4WARD
n = 220
CDP870-014
n = 247
RAPID1
n = 982
RAPID2
n = 619
Age (years) Mean SD 53.8 (12.2)
Cer 400mg 52.7 (12.7)
Placebo 54.0 (11.6)
54.3 (12.05) 52.0 (11.6)
Cer 200mg 51.4 (11.6)
Cer 400 mg 52.4 (11.7)
Placebo 52.2 (11.2)
51.9 (11.5)
Cer 200mg 52.2 (11.1)
Cer 400 mg 51.9 (11.8)
Placebo 51.5 (11.8)
Follow up 24 weeks 24 weeks 52 weeks 24 weeks
Female n (%) 83.6% 69.2% 83.2%
Cer 200mg 324 (82.4%)
Cer 400mg326 (83.6%)
Placebo 167 (83.9%)
81.6%
Cer 200mg 206 (83.7%)
Cer 400 mg 192 (78%)
Placebo 107 (84.3%)
Disease duration (years)
Mean (SD)
9.5 (NC)
Cer 400mg 8.7 (8.2)
Placebo 10.4 (9.6)
9.6 (NC) 6.1 (4.3)
Cer 200mg 6.1 (4.2)
Cer 400 mg 6.2 (4.4)
Placebo 6.2 (4.4)
6.2 (4.2)
Cer 200mg 6.1 (4.1)
Cer 400 mg 6.5 (4.3)
Placebo 5.6 (3.9)
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(Continued)
RF positive ([³ 14 IU/
ml] (%)
100%
Cer 400mg 110 (99.9%)
Placebo 109 (100%)
78% 81.8%
Cer 200mg 312 (79.6%)
Cer 400mg326 (83.6%)
Placebo 164 (82.8%)
76.9%
Cer 200mg 186 (77.5%)
Cer 400mg179 (75.5%)
Placebo 97 (78.2%)
MTX concomitant dose
(mg/Week) Mean(SD)
N/A 16.8 13.6
Cer 200mg 13.6 (4.3)
Cer 400 mg 13.6 (4)
Placebo 13.4 (4.2)
12.5
Cer 200mg 12.5 (3.6)
Cer 400 mg 12.6 (3.7)
Placebo 12.2 (3.3)
Number of previous
DMARDS Mean (SD)
2.0
Cer 400mg 2.0 (1.2)
Placebo 2.0 (1.3)
1.3 1.3
Cer 200mg 1.3 (1.3)
Cer 400 mg 1.3 (1.3)
Placebo 1.4(1.4)
1.2
Cer 200mg 1.2 (1.3)
Cer 400 mg 1.3 (1.2)
Placebo 1.2 (1.2)
Tender Joint count
Mean (SD)
29.0 (13.13) 30.0 (12.28) 30.7 (12.9) 30.2 (14.0)
Swollen Joint Count
Mean (SD)
20.5 (9.67) 22.5 (9.48) 21.5 (9.8) 21.0 (9.8)
HAQ-DI mean (SD) 1.5 (0.64) 1.4 (0.63) 1.7 (0.60) 1.6 (0.59)
CRP (mg/L) Geometric
mean (CV)
11.5 (NC) 12.4 (NC) 14.7 (144.2) 13.6 (180.9)
DAS28(ESR) Mean
(SD)
6.3 (1.00) 6.2 (0.99) 6.9 (0.8) 6.8 (0.83)
Notes: Cer= Certolizumab; CV = coefficient of variation; DAS = disease activity score; DMARD = disease-modifying antirheumatic
drug; ESR = erythrocyte sedimentation rate; IU = international units; L = liter; mg = milligrams; mL = millilitres; RF= rheumatoid
factor; SD = standard deviation; y = years; NC= not calculated; N/A=not applicable All randomised subjects; the actual numbers vary
slightly across parameters
Appendix 9. Flow of patients in the phase III studies retrieved
Study Placebo Certolizumab 200mg Certolizumab 400mg
RAPID1
n = 982
ITT n = 199
Safety n = 199
ITT n = 393
Safety a n = 392
ITT n = 390
Safety n = 389
Withdrawn at week 16 due to lack
of efficacy
n = 125 (62.8%)
Withdrawn at week 16 due to lack
of efficacy
n = 83 (21.1%)
Withdrawn at week 16 due to lack
of efficacy
n = 68 (17.4%)
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(Continued)
All withdrawn
n = 156 (78.4%)
All withdrawn
n = 138 (35.1)
All withdrawn
n = 116 (39.7%)
Completed
n = 43 (21.6%)
Completed
n = 255 (64.9%)
Completed
n = 274 (70.3%)
RAPID2
n = 619
ITT n = 127c
Safety n = 125
ITT n = 246
Safety n = 248
ITT n = 246
Safety n = 246
Withdrawn at week 16 due to lack
of efficacy
n = 103 (81%)
Withdrawn at week 16 due to lack
of efficacy
n = 52 (21.1%)
Withdrawn at week 16 due to lack
of efficacy
n = 52 (21.1%)
All withdrawn
n = 110 (86%)
All withdrawn
n = 72 (29.3%)
All withdrawn
n = 65 (26.4%)
Completed
n = 17 (13.4%)
Completed
n = 174 (70.7%)
Completed
n = 181 (73.6%)
FAST4WARD ITT n = 109
Safety n = 109
ITT n = 111
Safety n = 111
All withdrawn
n = 81 (74%)
75 (68.8%) Lack of efficacy
2 (1.8%) Adverse event
1 (0.9%) Protocol violation
3 (2.8) Lost to follow-up
All withdrawn
n = 35 (31.5%)
24 (21.6%) Lack of efficacy
5 (4.5%) Adverse event
4 (3.6%) Protocol violation
2 (1.8%) Consent withdrawn
Completed
n = 28(25.7%)
Completed
n = 76(68.5%)
CDP870-014 ITT n = 121d
Safety n = 119
ITT n = 126 d
Safety n = 124
All withdrawn
n = 56 (46.3%)
45 (37.2%) Lack of efficacy
6 (5%) Adverse event
5 (4.1%) Other reasons
All withdrawn
n = 28 (22.2%)
16 (12.7%) Lack of efficacy
7 (5.6%) Adverse event
5 (4%) Other reasons
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(Continued)
Completed
n = 65 (53.7%)
Completed
n = 98 (77.8%)
a One patient withdrew by her own decision
b One patient was discontinued due to the ESR/CRP not meeting criteria
c Two patients in the placebo group received certolizumab and were included for safety in the 200 mg Group
d Two patients in the each of treatment groups did not take study medication. Manufactures reported efficacy calculations from
Placebo n = 119 and Certol n = 124
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drugs.
Dr Jose Galvez and Dr Encarnación Saez have, in the past, been involved in two randomised clinical trials, one phase III with etoricoxib
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S O U R C E S O F S U P P O R T
Internal sources
• Grant from, Spain.
Instituto de Salud Carlos III. Ministerio de Sanidad. FIS number PI08˙90617.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Subgroup analyses were planned for the duration of the illness (approximately of three years evolution), patients’ sex, drug dose,
administration and methodological quality, but only subgroup analysis regarding the dose of certolizumab pegol was performed. All
phase III trials were performed in patients with a high mean duration of RA (from 6.1 to 9.5 years) and we could not obtain any data
categorized by sex. All phase III trials allowed previous DMARD treatments (mean from 1.2 to 2 years). All phase III trials used in the
meta-analysis were rated as high quality, and so we did not perform more subgroup analysis.
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